aspirin has been researched along with Chronic Disease in 576 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This trial will test the efficacy of novel methods for implementing national guidelines to support informed decision-making about taking aspirin in 50-70-year-olds to reduce the risk of CRC and other chronic diseases." | 9.41 | An RCT of a decision aid to support informed choices about taking aspirin to prevent colorectal cancer and other chronic diseases: a study protocol for the SITA (Should I Take Aspirin?) trial. ( Boyd, L; Broun, K; Chondros, P; Emery, J; Fishman, G; Forbes, C; Gutierrez, JM; Jenkins, M; Karnchanachari, N; Macrae, F; Marker, J; McGill, S; McIntosh, J; Milton, S; Novy, K; Saya, S; Shub, M; Taylor, N; Trevena, L; Walter, FM; Whitburn, S, 2021) |
| " The COMMANDER HF randomized clinical trial evaluated the effects of adding low-dose rivaroxaban to antiplatelet therapy in patients with recent worsening of chronic HF with reduced ejection fraction, coronary artery disease (CAD), and sinus rhythm." | 9.30 | Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. ( Anker, SD; Byra, WM; Cleland, JGF; Deng, H; Fu, M; Greenberg, B; La Police, DA; Lam, CSP; Mehra, MR; Neaton, JD; Nessel, CC; Spiro, TE; van Veldhuisen, DJ; Vanden Boom, CM; Zannad, F, 2019) |
| "Aspirin-induced chronic rhinosinusitis (CRS) is a severe progressive persistent disease, usually associated with nasal polyps (NPs)." | 9.30 | Efficacy of hypertonic (2.3%) sea water in patients with aspirin-induced chronic rhinosinusitis following endoscopic sinus surgery. ( Barać, A; Gaćeša, D; Jožin, SM; Kovačević, SV; Perić, A; Perić, AV, 2019) |
| "In patients with chronic coronary artery disease or peripheral artery disease and a history of mild or moderate HF, combination rivaroxaban and aspirin compared with aspirin alone produces similar relative but larger absolute benefits than in those without HF." | 9.30 | Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. ( Avezum, A; Bhatt, DL; Bosch, J; Branch, KR; Cheng, RK; Connolly, SJ; Eikelboom, JW; Fox, KAA; Maggioni, AP; Probstfield, JL; Shestakovska, O; Yusuf, S, 2019) |
| "Numerous open trials have demonstrated the beneficial clinical effects of aspirin desensitization (AD) in patients with aspirin-induced asthma (AIA)." | 9.19 | Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. ( Bochenek, G; Ćmiel, A; Gielicz, A; Niżankowska-Mogilnicka, E; Plutecka, H; Sanak, M; Stręk, P; Świerczyńska-Krępa, M; Szczeklik, A, 2014) |
| "To determine the effect of aspirin on ulcer healing rate in patients with chronic venous insufficiency, and to establish prognostic factors that influence ulcer evolution." | 9.16 | Influence of aspirin therapy in the ulcer associated with chronic venous insufficiency. ( Antonio, J; del Río Solá, ML; Fajardo, G; Vaquero Puerta, C, 2012) |
| "001) by adjusted-dose warfarin compared with aspirin/low-dose warfarin; there was no difference in major hemorrhage (5 patients versus 6 patients, respectively)." | 9.15 | Warfarin in atrial fibrillation patients with moderate chronic kidney disease. ( Asinger, RW; Hart, RG; Herzog, CA; Pearce, LA, 2011) |
| "The objective was to determine the main parameters taken into account for the decision of antithrombotic treatment of atrial fibrillation (AF) by vitamin K antagonist or aspirin." | 9.13 | Which parameters differ in very old patients with chronic atrial fibrillation treated by anticoagulant or aspirin? Antithrombotic treatment of atrial fibrillation in the elderly. ( Delaunay, O; Doucet, J; Gréboval-Furstenfeld, E; M'bello, L; Moirot, P; Mouton-Schleifer, D; Pesqué, T; Tavildari, A, 2008) |
| "Aspirin-exacerbated respiratory disease (AERD) is characterized by the clinical triad of chronic rhinosinusitis with nasal polyps, asthma, and an intolerance to medications that inhibit the cycloxgenase-1 enzyme." | 9.12 | The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, ( Baptist, AP; Borish, L; Bosso, JV; Buchheit, KM; Cahill, KN; Campo, P; Cho, SH; Jerschow, E; Keswani, A; Laidlaw, TM; Levy, JM; Nanda, A; Stevens, WW; White, AA, 2021) |
| "This study was designed to investigate whether or not combination aspirin-clopidogrel therapy would reduce markers of thrombogenesis and platelet activation in atrial fibrillation (AF), in a manner similar to warfarin." | 9.10 | A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. ( Blann, AD; Chin, BS; Kamath, S; Lip, GY, 2002) |
| "Heightened platelet reactivity may affect the occurrence of ischemic events in patients with coronary artery disease on aspirin therapy." | 9.10 | The stratification of platelet reactivity and activation in patients with stable coronary artery disease on aspirin therapy. ( Bliden, KP; Gurbel, PA, 2003) |
| "We sought to determine the effect of aspirin on the venodilator effect of furosemide in patients with chronic heart failure (CHF) BACKGROUND: Furosemide has an acute venodilator effect preceding its diuretic action, which is blocked by nonsteroidal anti-inflammatory, drugs." | 9.09 | Aspirin inhibits the acute venodilator response to furosemide in patients with chronic heart failure. ( Davie, AP; Jhund, PS; McMurray, JJ, 2001) |
| "The results of this comparative study demonstrate that montelukast orally administered once a day is very effective for the treatment of cutaneous symptoms in patients with chronic urticaria due to food additives and/or ASA." | 9.09 | Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. ( Corrocher, R; Di Lorenzo, G; Pacor, ML, 2001) |
| "To evaluate the effectiveness of topical application of aspirin in chloroform as an adjuvant in the management of chronic neurogenic pain." | 9.08 | Aspirin in chloroform as an effective adjuvant in the management of chronic neurogenic pain. ( Bhattacharji, S; Tharion, G, 1997) |
| "We performed a double-blind, crossover, placebo-controlled study on the effect of fluticasone propionate (FP) treatment on chronic eosinophilic rhinosinusitis in 15 patients with aspirin-induced asthma (AIA)." | 9.08 | Intranasal fluticasone propionate for chronic eosinophilic rhinitis in patients with aspirin-induced asthma. ( Duplaga, M; Mastalerz, L; Milewski, M; Nizankowska, E; Szczeklik, A, 1997) |
| "The comparative study of the efficacy of coumadin and aspirin in primary cardioembolic stroke prevention of chronic rheumatic heart disease (mitral stenosis) with atrial fibrillation was conducted at Siriraj Hospital, Mahidol University, Bangkok, Thailand." | 9.07 | A comparative study of coumadin and aspirin for primary cardioembolic stroke and thromboembolic preventions of chronic rheumatic mitral stenosis with atrial fibrillation. ( Chaithiraphan, S; Opartkiattikul, N; Poungvarin, N; Viriyavejakul, A, 1994) |
| "This study was undertaken to determine if a standard dose of aspirin interacts relevantly with the circulatory effects of enalapril in severe heart failure." | 9.07 | Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. ( Hall, D; Rudolph, W; Zeitler, H, 1992) |
| "From November, 1985, to June, 1988, 1007 outpatients with chronic non-rheumatic atrial fibrillation (AF) entered a randomised trial; 335 received anticoagulation with warfarin openly, and in a double-blind study 336 received aspirin 75 mg once daily and 336 placebo." | 9.06 | Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. ( Andersen, B; Andersen, ED; Boysen, G; Godtfredsen, J; Petersen, P, 1989) |
| "Controlled clinical research has been carried out on the activity and tolerance of a new active principle, guacetisal (Broncaspin) obtained from the esterification of acetylsalicylic acid with guaiacol, in the treatment of chronic bronchitis." | 9.05 | [Controlled clinical study of the treatment of chronic bronchitis with guacetisal]. ( Caltagirone, S; Crimi, N; Cusmano, F; Di Maria, GU; Palermo, F; Vagliasindi, M, 1981) |
| "Naproxen at 10 mg per kg body weight was compared with aspirin at 80 mg per kg body weight in children suffering from juvenile chronic polyarthritis." | 9.04 | Naproxen in juvenile chronic polyarthritis. ( Ansell, BM; Engler, C; Hall, M; Hanna, DB; Moran, H, 1979) |
| "In 131 patients with chronic urticaria, including physical urticarias, oral provocation tests were done with aspirin." | 9.04 | Reactions to aspirin and food additives in patients with chronic urticaria, including the physical urticarias. ( Doeglas, HM, 1975) |
| "Aspirin-Exacerbated Respiratory Disease (AERD) and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) are both characterized by the presence of chronic sinonasal inflammation and nasal polyps." | 8.93 | Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis. ( Schleimer, RP; Stevens, WW, 2016) |
| "Aspirin-exacerbated respiratory disease (AERD) is a clinical condition which results in adverse upper and lower respiratory symptoms, particularly rhinitis, conjunctivitis, bronchospasm, and/or laryngospasm, following exposure to cyclooxygenase-1 (COX-1) inhibiting drugs, namely aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)." | 8.91 | Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD). ( Dazy, KM; Simon, RA; Waldram, JD, 2015) |
| "Chronic rhinosinusitis patients with nasal polyps can be aspirin sensitive or aspirin tolerant." | 8.90 | Topical nasal lysine aspirin in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis with nasal polyposis. ( Parikh, A; Scadding, GK, 2014) |
| "While previous meta-analysis have investigated the efficacy of cilostazol in the secondary prevention of ischemic stroke, they were criticized for their methodology, which confused the acute and chronic phases of stroke." | 8.90 | The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population--an updated meta-analysis. ( Chen, S; Malaguit, J; Pu, J; Shi, L; Xu, L; Zhang, J, 2014) |
| "This review is set to revisit the pathogenesis of aspirin-exacerbated respiratory disease (AERD), the diagnostic method used, and finally the real impact of aspirin desensitization on chronic sinusitis with nasal polyposis (CRSwNP) in aspirin intolerant patients." | 8.87 | Role of aspirin desensitization in the management of chronic rhinosinusitis. ( Rizk, H, 2011) |
| "The purpose of this review is to highlight recent advances in gene-expression profiling of nasal polyps in patients with chronic rhinosinusitis and aspirin-sensitive asthma." | 8.85 | Gene-expression signatures of nasal polyps associated with chronic rhinosinusitis and aspirin-sensitive asthma. ( Metson, R; Platt, M; Stankovic, K, 2009) |
| "Aspirin-exacerbated respiratory disease (AERD) is a chronic inflammatory disease characterized by chronic rhinosinusitis, nasal polyposis, asthma, and airway reactivity to aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs)." | 8.84 | The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis. ( Williams, AN; Woessner, KM, 2008) |
| "In some patients with chronic idiopathic urticaria (CIU), aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase 1 (COX-1) precipitate wheals and swelling." | 8.82 | Mechanism of chronic urticaria exacerbation by aspirin. ( Mastalerz, L; Setkowicz, M; Szczeklik, A, 2005) |
| "This study aimed to estimate the risk of bleeding following minor oral surgical procedures and uninterrupted aspirin therapy in high-risk patients or patients with existing chronic diseases compared to patients who did not use aspirin during minor oral surgery at a public hospital." | 7.85 | Risk of Hemorrhage Attributed to Underlying Chronic Diseases and Uninterrupted Aspirin Therapy of Patients Undergoing Minor Oral Surgical Procedures: A Retrospective Cohort Study. ( Limsawan, S; Rojanaworarit, C, 2017) |
| "The consequences of using aspirin (ASA) for the pathogenesis of Chagas disease are unclear." | 7.85 | Aspirin prevents atrophy of esophageal nitrergic myenteric neurons in a mouse model of chronic Chagas disease. ( Araújo, EJ; Massocatto, CL; Moreira, NM; Muniz, E; Pinge-Filho, P; Rossi, RM; Sant'Ana, DM, 2017) |
| "Aspirin hypersensitivity associated with chronic rhinosinusitis-with or without nasal polyposis-and asthma resistant to conventional therapy defines the aspirin-exacerbated respiratory disease (AERD)." | 7.85 | Omalizumab in patient with aspirin exacerbated respiratory disease and chronic idiopathic urticaria. ( Cutrera, R; Di Marco, A; Porcaro, F, 2017) |
| "Aspirin use in patients with chronic systolic heart failure and mild symptoms did not substantially reduce the overall beneficial effects of the MRA eplerenone contrary to what has been described in some studies with ACE inhibitors." | 7.83 | Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study. ( Chin, KL; Collier, TJ; Krum, H; McMurray, JJ; Pitt, B; Pocock, SJ; Swedberg, K; Turgonyi, E; van Veldhuisen, DJ; Vincent, J; Zannad, F, 2016) |
| " In our previous studies, we showed that the TNFA -308A allele is a genetic predisposition factor in a subgroup of aspirin-sensitive (ASA+) CRS patients suffering from nasal polyps (NP) in the Hungarian population." | 7.81 | A conserved linkage group on chromosome 6, the 8.1 ancestral haplotype, is a predisposing factor of chronic rhinosinusitis associated with nasal polyposis in aspirin-sensitive Hungarians. ( Bella, Z; Hirschberg, A; Kadocsa, E; Kemény, L; Kiricsi, Á; Polyánka, H; Révész, M; Szabó, K; Szabó, Z; Széll, M; Vóna, I, 2015) |
| " The levels were not significantly different according to urticaria symptom score, symptom control status, and aspirin intolerance." | 7.80 | Elevated platelet activation in patients with chronic urticaria: a comparison between aspirin-intolerant and aspirin-tolerant groups. ( Kim, SH; Palikhe, NS; Palikhe, S; Park, HS; Shin, YS; Yoo, HS, 2014) |
| "The benefits of taking of aspirin, clopidogrel, and warfarin in relation to cardiovascular mortality and re-hospitalization in chronic heart failure (HF) patients have been called into question." | 7.78 | Aspirin, clopidogrel, and warfarin use and outcomes in a cohort of 580 patients discharged after hospitalization for decompensated heart failure. ( Celikyurt, U; Ertaş, G; Kılıç, T; Kozdağ, G; Sahin, T; Ural, D; Yaymacı, M, 2012) |
| " We aimed at assessing the predictors of higher plasma levels of TxB2, the stable metabolite of TxA2, in consecutive patients presenting with non-ST-elevation acute coronary syndrome (NSTE-ACS) on previous aspirin (ASA) treatment undergoing coronary angiography." | 7.78 | Predictors of thromboxane levels in patients with non-ST-elevation acute coronary syndromes on chronic aspirin therapy. ( Biasucci, LM; Burzotta, F; Cataneo, L; Cosentino, N; Crea, F; Fracassi, F; Giubilato, S; Leo, A; Leone, AM; Narducci, ML; Niccoli, G; Porto, I; Pulcinelli, FM; Trani, C, 2012) |
| "As the management of patients treated with anticoagulants and antiplatelet drugs entails balancing coagulation levels, we evaluated the net clinical benefit of warfarin and aspirin on stroke in a large cohort of patients with atrial fibrillation (AF)." | 7.78 | A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case-control study. ( Azoulay, L; Dell'Aniello, S; Langleben, D; Renoux, C; Simon, TA; Suissa, S, 2012) |
| "Chronic rhinosinusitis (CRS) with nasal polyposis (NP) may be associated with hypersensitivity to nonsteroidal anti-inflammatory drugs, representing a syndrome of aspirin-exacerbated respiratory disease (AERD)." | 7.78 | Incidence of aspirin hypersensitivity in patients with chronic rhinosinusitis and diagnostic value of urinary leukotriene E4. ( Celejewska-Wójcik, N; Cybulska, A; Hartwich, P; Hydzik-Sobocińska, K; Januszek, R; Mastalerz, L; Nieckarz, R; Oleś, K; Sanak, M; Stręk, P; Szaleniec, J; Wójcik, K, 2012) |
| "Aspirin is the most commonly used antiplatelet agent in patients with coronary artery disease (CAD)." | 7.78 | Aspirin sensitivity and coronary artery disease: implications for the practicing cardiologist. ( Das, P; Lieberman, P; Pattanaik, D, 2012) |
| " cruzi infection (Brazil strain) beginning 5 days post infection (dpi) with aspirin (ASA) increased mortality (2-fold) and parasitemia (12-fold)." | 7.77 | Aspirin treatment of mice infected with Trypanosoma cruzi and implications for the pathogenesis of Chagas disease. ( Ashton, AW; Collado, JE; Factor, SM; Fine, EJ; Huang, H; Jelicks, LA; Koba, W; Machado, FS; Mukherjee, S; Oz, HS; Prado, CM; Tanowitz, HB; Weiss, LM; Zhao, D, 2011) |
| "The objective of this study was to evaluate the rate of stroke associated with aspirin and warfarin in routine clinical practice." | 7.75 | How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database. ( Gallagher, AM; Plumb, JM; Rietbrock, S; van Staa, TP, 2009) |
| "Aim of the study was to investigate in dynamics peculiarities of hemostasis including platelet aggregation and activity of NADP-dependent dehydrogenases in platelets, as well as prevalence of resistance to aspirin in patients with functional class II-III chronic heart failure (CHF)." | 7.74 | [Peculiarities of hemostasis, metabolic activity of platelets, and rate of aspirin resistance in patients with chronic heart failure after aorto-coronary bypass surgery]. ( Grinshteĭn, IIu; Grinshteĭn, IuI; Savchenko, AA; Savchenko, EA, 2008) |
| "Although the mechanism that underlies aspirin hypersensitivity is not completely understood, an IgE-mediated response was reported for a patient with aspirin-intolerant chronic urticaria (AICU)." | 7.74 | Significant association of FcepsilonRIalpha promoter polymorphisms with aspirin-intolerant chronic urticaria. ( Bae, JS; Kim, SH; Nahm, DH; Park, HS; Suh, CH; Ye, YM; Yoon, HJ, 2007) |
| "To identify genes whose expression is most characteristic of chronic rhinosinusitis and aspirin-sensitive asthma through genome-wide transcriptional profiling of nasal polyp tissue." | 7.74 | Gene expression profiling of nasal polyps associated with chronic sinusitis and aspirin-sensitive asthma. ( Goldsztein, H; Metson, R; Platt, MP; Reh, DD; Stankovic, KM, 2008) |
| "Cysteinyl leukotrienes play a disease-regulating role in rhinosinusitis and asthma, particularly aspirin-sensitive disease." | 7.73 | Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. ( Corrigan, C; Lee, T; Mallett, K; Parikh, A; Roberts, D; Scadding, G; Ying, S, 2005) |
| "To compare quality-adjusted survival and cost among 3 alternative therapies for patients with chronic atrial fibrillation: ximelagatran, warfarin, and aspirin." | 7.73 | Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. ( Gage, BF; O'Brien, CL, 2005) |
| "Data were compared between asthmatic patients who reported exacerbations after aspirin ingestion and those who did not." | 7.73 | Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease. ( Borish, L; Hunt, J; Mascia, K; Patrie, J; Phillips, CD; Steinke, JW, 2005) |
| "There has been ongoing controversy as to whether aspirin should be used in patients with chronic heart failure (CHF)." | 7.73 | Aspirin use in chronic heart failure: what should we recommend to the practitioner? ( Massie, BM, 2005) |
| "Hypersensitivity to aspirin usually takes the form of a clinical syndrome combining chronic rhinitis, nasal polyposis and asthma attacks that are exacerbated by aspirin or other non steroidal anti-inflammatory drugs (NSAIDs)." | 7.73 | [New pathophysiological concepts on aspirin hypersensitivity (Widal syndrome); diagnostic and therapeutic consequences]. ( de Weck, A; Gamboa, P; Sanz, ML, 2005) |
| "To address the hypothesis that expression of 1 or more EP receptors on nasal mucosal inflammatory cells is deficient in patients with aspirin-sensitive compared with nonaspirin-sensitive polypoid rhinosinusitis." | 7.73 | Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells. ( Corrigan, CJ; Lee, TH; Meng, Q; Parikh, A; Scadding, G; Ying, S, 2006) |
| "By inhibiting prostaglandin synthesis, aspirin can interfere with both arterial functional and angiotensin-converting enzyme inhibitor (ACEI) properties and be deleterious in chronic heart failure (CHF)." | 7.72 | Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: a dose-mediated deleterious effect. ( Bergmann, JF; Caulin, C; Cohen-Solal, A; Habib, A; Jondeau, G; Kevorkian, JP; Knellwolf, AL; Lebret, M; Levy, B; Mahé, I; Meune, C; Mourad, JJ; Simoneau, G, 2003) |
| "It is debated whether in patients with chronic heart failure (CHF), aspirin may contrast the clinical benefits of angiotensin-converting enzyme inhibitors (ACEIs)." | 7.72 | Aspirin-angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure: a dose-related adverse effect of aspirin. ( Brambilla, R; Guazzi, M; Guazzi, MD; Reina, G; Tumminello, G, 2003) |
| "The urinary leukotriene E4 (U-LTE4) concentration is significantly increased in patients with aspirin-intolerant asthma (AIA)." | 7.72 | Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. ( Akiyama, K; Higashi, A; Higashi, N; Ishii, T; Kawagishi, Y; Mita, H; Osame, M; Taniguchi, M, 2004) |
| "Although administration of gastroprotective drugs may reduce the risk of peptic ulcers associated with the chronic use of non-steroidal anti-inflammatory drugs or aspirin, no consensus exists as to whether this co-therapy is effective for short-term prevention, particularly in old age." | 7.72 | Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. ( Andriulli, A; Cascavilla, L; Di Mario, F; Franceschi, M; Leandro, G; Longo, MG; Niro, V; Paris, F; Pilotto, A; Scarcelli, C, 2004) |
| "There was a significantly lower rate of primary allograft thrombosis in patients treated with aspirin (none of 105) compared with that in the control group (six (5 per cent) of 121; P = 0." | 7.71 | Influence of aspirin on early allograft thrombosis and chronic allograft nephropathy following renal transplantation. ( Metcalfe, M; Murphy, GJ; Nicholson, ML; Taha, R; Windmill, DC, 2001) |
| "The diagnosis of two patients with aspirin-induced urticaria (AIU) was confirmed by oral provocation with aspirin, other non-steroidal anti-inflammatory drugs, and food additives." | 7.70 | Aspirin-sensitive urticaria: provocation with a leukotriene receptor antagonist. ( Horio, T; Mitsuya, K; Ohnishi-Inoue, Y, 1998) |
| "To investigate the incidence of new thromboembolic (TE) stroke in older persons with chronic atrial fibrillation treated with oral warfarin versus aspirin." | 7.70 | Incidence of new thromboembolic stroke in persons 62 years and older with chronic atrial fibrillation treated with warfarin versus aspirin. ( Ahn, C; Aronow, WS; Gutstein, H; Kronzon, I, 1999) |
| "The aspirin triad (nasal polyposis, asthma and sensitivity to aspirin) is a well-recognized clinical entity, also known as aspirin-induced asthma (AIA)." | 7.70 | Effects of sinus surgery on asthma in aspirin triad patients. ( Higuchi, Y; Kawasaki, M; Nakamura, H; Takahashi, S, 1999) |
| "The value of warfarin in preventing stroke in patients with chronic atrial fibrillation is well established." | 7.70 | Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. ( Almoznino-Sarafian, D; Alon, I; Chachashvily, S; Cohen, N; Gorelik, O; Koopfer, M; Litvinjuk, V; Modai, D; Shteinshnaider, M, 2000) |
| "Biochemical and immunological studies were performed to study hepatic function in 137 patients, out of whom 74 were found to have aspirin-induced bronchial asthma, 23 atopic bronchial asthma, 23 infectious allergic bronchial asthma, 17 chronic persistent hepatitis." | 7.69 | [Liver function in patients with aspirin-induced bronchial asthma]. ( Efimova, NIu; Sizykh, TP, 1994) |
| " In contrast, the sinusitis of the aspirin triad syndrome is often fulminate, expansive, and recurrent, and complications may be more frequent." | 7.69 | Orbital complications of sinusitis in the aspirin triad syndrome. ( Massaro, BM; McFadden, EA; Toohill, RJ; Woodson, BT, 1996) |
| "The effects of chronic anemia on gastric damage induced by ethanol or aspirin have been investigated in rats." | 7.69 | [Chronic anemia protects against gastric damage by alcohol and aspirin. The role of the toxic radicals and lipid peroxidation]. ( Brugnara, L; Casadevall, M; Esser, T; Marroni, CA; Marroni, NP; Piqué, JM, 1996) |
| "An 11-year retrospective study was conducted to evaluate the surgical treatment of sinusitis in aspirin-triad patients." | 7.68 | Surgery for sinusitis and aspirin triad. ( Fink, JN; Kany, RJ; McFadden, EA; Toohill, RJ, 1990) |
| "The role of a commonly ingested food additive, the preservative sodium metabisulfite (MBS), and aspirin (ASA), in chronic asthma has been studied in 29 children." | 7.67 | Role of acetyl salicylic acid and sodium metabisulfite in chronic childhood asthma. ( Mellis, CM; Towns, SJ, 1984) |
| "Incidences of cardiovascular diseases, cancers, gastrointestinal bleeding, ulcers, and cataracts were compared in participants who did and did not take aspirin daily." | 7.67 | Aspirin use and chronic diseases: a cohort study of the elderly. ( Chao, A; Henderson, BE; Paganini-Hill, A; Ross, RK, 1989) |
| "This study attempted to determine whether or not nasal and sinus surgery had a beneficial or deleterious effect upon the asthma of patients with nasal polyps and aspirin idiosyncrasy." | 7.67 | Nasal polypectomy and sinus surgery in patients with asthma and aspirin idiosyncrasy. ( English, GM, 1986) |
| "This study undertook to determine the usefulness of tartrazine and benzoate challenge and dietary avoidance in the management of patients with chronic asthma." | 7.66 | Tartrazine and benzoate challenge and dietary avoidance in chronic asthma. ( Broder, I; Tarlo, SM, 1982) |
| "In a pain management program (200 patients), a group of daily users of oxycodone compound (29 patients) and a subgroup who were taking a "high dose" of oxycodone compound (13 patients) were compared with a group of 171 non-users of oxycodone compound." | 7.66 | Problems with the use of oxycodone compound in patients with chronic pain. ( Maruta, T; Swanson, DW, 1981) |
| "A patient with chronic erythema nodosum of two years' duration, who did not respond to treatment with aspirin or with phenylbutazone therapy, had a dramatic response and improvement when treated with naproxen." | 7.66 | Control of chronic erythema nodosum with naproxen. ( Lehman, CW, 1980) |
| "Although acetylsalicylic acid (aspirin) can cause acute damage to human gastric mucosa, its relationship to chronic gastric ulcer has been less documented." | 7.65 | Aspirin and gastric ulcer. ( Cameron, AJ, 1975) |
| " We conducted network meta-analysis of sinusitis symptoms, heath-related quality of life, rescue oral corticosteroids and surgery, endoscopic and radiologic scores, and adverse events." | 6.82 | Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis. ( Bousquet, J; Brignardello-Petersen, R; Chu, DK; Kennedy, DW; Oykhman, P; Paramo, FA, 2022) |
| "The rate of superimposed preeclampsia was 28." | 6.79 | Aspirin plus calcium supplementation to prevent superimposed preeclampsia: a randomized trial. ( Atallah, AN; Kulay, L; Santos, GM; Sass, N; Souza, EV; Torloni, MR, 2014) |
| "Whether low-dose aspirin prevents preeclampsia is unclear." | 6.69 | Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. ( Caritis, S; Hauth, J; Klebanoff, M; Landon, M; Lindheimer, MD; Meis, P; Miodovnik, M; Paul, R; Sibai, B; Thom, E; Thurnau, G; VanDorsten, P, 1998) |
| "Aspirin was also associated with significantly fewer reinfarctions and strokes." | 6.38 | Aspirin in chronic cardiovascular disease and acute myocardial infarction. ( Hennekens, CH, 1990) |
| "Aspirin sensitivity has a highly significant association with AFRS." | 5.48 | Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study. ( Ahmed, S; Almeyda, R; Anari, S; Carrie, S; Cathcart, R; Clark, A; Coombes, E; Erskine, S; Farboud, A; Hobson, J; Hopkins, C; Jervis, P; Kara, N; Khalil, H; Kumar, N; Mansell, N; Panesaar, J; Philpott, C; Philpott, CM; Prinsley, P; Ray, J; Robertson, A; Salam, M; Sunkaraneni, S; Sunkaraneni, V; Wilson, A; Woods, J, 2018) |
| "Thus treatment with aspirin in the chronic phase of Chagas' disease changes the natural history of the disease and raises the possibility of using it as a new therapeutic approach to the treatment of this aspect of Chagas' disease pathology." | 5.46 | Treatment with low doses of aspirin during chronic phase of experimental Chagas' disease increases oesophageal nitrergic neuronal subpopulation in mice. ( de Almeida Araújo, EJ; de Mello Gonçales Sant'ana, D; Marques de Araújo, S; Martins Moreira, N; Massocatto, CL; Muniz, E; Pinge-Filho, P; Rossi, RM, 2017) |
| "Aspirin-exacerbated respiratory disease (AERD) is characterized by abnormal arachidonic acid metabolism leading to chronic rhinosinusitis with nasal polyposis (CRSwNP), asthma, and upper and/or lower respiratory symptoms after ingestion of cyclooxygenase-1 inhibiting nonsteroidal antiinflammatory drugs." | 5.41 | Aspirin-Exacerbated Respiratory Disease and the Unified Airway: A Contemporary Review. ( Choby, G; Divekar, RD; Hagan, JB; O'Brien, EK; Pinheiro-Neto, CD; Stokken, JK; Walters, BK; Willson, TJ, 2023) |
| "Aspirin-exacerbated respiratory disease (AERD) is a chronic respiratory condition characterized by severe chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic asthma, and respiratory reactions to cyclooxygenase inhibitors." | 5.41 | Aspirin-exacerbated respiratory disease: Updates in the era of biologics. ( Buchheit, KM; Mullur, J, 2023) |
| "This trial will test the efficacy of novel methods for implementing national guidelines to support informed decision-making about taking aspirin in 50-70-year-olds to reduce the risk of CRC and other chronic diseases." | 5.41 | An RCT of a decision aid to support informed choices about taking aspirin to prevent colorectal cancer and other chronic diseases: a study protocol for the SITA (Should I Take Aspirin?) trial. ( Boyd, L; Broun, K; Chondros, P; Emery, J; Fishman, G; Forbes, C; Gutierrez, JM; Jenkins, M; Karnchanachari, N; Macrae, F; Marker, J; McGill, S; McIntosh, J; Milton, S; Novy, K; Saya, S; Shub, M; Taylor, N; Trevena, L; Walter, FM; Whitburn, S, 2021) |
| "In aspirin-treated ACS patients, MRP-8/14 and 11-dehydro-TXB2 were lower versus those not receiving aspirin (P<0." | 5.40 | Circulating myeloid-related protein-8/14 is related to thromboxane-dependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment. ( Davì, G; Di Marco, M; Di Nicola, M; La Barba, S; Lattanzio, S; Liani, R; Mascellanti, M; Paloscia, L; Pascale, S; Santilli, F, 2014) |
| "Aspirin was given as 160 mg/day and clopidogrel as 300 mg loading dose followed by 75 mg/day." | 5.35 | Clopidogrel inhibits platelet aggregation in patients on aspirin with stable chronic angina pectoris. ( Agewall, S; Berglund, M; Gordon, A; Saha, S; Sylvén, C, 2008) |
| "Aspirin was administered for vascular event prevention." | 5.32 | Aspirin withdrawal and acute lower limb ischemia. ( Albaladejo, P; Castier, Y; Francis, F; Geeraerts, T; Lesèche, G; Marty, J, 2004) |
| "We describe a case of thoracic aortic aneurysm complicated by chronic disseminated intravascular coagulation (DIC)." | 5.31 | [Thoracic aortic aneurysm with chronic disseminated intravascular coagulation treated successfully with orally administered camostat mesilate, warfarin and aspirin]. ( Fukuda, N; Nakamori, Y; Oeda, E; Sato, Y; Shimohakamada, Y; Shinohara, K; Takahashi, T; Tominaga, T, 2002) |
| "These post hoc analyses of pooled data from 2 BREATH phase 3 clinical trials, studies 1 and 2 (NCT01287039 and NCT01285323), examined asthma-related outcomes in patients with comorbid, self-reported CRSwNP with and without aspirin sensitivity." | 5.30 | Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps. ( Bardin, P; Bateman, ED; Garin, M; Germinaro, M; Hoyte, FCL; Katial, RK; Korn, S; McDonald, M; Weinstein, SF, 2019) |
| " In patients with prior coronary artery disease or peripheral arterial disease the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial revealed that compared with acetylsalicylic acid alone, dual pathway inhibition with low-dose rivaroxaban (2." | 5.30 | Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. ( Coppens, M; Eikelboom, JWA; Weitz, JI, 2019) |
| " The COMMANDER HF randomized clinical trial evaluated the effects of adding low-dose rivaroxaban to antiplatelet therapy in patients with recent worsening of chronic HF with reduced ejection fraction, coronary artery disease (CAD), and sinus rhythm." | 5.30 | Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. ( Anker, SD; Byra, WM; Cleland, JGF; Deng, H; Fu, M; Greenberg, B; La Police, DA; Lam, CSP; Mehra, MR; Neaton, JD; Nessel, CC; Spiro, TE; van Veldhuisen, DJ; Vanden Boom, CM; Zannad, F, 2019) |
| "Aspirin-induced chronic rhinosinusitis (CRS) is a severe progressive persistent disease, usually associated with nasal polyps (NPs)." | 5.30 | Efficacy of hypertonic (2.3%) sea water in patients with aspirin-induced chronic rhinosinusitis following endoscopic sinus surgery. ( Barać, A; Gaćeša, D; Jožin, SM; Kovačević, SV; Perić, A; Perić, AV, 2019) |
| "In patients with chronic coronary artery disease or peripheral artery disease and a history of mild or moderate HF, combination rivaroxaban and aspirin compared with aspirin alone produces similar relative but larger absolute benefits than in those without HF." | 5.30 | Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. ( Avezum, A; Bhatt, DL; Bosch, J; Branch, KR; Cheng, RK; Connolly, SJ; Eikelboom, JW; Fox, KAA; Maggioni, AP; Probstfield, JL; Shestakovska, O; Yusuf, S, 2019) |
| "They found that in the course of treatment proteinuria did not change and glomerular filtration declined insignificantly." | 5.28 | [The effect of acetylsalicylic acid and dipyridamole on glomerular filtration and proteinuria in chronic glomerulonephritis]. ( Jáchymová, M; Knotková, V; Nĕmecek, K; Petrů, I, 1990) |
| " Failures (22%) were due to such factors as insufficient dosage at the very beginning of our experience or severe depressive syndrome." | 5.27 | [Chronic refractory pain in cancer patients. Value of the spinal injection of lysine acetylsalicylate. 60 cases]. ( Abergel, A; Amiot, JF; Babinet, P; Boule, D; Glowinski, J; Hardy, F; Mechali, D; Palacci, JH; Pellerin, M; Wingtin, LN, 1987) |
| " Three weeks later these rats were orally dosed each day with aspirin (375 mg/kg) for six months." | 5.27 | Molecular weight of gastric mucus glycoprotein is a determinant of the degree of subsequent aspirin induced chronic gastric ulceration in the rat. ( Bagshaw, PF; Munster, DJ; Wilson, JG, 1987) |
| "Treatment with Verapamil or aspirin reduced both chronic hypoxic pulmonary hypertension and the hypertrophy of the right ventricle." | 5.26 | Effects of verapamil and aspirin on experimental chronic hypoxic pulmonary hypertension and right ventricular hypertrophy in rats. ( Kentera, D; Susić, D; Zdravković, M, 1979) |
| "Numerous open trials have demonstrated the beneficial clinical effects of aspirin desensitization (AD) in patients with aspirin-induced asthma (AIA)." | 5.19 | Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. ( Bochenek, G; Ćmiel, A; Gielicz, A; Niżankowska-Mogilnicka, E; Plutecka, H; Sanak, M; Stręk, P; Świerczyńska-Krępa, M; Szczeklik, A, 2014) |
| "To determine the effect of aspirin on ulcer healing rate in patients with chronic venous insufficiency, and to establish prognostic factors that influence ulcer evolution." | 5.16 | Influence of aspirin therapy in the ulcer associated with chronic venous insufficiency. ( Antonio, J; del Río Solá, ML; Fajardo, G; Vaquero Puerta, C, 2012) |
| "001) by adjusted-dose warfarin compared with aspirin/low-dose warfarin; there was no difference in major hemorrhage (5 patients versus 6 patients, respectively)." | 5.15 | Warfarin in atrial fibrillation patients with moderate chronic kidney disease. ( Asinger, RW; Hart, RG; Herzog, CA; Pearce, LA, 2011) |
| "Twenty-one adult patients with asthma, chronic polypoid sinusitis, and a convincing history of acute respiratory reaction to the ingestion of aspirin or nonsteroidal anti-inflammatory drugs were selected." | 5.14 | The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases. ( Alam, R; Katial, RK; Leung, R; Prasertsuntarasai, T; Strand, M; Zheng, W, 2010) |
| "The HOT (Hypertension Optimal Treatment) study randomly assigned participants with diastolic hypertension to aspirin (75 mg) or placebo." | 5.14 | Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. ( Cass, A; Chalmers, J; Gallagher, MP; Jardine, MJ; Lambers Heerspink, HJ; Ninomiya, T; Perkovic, V; Turnbull, F; Zanchetti, A; Zoungas, S, 2010) |
| "The objective was to determine the main parameters taken into account for the decision of antithrombotic treatment of atrial fibrillation (AF) by vitamin K antagonist or aspirin." | 5.13 | Which parameters differ in very old patients with chronic atrial fibrillation treated by anticoagulant or aspirin? Antithrombotic treatment of atrial fibrillation in the elderly. ( Delaunay, O; Doucet, J; Gréboval-Furstenfeld, E; M'bello, L; Moirot, P; Mouton-Schleifer, D; Pesqué, T; Tavildari, A, 2008) |
| "Aspirin-exacerbated respiratory disease (AERD) is characterized by the clinical triad of chronic rhinosinusitis with nasal polyps, asthma, and an intolerance to medications that inhibit the cycloxgenase-1 enzyme." | 5.12 | The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, ( Baptist, AP; Borish, L; Bosso, JV; Buchheit, KM; Cahill, KN; Campo, P; Cho, SH; Jerschow, E; Keswani, A; Laidlaw, TM; Levy, JM; Nanda, A; Stevens, WW; White, AA, 2021) |
| " The evidence is uncertain if warfarin has any effect on all-cause death compared to placebo or no treatment, but it may increase the risk of major bleeding events." | 5.12 | Anticoagulation versus placebo for heart failure in sinus rhythm. ( Kozieł, M; Lip, GY; Shantsila, E, 2021) |
| "During a 1-year treatment period, simvastatin, 20 mg/d, produced a sustained reduction of approximately one quarter in low-density lipoprotein cholesterol levels, with no evidence of toxicity, and aspirin, 100 mg/d, did not substantially increase the risk for a major bleeding episode." | 5.11 | First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. ( Altmann, P; Armitage, J; Baigent, C; Baxter, A; Cairns, HS; Collins, R; Foley, RN; Frighi, V; Kourellias, K; Landray, M; Leaper, C; Ratcliffe, PJ; Rogerson, M; Scoble, JE; Tomson, CR; Warwick, G; Wheeler, DC, 2005) |
| "This study was designed to investigate whether or not combination aspirin-clopidogrel therapy would reduce markers of thrombogenesis and platelet activation in atrial fibrillation (AF), in a manner similar to warfarin." | 5.10 | A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. ( Blann, AD; Chin, BS; Kamath, S; Lip, GY, 2002) |
| "Heightened platelet reactivity may affect the occurrence of ischemic events in patients with coronary artery disease on aspirin therapy." | 5.10 | The stratification of platelet reactivity and activation in patients with stable coronary artery disease on aspirin therapy. ( Bliden, KP; Gurbel, PA, 2003) |
| "We sought to determine the effect of aspirin on the venodilator effect of furosemide in patients with chronic heart failure (CHF) BACKGROUND: Furosemide has an acute venodilator effect preceding its diuretic action, which is blocked by nonsteroidal anti-inflammatory, drugs." | 5.09 | Aspirin inhibits the acute venodilator response to furosemide in patients with chronic heart failure. ( Davie, AP; Jhund, PS; McMurray, JJ, 2001) |
| "The results of this comparative study demonstrate that montelukast orally administered once a day is very effective for the treatment of cutaneous symptoms in patients with chronic urticaria due to food additives and/or ASA." | 5.09 | Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. ( Corrocher, R; Di Lorenzo, G; Pacor, ML, 2001) |
| "To evaluate the effectiveness of topical application of aspirin in chloroform as an adjuvant in the management of chronic neurogenic pain." | 5.08 | Aspirin in chloroform as an effective adjuvant in the management of chronic neurogenic pain. ( Bhattacharji, S; Tharion, G, 1997) |
| "We performed a double-blind, crossover, placebo-controlled study on the effect of fluticasone propionate (FP) treatment on chronic eosinophilic rhinosinusitis in 15 patients with aspirin-induced asthma (AIA)." | 5.08 | Intranasal fluticasone propionate for chronic eosinophilic rhinitis in patients with aspirin-induced asthma. ( Duplaga, M; Mastalerz, L; Milewski, M; Nizankowska, E; Szczeklik, A, 1997) |
| "The comparative study of the efficacy of coumadin and aspirin in primary cardioembolic stroke prevention of chronic rheumatic heart disease (mitral stenosis) with atrial fibrillation was conducted at Siriraj Hospital, Mahidol University, Bangkok, Thailand." | 5.07 | A comparative study of coumadin and aspirin for primary cardioembolic stroke and thromboembolic preventions of chronic rheumatic mitral stenosis with atrial fibrillation. ( Chaithiraphan, S; Opartkiattikul, N; Poungvarin, N; Viriyavejakul, A, 1994) |
| "This study was undertaken to determine if a standard dose of aspirin interacts relevantly with the circulatory effects of enalapril in severe heart failure." | 5.07 | Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. ( Hall, D; Rudolph, W; Zeitler, H, 1992) |
| "To evaluate the efficacy of low-dose aspirin in the primary prevention of myocardial infarction among patients with chronic stable angina." | 5.07 | Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. ( Buring, JE; Gaziano, JM; Hennekens, CH; Manson, JE; Ridker, PM, 1991) |
| "Seventeen chronic urticaria patients with a history suggestive of acetylsalicylic acid (ASA, Aspirin)-intolerance were challenged with ASA; only 2 patients showed marked clinical reactions." | 5.06 | Increased urinary excretion of the histamine metabolite N tau-methylhistamine during acetylsalicylic acid provocation in chronic urticaria patients. ( de Monchy, JG; Doeglas, HM; Kardaun, SH; Los, P; Oosting, E, 1990) |
| "From November, 1985, to June, 1988, 1007 outpatients with chronic non-rheumatic atrial fibrillation (AF) entered a randomised trial; 335 received anticoagulation with warfarin openly, and in a double-blind study 336 received aspirin 75 mg once daily and 336 placebo." | 5.06 | Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. ( Andersen, B; Andersen, ED; Boysen, G; Godtfredsen, J; Petersen, P, 1989) |
| "In this review, the role of the rivaroxaban-plus-aspirin approach (dual pathway inhibition - DPI) in patients with chronic coronary syndrome (CCS) and to perform practical recommendations about its use was updated." | 5.05 | Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition. ( Almendro-Delia, M; Bellmunt-Montoya, S; Cosín-Sales, J; García-Alegría, J; García-Moll, X; Gómez-Doblas, JJ; González-Juanatey, JR; Hernández, JL; Lozano, FS; Riambau, V; Suarez Fernández, C, 2020) |
| "Twenty patients with chronic urticaria exacerbated by aspirin or tartrazine were challenged with the offending substance after pre-treatment with either oral sodium cromoglycate or placebo in a double-blind, crossover study." | 5.05 | Sodium cromoglycate and provocation tests in chronic urticaria. ( Bellani, M; Cornelli, U; Ortolani, C; Pastorello, E; Zanussi, C, 1982) |
| "Controlled clinical research has been carried out on the activity and tolerance of a new active principle, guacetisal (Broncaspin) obtained from the esterification of acetylsalicylic acid with guaiacol, in the treatment of chronic bronchitis." | 5.05 | [Controlled clinical study of the treatment of chronic bronchitis with guacetisal]. ( Caltagirone, S; Crimi, N; Cusmano, F; Di Maria, GU; Palermo, F; Vagliasindi, M, 1981) |
| "Naproxen at 10 mg per kg body weight was compared with aspirin at 80 mg per kg body weight in children suffering from juvenile chronic polyarthritis." | 5.04 | Naproxen in juvenile chronic polyarthritis. ( Ansell, BM; Engler, C; Hall, M; Hanna, DB; Moran, H, 1979) |
| "In 131 patients with chronic urticaria, including physical urticarias, oral provocation tests were done with aspirin." | 5.04 | Reactions to aspirin and food additives in patients with chronic urticaria, including the physical urticarias. ( Doeglas, HM, 1975) |
| "We know from adult randomised controlled trials that some NSAIDs, such as ibuprofen, naproxen, and aspirin, can be effective in certain chronic pain conditions." | 4.95 | Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents. ( Anderson, B; Cooper, TE; Eccleston, C; Fisher, E; Wilkinson, NM, 2017) |
| "Aspirin-Exacerbated Respiratory Disease (AERD) and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) are both characterized by the presence of chronic sinonasal inflammation and nasal polyps." | 4.93 | Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis. ( Schleimer, RP; Stevens, WW, 2016) |
| "Aspirin-exacerbated respiratory disease is defined by the clinical tetrad of aspirin sensitivity, nasal polyps, asthma, and chronic rhinosinusitis." | 4.93 | Current complications and treatment of aspirin-exacerbated respiratory disease. ( Cook, KA; Stevenson, DD, 2016) |
| "Aspirin-exacerbated respiratory disease (AERD) is a clinical condition which results in adverse upper and lower respiratory symptoms, particularly rhinitis, conjunctivitis, bronchospasm, and/or laryngospasm, following exposure to cyclooxygenase-1 (COX-1) inhibiting drugs, namely aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)." | 4.91 | Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD). ( Dazy, KM; Simon, RA; Waldram, JD, 2015) |
| "Hypersensitivity to acetylsalicylic acid (ASA) is characterized by the co-occurrence of symptoms so-called aspirin triad, which include bronchial asthma, chronic rhinitis and sinusitis and the nasal mucosa polyps." | 4.91 | [Hypersensitivity to acetylsalicylic acid]. ( Skrętkowicz, J; Wojtczak, A, 2015) |
| "Chronic rhinosinusitis patients with nasal polyps can be aspirin sensitive or aspirin tolerant." | 4.90 | Topical nasal lysine aspirin in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis with nasal polyposis. ( Parikh, A; Scadding, GK, 2014) |
| "While previous meta-analysis have investigated the efficacy of cilostazol in the secondary prevention of ischemic stroke, they were criticized for their methodology, which confused the acute and chronic phases of stroke." | 4.90 | The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population--an updated meta-analysis. ( Chen, S; Malaguit, J; Pu, J; Shi, L; Xu, L; Zhang, J, 2014) |
| "This review is set to revisit the pathogenesis of aspirin-exacerbated respiratory disease (AERD), the diagnostic method used, and finally the real impact of aspirin desensitization on chronic sinusitis with nasal polyposis (CRSwNP) in aspirin intolerant patients." | 4.87 | Role of aspirin desensitization in the management of chronic rhinosinusitis. ( Rizk, H, 2011) |
| "The purpose of this review is to highlight recent advances in gene-expression profiling of nasal polyps in patients with chronic rhinosinusitis and aspirin-sensitive asthma." | 4.85 | Gene-expression signatures of nasal polyps associated with chronic rhinosinusitis and aspirin-sensitive asthma. ( Metson, R; Platt, M; Stankovic, K, 2009) |
| "Aspirin-exacerbated respiratory disease (AERD) is a chronic inflammatory disease characterized by chronic rhinosinusitis, nasal polyposis, asthma, and airway reactivity to aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs)." | 4.84 | The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis. ( Williams, AN; Woessner, KM, 2008) |
| "Recent findings supporting mechanisms that promote eosinophilic infiltration are discussed and include the following subcategories: super antigen-induced eosinophilic chronic rhinosinusitis, allergic fungal sinusitis, nonallergic fungal eosinophilic chronic rhinosinusitis, and aspirin-exacerbated eosinophilic chronic rhinosinusitis." | 4.82 | Categorization of eosinophilic chronic rhinosinusitis. ( Ferguson, BJ, 2004) |
| " However, recently there has been some progress in elucidating the etiology of nasal polyposis, especially regarding tissue eosinophilia as well as the role of aspirin intolerance and eicosanoid mediators." | 4.82 | Current concepts in therapy of chronic rhinosinusitis and nasal polyposis. ( Gosepath, J; Mann, WJ, 2005) |
| "In some patients with chronic idiopathic urticaria (CIU), aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase 1 (COX-1) precipitate wheals and swelling." | 4.82 | Mechanism of chronic urticaria exacerbation by aspirin. ( Mastalerz, L; Setkowicz, M; Szczeklik, A, 2005) |
| " Epidermal growth factor prevents efficiently the experimentally induced acute gastric mucosal lesions induced by aspirin, absolute ethanol, HCl, NaCl, immobilization, and immersion and it accelerates the healing of acetic acid-induced chronic gastric and cysteamine-induced chronic duodenal ulcers." | 4.79 | [Growth factors in experimental ulcer]. ( Buzás, G, 1994) |
| "In the absence of randomized, controlled trials of low-dose amiodarone in atrial fibrillation or a randomized, controlled trial of ventricular rate control versus antifibrillatory therapy, a Markov decision analysis is useful in comparing different therapeutic strategies for atrial fibrillation." | 4.79 | Therapeutic strategies for atrial fibrillation. The value of decision analysis. ( Disch, DL; Greenberg, ML; Malenka, DJ, 1996) |
| " Patients with rheumatic heart disease complicated by atrial fibrillation should receive long-term warfarin therapy to reduce the risk of stroke unless an absolute contraindication exists." | 4.78 | Anticoagulant therapy for atrial fibrillation. Recommendations from major studies. ( Kahn, JK, 1992) |
| "Aspirin desensitization (AD) is effective in relieving asthma and sinonasal outcomes in patients with non-steroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD)." | 4.31 | Aspirin desensitization following endoscopic sinus surgery is effective in patients with nonsteroidal antiinflammatory drug exacerbated respiratory disease. ( Anadolu, Y; Atmiş, EÖ; Aydin, Ö; Çelik, GE; Yorulmaz, İ, 2023) |
| "These evidence-based guidelines support patients, clinicians, and other stakeholders in decisions about the use of intranasal corticosteroids (INCS), biologics, and aspirin therapy after desensitization (ATAD) for the management of chronic rhinosinusitis with nasal polyposis (CRSwNP)." | 4.31 | The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis. ( Bernstein, JA; Bognanni, A; Chu, DK; Ellis, AK; Golden, DBK; Greenhawt, M; Horner, CC; Ledford, DK; Lieberman, J; Luong, AU; Orlandi, RR; Oykhman, P; Peters, AT; Rank, MA; Samant, SA; Shaker, MS; Soler, ZM; Stevens, WW; Stukus, DR; Wang, J, 2023) |
| "Aspirin-exacerbated respiratory disease (AERD) is a unique and often clinically severe disease affecting a subgroup of adults with asthma and chronic rhinosinusitis with nasal polyposis." | 4.31 | Mechanistic and clinical updates in AERD: 2021-2022. ( Cahill, KN; Stevens, WW, 2023) |
| " Quantitative and descriptive analyses of age, gender, nationality, presence of polyps, aspirin sensitivity, presence of urticaria, asthma, and allergies were performed." | 4.31 | Demographic and clinical profile of patients with chronic rhinosinusitis in Saudi Arabia. ( Alanazy, F; Alfallaj, R; Almousa, H; Aloulah, M; Alrasheed, A; Alromaih, S; Alroqi, AS; Alsaleh, S; Dousary, SA; Ismail, D; Mahjoub, S; Obaid, SB, 2023) |
| "Aspirin-exacerbated respiratory disease (AERD) consists of chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, and hypersensitivity to aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)." | 4.31 | Association Between Aspirin-Exacerbated Respiratory Disease and Atherosclerotic Cardiovascular Disease: A Retrospective Review of US Claims Data. ( Adame, MJ; Kuo, YF; Raji, M; Shan, Y; Tripple, JW; Zhang, Y, 2023) |
| "Aspirin-exacerbated respiratory disease (AERD) is a syndrome characterised by chronic rhinosinusitis, nasal polyps, asthma and aspirin intolerance." | 4.02 | Transcriptome Analysis Identifies Doublesex and Mab-3 Related Transcription Factor (DMRT3) in Nasal Polyp Epithelial Cells of Patients Suffering from Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease (AERD). ( de Graaf, J; Gratziou, C; Jiménez-Chobillon, MA; Porras Gutiérrez de Velasco, R; Priyadharshini, VS; Ramírez-Jiménez, F; Teran, LM, 2021) |
| "Aspirin-exacerbated respiratory disease (AERD) is a severe form of chronic rhinosinusitis with nasal polyps (CRSwNP) accompanied by asthma and an aspirin intolerance." | 3.96 | The time course of nasal cytokine secretion in patients with aspirin-exacerbated respiratory disease (AERD) undergoing aspirin desensitization: preliminary data. ( Eder, K; Gellrich, D; Gröger, M; Högerle, C; Pfrogner, E; San Nicoló, M, 2020) |
| "Aspirin-exacerbated respiratory disease (AERD) represents a severe endotype of chronic rhinosinusitis with nasal polyposis." | 3.96 | Surgical outcomes in aspirin-exacerbated respiratory disease without aspirin desensitization. ( Cottrell, J; Grose, E; Lee, DJ; Lee, JK; Lee, JM; Sykes, J; Yip, J, 2020) |
| " CRSwNP may be associated with comorbidity, mainly concerning asthma, aspirin intolerance, and allergy." | 3.96 | Clinical-Cytological-Grading and phenotyping in patients with chronic rhinosinusitis with nasal polyps: the relevance in clinical practice. ( Cassano, M; Ciprandi, G; Gelardi, M; Porro, G; Quaranta, N; Quaranta, V; Study Group On CRSwNP, I, 2020) |
| "Background Aspirin-exacerbated respiratory disease (AERD), also known as Samter's triad or aspirin (ASA)-intolerant asthma, affects 7% of asthmatics and has a higher prevalence in those with chronic rhinosinusitis and concomitant nasal polyposis." | 3.88 | Long-term Clinical Outcomes of Aspirin Desensitization With Continuous Daily Aspirin Therapy in Aspirin-exacerbated Respiratory Disease. ( Waldram, JD; Walters, KM; White, AA; Woessner, KM, 2018) |
| "This study aimed to estimate the risk of bleeding following minor oral surgical procedures and uninterrupted aspirin therapy in high-risk patients or patients with existing chronic diseases compared to patients who did not use aspirin during minor oral surgery at a public hospital." | 3.85 | Risk of Hemorrhage Attributed to Underlying Chronic Diseases and Uninterrupted Aspirin Therapy of Patients Undergoing Minor Oral Surgical Procedures: A Retrospective Cohort Study. ( Limsawan, S; Rojanaworarit, C, 2017) |
| "The consequences of using aspirin (ASA) for the pathogenesis of Chagas disease are unclear." | 3.85 | Aspirin prevents atrophy of esophageal nitrergic myenteric neurons in a mouse model of chronic Chagas disease. ( Araújo, EJ; Massocatto, CL; Moreira, NM; Muniz, E; Pinge-Filho, P; Rossi, RM; Sant'Ana, DM, 2017) |
| "Aspirin hypersensitivity associated with chronic rhinosinusitis-with or without nasal polyposis-and asthma resistant to conventional therapy defines the aspirin-exacerbated respiratory disease (AERD)." | 3.85 | Omalizumab in patient with aspirin exacerbated respiratory disease and chronic idiopathic urticaria. ( Cutrera, R; Di Marco, A; Porcaro, F, 2017) |
| "Oral aspirin challenge (OAC) reveals aspirin-exacerbated respiratory disease (AERD) in approximately 50% of unselected patients with chronic rhinosinusitis with nasal polyposis (CRSwNP)." | 3.85 | Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without AERD: a cross-sectional and longitudinal study. ( Gudziol, V; Hummel, T; Koschel, D; Michel, M; Sonnefeld, C, 2017) |
| "Aspirin use in patients with chronic systolic heart failure and mild symptoms did not substantially reduce the overall beneficial effects of the MRA eplerenone contrary to what has been described in some studies with ACE inhibitors." | 3.83 | Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study. ( Chin, KL; Collier, TJ; Krum, H; McMurray, JJ; Pitt, B; Pocock, SJ; Swedberg, K; Turgonyi, E; van Veldhuisen, DJ; Vincent, J; Zannad, F, 2016) |
| " In our previous studies, we showed that the TNFA -308A allele is a genetic predisposition factor in a subgroup of aspirin-sensitive (ASA+) CRS patients suffering from nasal polyps (NP) in the Hungarian population." | 3.81 | A conserved linkage group on chromosome 6, the 8.1 ancestral haplotype, is a predisposing factor of chronic rhinosinusitis associated with nasal polyposis in aspirin-sensitive Hungarians. ( Bella, Z; Hirschberg, A; Kadocsa, E; Kemény, L; Kiricsi, Á; Polyánka, H; Révész, M; Szabó, K; Szabó, Z; Széll, M; Vóna, I, 2015) |
| "To demonstrate that quality-of-life outcomes after endoscopic sinus surgery are not compromised in patients with Samter's triad (asthma, nasal polyps, aspirin sensitivity) when compared to patients with eosinophilic chronic rhinosinusitis with nasal polyposis (eCRSwP) who are not aspirin sensitive." | 3.80 | Aspirin sensitivity does not compromise quality-of-life outcomes in patients with Samter's triad. ( Comer, BT; Jang, DW; Kountakis, SE; Lachanas, VA, 2014) |
| " CRSwNP was subdivided into allergic fungal rhinosinusitis (AFRS), aspirin-exacerbated respiratory disease (AERD), and other CRSwNP." | 3.80 | Impact of vitamin D deficiency upon clinical presentation in nasal polyposis. ( Mulligan, JK; Schlosser, RJ; Schmedes, GW; Soler, ZM; Storck, K, 2014) |
| " The levels were not significantly different according to urticaria symptom score, symptom control status, and aspirin intolerance." | 3.80 | Elevated platelet activation in patients with chronic urticaria: a comparison between aspirin-intolerant and aspirin-tolerant groups. ( Kim, SH; Palikhe, NS; Palikhe, S; Park, HS; Shin, YS; Yoo, HS, 2014) |
| "Samter's triad is a well described condition manifesting as chronic rhinosinusitis with nasal polyposis, asthma and aspirin intolerance in a non-atopic individual." | 3.80 | Samter's triad with aural involvement: a novel approach to management. ( Heywood, R; Narula, A; Sethukumar, P, 2014) |
| " The impact of surgery and factors such as the presence of polyps, asthma, and aspirin sensitivity on the bacterial state are poorly understood." | 3.79 | The bacteriology of chronic rhinosinusitis and the pre-eminence of Staphylococcus aureus in revision patients. ( Bassiouni, A; Cleland, EJ; Wormald, PJ, 2013) |
| "Non-steroidal anti-inflammatory drugs (NSAIDs), especially aspirin, and food additives (FAs) may exacerbate allergic symptoms in patients with chronic idiopathic urticaria and food-dependent exercise-induced anaphylaxis (FDEIA)." | 3.79 | Aspirin augments IgE-mediated histamine release from human peripheral basophils via Syk kinase activation. ( Hide, M; Hiragun, T; Ishii, K; Matsuo, H; Mihara, S; Morita, H; Ooi, M; Takahagi, S; Urata, K; Yanase, Y; Yokooji, T, 2013) |
| "The benefits of taking of aspirin, clopidogrel, and warfarin in relation to cardiovascular mortality and re-hospitalization in chronic heart failure (HF) patients have been called into question." | 3.78 | Aspirin, clopidogrel, and warfarin use and outcomes in a cohort of 580 patients discharged after hospitalization for decompensated heart failure. ( Celikyurt, U; Ertaş, G; Kılıç, T; Kozdağ, G; Sahin, T; Ural, D; Yaymacı, M, 2012) |
| " We aimed at assessing the predictors of higher plasma levels of TxB2, the stable metabolite of TxA2, in consecutive patients presenting with non-ST-elevation acute coronary syndrome (NSTE-ACS) on previous aspirin (ASA) treatment undergoing coronary angiography." | 3.78 | Predictors of thromboxane levels in patients with non-ST-elevation acute coronary syndromes on chronic aspirin therapy. ( Biasucci, LM; Burzotta, F; Cataneo, L; Cosentino, N; Crea, F; Fracassi, F; Giubilato, S; Leo, A; Leone, AM; Narducci, ML; Niccoli, G; Porto, I; Pulcinelli, FM; Trani, C, 2012) |
| "SPINK5 single-nucleotide polymorphisms (SNPs) and SPINK5 expression levels were correlated with CRS without (CRSsNP) and with nasal polyps (CRSwNP), aspirin intolerance, asthma, and allergies." | 3.78 | Low SPINK5 expression in chronic rhinosinusitis. ( Brieger, J; Fruth, K; Goebel, G; Gosepath, J; Koutsimpelas, D; Mann, WJ; Schmidtmann, I, 2012) |
| "As the management of patients treated with anticoagulants and antiplatelet drugs entails balancing coagulation levels, we evaluated the net clinical benefit of warfarin and aspirin on stroke in a large cohort of patients with atrial fibrillation (AF)." | 3.78 | A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case-control study. ( Azoulay, L; Dell'Aniello, S; Langleben, D; Renoux, C; Simon, TA; Suissa, S, 2012) |
| "Chronic rhinosinusitis (CRS) with nasal polyposis (NP) may be associated with hypersensitivity to nonsteroidal anti-inflammatory drugs, representing a syndrome of aspirin-exacerbated respiratory disease (AERD)." | 3.78 | Incidence of aspirin hypersensitivity in patients with chronic rhinosinusitis and diagnostic value of urinary leukotriene E4. ( Celejewska-Wójcik, N; Cybulska, A; Hartwich, P; Hydzik-Sobocińska, K; Januszek, R; Mastalerz, L; Nieckarz, R; Oleś, K; Sanak, M; Stręk, P; Szaleniec, J; Wójcik, K, 2012) |
| "Aspirin is the most commonly used antiplatelet agent in patients with coronary artery disease (CAD)." | 3.78 | Aspirin sensitivity and coronary artery disease: implications for the practicing cardiologist. ( Das, P; Lieberman, P; Pattanaik, D, 2012) |
| " cruzi infection (Brazil strain) beginning 5 days post infection (dpi) with aspirin (ASA) increased mortality (2-fold) and parasitemia (12-fold)." | 3.77 | Aspirin treatment of mice infected with Trypanosoma cruzi and implications for the pathogenesis of Chagas disease. ( Ashton, AW; Collado, JE; Factor, SM; Fine, EJ; Huang, H; Jelicks, LA; Koba, W; Machado, FS; Mukherjee, S; Oz, HS; Prado, CM; Tanowitz, HB; Weiss, LM; Zhao, D, 2011) |
| "The present study was undertaken to assess the activity/anti-inflammatory potential of Linum usitatissimum fixed oil against castor oil-induced diarrhoea, turpentine oil-induced joint oedema, formaldehyde and Complete Freund's Adjuvant (CFA)-induced arthritis in Wistar albino rats." | 3.76 | Therapeutic effect of Linum usitatissimum (flaxseed/linseed) fixed oil on acute and chronic arthritic models in albino rats. ( Kaithwas, G; Majumdar, DK, 2010) |
| "There is a well-recognized association of aspirin sensitivity, aspirin-induced asthma, nasal polyposis or sinusitis, known as Samter's triad." | 3.76 | Aspirin sensitivity and the nose. ( Douglas, GC; Karkos, PD; Swift, AC, 2010) |
| "It was the aim of this study to investigate the prevalence of otologic manifestations in a cohort of Samter's syndrome patients (nasal polyps with chronic rhinosinusitis, aspirin intolerance and asthma)." | 3.75 | Otologic manifestations in Samter's syndrome. ( Caversaccio, M; Häusler, R; Helbling, A, 2009) |
| "To investigate the functional variability of HNMT gene in relation to genetic polymorphisms in patients with aspirin intolerant chronic urticaria (AICU)." | 3.75 | Histamine N-methyltransferase 939A>G polymorphism affects mRNA stability in patients with acetylsalicylic acid-intolerant chronic urticaria. ( Cho, BY; Hur, GY; Kang, YM; Kim, SH; Park, HS; Ye, YM, 2009) |
| "The objective of this study was to evaluate the rate of stroke associated with aspirin and warfarin in routine clinical practice." | 3.75 | How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database. ( Gallagher, AM; Plumb, JM; Rietbrock, S; van Staa, TP, 2009) |
| " Severe uncontrolled allergic rhinitis, nonallergic rhinitis, chronic rhinosinusitis, aspirin-exacerbated respiratory diseases, or occupational airway diseases are defined as SCUADs." | 3.75 | Unmet needs in severe chronic upper airway disease (SCUAD). ( Bachert, C; Bousquet, J; Canonica, GW; Casale, TB; Cruz, AA; Lockey, RJ; Zuberbier, T, 2009) |
| " The patient had been treated for chronic heart failure and prescribed 100 mg/day of acetylsalicylic acid (aspirin) for its antiplatelet effect." | 3.75 | Detection of presumed hemorrhage in the ampullar endolymph of the semicircular canal: a case report. ( Ishihara, S; Iwano, S; Naganawa, S; Nakashima, T; Sone, M, 2009) |
| "Substituted thiazoles with different structural features were synthesized and screened for their anti-inflammatory activity in acute carrageenin induced rat paw edema model and chronic formalin induced rat paw edema model." | 3.74 | 2-Amino-5-thiazolyl motif: a novel scaffold for designing anti-inflammatory agents of diverse structures. ( Franklin, PX; Nivsarkar, M; Padh, H; Pillai, AD; Rathod, PD; Sudarsanam, V; Vasu, KK; Yerande, S, 2008) |
| "Aim of the study was to investigate in dynamics peculiarities of hemostasis including platelet aggregation and activity of NADP-dependent dehydrogenases in platelets, as well as prevalence of resistance to aspirin in patients with functional class II-III chronic heart failure (CHF)." | 3.74 | [Peculiarities of hemostasis, metabolic activity of platelets, and rate of aspirin resistance in patients with chronic heart failure after aorto-coronary bypass surgery]. ( Grinshteĭn, IIu; Grinshteĭn, IuI; Savchenko, AA; Savchenko, EA, 2008) |
| " In these cases, CRS tends to be associated with bronchial asthma (BA), especially, aspirin-intolerant asthma (AIA)." | 3.74 | Correlation between the prostaglandin D(2)/E(2) ratio in nasal polyps and the recalcitrant pathophysiology of chronic rhinosinusitis associated with bronchial asthma. ( Haruna, S; Moriyama, H; Otori, N; Yoshikawa, M; Yoshimura, T, 2008) |
| " We investigated the clinical significance of serum specific immunoglobulin E (lgE) to the staphylococcal superantigens staphylococcal enterotoxin A (SEA), staphylococcal enterotoxin B (SEB), and toxic shock syndrome toxin (TSST)-1 in patients with chronic urticaria (CU), focusing on the differences in these prevalences between aspirin-intolerant CU (AICU) and aspirin-tolerant CU (ATCU) patients." | 3.74 | Association of specific IgE to staphylococcal superantigens with the phenotype of chronic urticaria. ( Hur, GY; Kim, HM; Kim, SH; Park, HJ; Park, HS; Ye, YM, 2008) |
| "Although the mechanism that underlies aspirin hypersensitivity is not completely understood, an IgE-mediated response was reported for a patient with aspirin-intolerant chronic urticaria (AICU)." | 3.74 | Significant association of FcepsilonRIalpha promoter polymorphisms with aspirin-intolerant chronic urticaria. ( Bae, JS; Kim, SH; Nahm, DH; Park, HS; Suh, CH; Ye, YM; Yoon, HJ, 2007) |
| "We conducted a retrospective study to determine the prevalence of Samter's triad (nasal polyps, asthma, and aspirin sensitivity) in 208 consecutively presenting patients who had undergone functional endoscopic sinus surgery (FESS) for chronic rhinosinusitis from September 2001 through August 2003." | 3.74 | The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery. ( Kim, JE; Kountakis, SE, 2007) |
| "To identify genes whose expression is most characteristic of chronic rhinosinusitis and aspirin-sensitive asthma through genome-wide transcriptional profiling of nasal polyp tissue." | 3.74 | Gene expression profiling of nasal polyps associated with chronic sinusitis and aspirin-sensitive asthma. ( Goldsztein, H; Metson, R; Platt, MP; Reh, DD; Stankovic, KM, 2008) |
| "Cysteinyl leukotrienes play a disease-regulating role in rhinosinusitis and asthma, particularly aspirin-sensitive disease." | 3.73 | Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. ( Corrigan, C; Lee, T; Mallett, K; Parikh, A; Roberts, D; Scadding, G; Ying, S, 2005) |
| "To compare quality-adjusted survival and cost among 3 alternative therapies for patients with chronic atrial fibrillation: ximelagatran, warfarin, and aspirin." | 3.73 | Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. ( Gage, BF; O'Brien, CL, 2005) |
| " albicans and vehicle inoculation on gastric secretion and healing of gastric ulcers induced by acetic acid in rats treated with 1) ranitidine (30 mg kg(-1) day(-1) s." | 3.73 | Influence of gastric colonization with Candida albicans on ulcer healing in rats: effect of ranitidine, aspirin and probiotic therapy. ( Bogdal, J; Brzozowski, T; Budak, A; Drozdowicz, D; Hahn, EG; Konturek, PC; Konturek, SJ; Kwiecien, S; Pawlik, WW; Stachura, J; Zwolinska-Wcislo, M, 2005) |
| "Data were compared between asthmatic patients who reported exacerbations after aspirin ingestion and those who did not." | 3.73 | Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease. ( Borish, L; Hunt, J; Mascia, K; Patrie, J; Phillips, CD; Steinke, JW, 2005) |
| "There has been ongoing controversy as to whether aspirin should be used in patients with chronic heart failure (CHF)." | 3.73 | Aspirin use in chronic heart failure: what should we recommend to the practitioner? ( Massie, BM, 2005) |
| "Hypersensitivity to aspirin usually takes the form of a clinical syndrome combining chronic rhinitis, nasal polyposis and asthma attacks that are exacerbated by aspirin or other non steroidal anti-inflammatory drugs (NSAIDs)." | 3.73 | [New pathophysiological concepts on aspirin hypersensitivity (Widal syndrome); diagnostic and therapeutic consequences]. ( de Weck, A; Gamboa, P; Sanz, ML, 2005) |
| "To address the hypothesis that expression of 1 or more EP receptors on nasal mucosal inflammatory cells is deficient in patients with aspirin-sensitive compared with nonaspirin-sensitive polypoid rhinosinusitis." | 3.73 | Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells. ( Corrigan, CJ; Lee, TH; Meng, Q; Parikh, A; Scadding, G; Ying, S, 2006) |
| "Twenty-seven patients with chronic myeloproliferative disorders and in vitro evidence of platelet hyperactivity on whole blood platelet lumi-aggregometry were commenced on anti-platelet therapy comprising aspirin, clopidogrel, and/or odorless garlic and the studies were repeated to assess the efficacy of the therapeutic agent(s)." | 3.73 | Use of whole blood platelet lumi-aggregometry to optimize anti-platelet therapy in patients with chronic myeloproliferative disorders. ( Gemmell, R; Hartwell, T; Manoharan, A, 2006) |
| "Medical records of all patients with atrial fibrillation admitted to acute internal medicine wards in April 2000 and between July and October 2001 were reviewed for details of antithrombotics given, results of international normalised ratio monitoring for patients receiving warfarin, side-effects, and additional risk factors for complications of atrial fibrillation." | 3.72 | Antithrombotic treatment of atrial fibrillation in a regional hospital in Hong Kong. ( Leung, CS; Tam, KM, 2003) |
| "By inhibiting prostaglandin synthesis, aspirin can interfere with both arterial functional and angiotensin-converting enzyme inhibitor (ACEI) properties and be deleterious in chronic heart failure (CHF)." | 3.72 | Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: a dose-mediated deleterious effect. ( Bergmann, JF; Caulin, C; Cohen-Solal, A; Habib, A; Jondeau, G; Kevorkian, JP; Knellwolf, AL; Lebret, M; Levy, B; Mahé, I; Meune, C; Mourad, JJ; Simoneau, G, 2003) |
| "It is debated whether in patients with chronic heart failure (CHF), aspirin may contrast the clinical benefits of angiotensin-converting enzyme inhibitors (ACEIs)." | 3.72 | Aspirin-angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure: a dose-related adverse effect of aspirin. ( Brambilla, R; Guazzi, M; Guazzi, MD; Reina, G; Tumminello, G, 2003) |
| "Polyposis, asthma, aspirin-intolerance and aspirin-triad are mostly accompanied with eosinophilia of mucosal airways." | 3.72 | RANTES, eotaxin and eotaxin-2 expression and production in patients with aspirin triad. ( Maune, S; Pods, R; Ross, D; Rudack, C; van Hülst, S, 2003) |
| "The urinary leukotriene E4 (U-LTE4) concentration is significantly increased in patients with aspirin-intolerant asthma (AIA)." | 3.72 | Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. ( Akiyama, K; Higashi, A; Higashi, N; Ishii, T; Kawagishi, Y; Mita, H; Osame, M; Taniguchi, M, 2004) |
| "Although recent randomized trials with antithrombotic therapy in nonrheumatic atrial fibrillation (AF) patients emphasized the benefits of warfarin in preventing stroke, warfarin treatment is still far from optimal." | 3.72 | Thromboembolic prophylaxis in nonrheumatic atrial fibrillation: utilization patterns, efficacy, and complications in a long-term follow-up of community patients. ( Blich, M; Gross, B, 2004) |
| "Although administration of gastroprotective drugs may reduce the risk of peptic ulcers associated with the chronic use of non-steroidal anti-inflammatory drugs or aspirin, no consensus exists as to whether this co-therapy is effective for short-term prevention, particularly in old age." | 3.72 | Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. ( Andriulli, A; Cascavilla, L; Di Mario, F; Franceschi, M; Leandro, G; Longo, MG; Niro, V; Paris, F; Pilotto, A; Scarcelli, C, 2004) |
| "Aspirin-exacerbated respiratory disease (AERD) is a clinical syndrome characterized by chronic rhinitis, nasal polyps, asthma, and precipitation of asthma and rhinitis attacks after ingestion of aspirin (ASA) and most nonsteroidal anti-inflammatory drugs (NSAIDs)." | 3.71 | The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. ( Berges-Gimeno, MP; Simon, RA; Stevenson, DD, 2002) |
| "There was a significantly lower rate of primary allograft thrombosis in patients treated with aspirin (none of 105) compared with that in the control group (six (5 per cent) of 121; P = 0." | 3.71 | Influence of aspirin on early allograft thrombosis and chronic allograft nephropathy following renal transplantation. ( Metcalfe, M; Murphy, GJ; Nicholson, ML; Taha, R; Windmill, DC, 2001) |
| "The diagnosis of two patients with aspirin-induced urticaria (AIU) was confirmed by oral provocation with aspirin, other non-steroidal anti-inflammatory drugs, and food additives." | 3.70 | Aspirin-sensitive urticaria: provocation with a leukotriene receptor antagonist. ( Horio, T; Mitsuya, K; Ohnishi-Inoue, Y, 1998) |
| ", age; left ventricular function; left main coronary artery disease; urgent priority; gender; previous cardiac surgery; concurrent cardiovascular surgery; chronic lung disease; creatinine concentration; hemoglobin concentration; diabetes; hypertension; cerebrovascular disease; recent myocardial infarction; prior vascular surgery; number of arteries bypassed; and regular daily treatment with beta-blockers, aspirin within 5 days, calcium antagonists, angiotensin converting enzyme (ACE) inhibitors, digoxin, or warfarin." | 3.70 | Drug therapy before coronary artery surgery: nitrates are independent predictors of mortality and beta-adrenergic blockers predict survival. ( Gibbs, NM; Mahon, BD; Newman, MA; Sheminant, MR; Weightman, WM; Whitford, EG, 1999) |
| "To investigate the incidence of new thromboembolic (TE) stroke in older persons with chronic atrial fibrillation treated with oral warfarin versus aspirin." | 3.70 | Incidence of new thromboembolic stroke in persons 62 years and older with chronic atrial fibrillation treated with warfarin versus aspirin. ( Ahn, C; Aronow, WS; Gutstein, H; Kronzon, I, 1999) |
| "The aspirin triad (nasal polyposis, asthma and sensitivity to aspirin) is a well-recognized clinical entity, also known as aspirin-induced asthma (AIA)." | 3.70 | Effects of sinus surgery on asthma in aspirin triad patients. ( Higuchi, Y; Kawasaki, M; Nakamura, H; Takahashi, S, 1999) |
| "Between 8-20 percent of adult asthmatics experience bronchospasm following ingestion of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs)." | 3.70 | NSAID-induced bronchospasm--a common and serious problem. A report from MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority. ( Sturtevant, J, 1999) |
| "The value of warfarin in preventing stroke in patients with chronic atrial fibrillation is well established." | 3.70 | Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. ( Almoznino-Sarafian, D; Alon, I; Chachashvily, S; Cohen, N; Gorelik, O; Koopfer, M; Litvinjuk, V; Modai, D; Shteinshnaider, M, 2000) |
| "Biochemical and immunological studies were performed to study hepatic function in 137 patients, out of whom 74 were found to have aspirin-induced bronchial asthma, 23 atopic bronchial asthma, 23 infectious allergic bronchial asthma, 17 chronic persistent hepatitis." | 3.69 | [Liver function in patients with aspirin-induced bronchial asthma]. ( Efimova, NIu; Sizykh, TP, 1994) |
| " In contrast, the sinusitis of the aspirin triad syndrome is often fulminate, expansive, and recurrent, and complications may be more frequent." | 3.69 | Orbital complications of sinusitis in the aspirin triad syndrome. ( Massaro, BM; McFadden, EA; Toohill, RJ; Woodson, BT, 1996) |
| "The effects of chronic anemia on gastric damage induced by ethanol or aspirin have been investigated in rats." | 3.69 | [Chronic anemia protects against gastric damage by alcohol and aspirin. The role of the toxic radicals and lipid peroxidation]. ( Brugnara, L; Casadevall, M; Esser, T; Marroni, CA; Marroni, NP; Piqué, JM, 1996) |
| " Twenty four patients aged 48 +/- 17 years (21 with idiopathic glomerulonephritis, one with systemic lupus erythematosus and two with type II diabetes mellitus) were treated with aspirin and dipyridamole or aspirin alone during 23." | 3.68 | [Is it justifiable to use antiplatelet drugs as a universal protection in patients with chronic glomerular damage?]. ( Duclos, J, 1993) |
| "An 11-year retrospective study was conducted to evaluate the surgical treatment of sinusitis in aspirin-triad patients." | 3.68 | Surgery for sinusitis and aspirin triad. ( Fink, JN; Kany, RJ; McFadden, EA; Toohill, RJ, 1990) |
| "The role of a commonly ingested food additive, the preservative sodium metabisulfite (MBS), and aspirin (ASA), in chronic asthma has been studied in 29 children." | 3.67 | Role of acetyl salicylic acid and sodium metabisulfite in chronic childhood asthma. ( Mellis, CM; Towns, SJ, 1984) |
| "Incidences of cardiovascular diseases, cancers, gastrointestinal bleeding, ulcers, and cataracts were compared in participants who did and did not take aspirin daily." | 3.67 | Aspirin use and chronic diseases: a cohort study of the elderly. ( Chao, A; Henderson, BE; Paganini-Hill, A; Ross, RK, 1989) |
| "In some cases of chronic urticaria it is suspected that food additives such as tartrazine and sodium benzoate or salicylates may play a role in the pathogenesis of the condition." | 3.67 | Cell-mediated immune responses to artificial food additives in chronic urticaria. ( McPhillips, S; Sauder, PJ; Warrington, RJ, 1986) |
| "This study attempted to determine whether or not nasal and sinus surgery had a beneficial or deleterious effect upon the asthma of patients with nasal polyps and aspirin idiosyncrasy." | 3.67 | Nasal polypectomy and sinus surgery in patients with asthma and aspirin idiosyncrasy. ( English, GM, 1986) |
| " Oral or intraduodenal administration of AG 629 in a dose range of 25-100 mg/kg inhibited water-immersion stress ulcer, exertion ulcer, Shay ulcer, indometacin- and acetylsalicylic acid (ASA)-induced gastric ulcer, and indomethacin-induced small intestinal ulcer in rats, histamine-induced gastric ulcer in guinea pigs, and ASA-induced gastric ulcer in dogs, though it was not effective against cysteamine-induced duodenal ulcer in rats." | 3.67 | Effects of 5-acetylspiro[benzofuran-2(3H),1'-cyclopropan]-3-one, a new anti-ulcer agent, on experimental acute and chronic ulcers. ( Hirata, T; Inada, I; Inatomi, N; Maki, Y; Satoh, H; Sino, A, 1985) |
| "19 aspirin-sensitive and 14 non-aspirin-sensitive patients with chronic urticaria were tested for the presence of specific anti-salicyloyl-IgE antibodies by prick testing, RAST and in vitro histamine release using an aspirin-polylysine conjugate." | 3.66 | Investigation of the possible involvement of IgE anti-salicyloyl antibodies in patients with urticaria. ( Baldo, BA; Basten, A; Gregson, RP; Krilis, S, 1981) |
| "This study undertook to determine the usefulness of tartrazine and benzoate challenge and dietary avoidance in the management of patients with chronic asthma." | 3.66 | Tartrazine and benzoate challenge and dietary avoidance in chronic asthma. ( Broder, I; Tarlo, SM, 1982) |
| "In a pain management program (200 patients), a group of daily users of oxycodone compound (29 patients) and a subgroup who were taking a "high dose" of oxycodone compound (13 patients) were compared with a group of 171 non-users of oxycodone compound." | 3.66 | Problems with the use of oxycodone compound in patients with chronic pain. ( Maruta, T; Swanson, DW, 1981) |
| "A patient with chronic erythema nodosum of two years' duration, who did not respond to treatment with aspirin or with phenylbutazone therapy, had a dramatic response and improvement when treated with naproxen." | 3.66 | Control of chronic erythema nodosum with naproxen. ( Lehman, CW, 1980) |
| " Concomitant oral administration of aspirin or subcutaneous administration of indomethacin revealed an aggravation of aspirin-induced gastric ulcers by betamethasone valerate and inhibition of indomethacin-induced intestinal ulcers by beta-methasone dipropionate." | 3.66 | [Irritative activity of antiinflammatory agents, betamethasone 17-valerate, beclomethasone 17, 21-dipropionate, betamethasone 17, 21-dipropionate, or indomethacin on the gastrointestinal tract in rats and dogs (author's transl)]. ( Ishihara, Y; Izumi, K; Kunimi, H; Okabe, S; Tabata, K; Uchida, N, 1978) |
| "Although acetylsalicylic acid (aspirin) can cause acute damage to human gastric mucosa, its relationship to chronic gastric ulcer has been less documented." | 3.65 | Aspirin and gastric ulcer. ( Cameron, AJ, 1975) |
| "Aspirin is an inexpensive, widely used medication but its safety and efficacy in the treatment of VLUs remains to be established." | 2.87 | AVURT: aspirin versus placebo for the treatment of venous leg ulcers - a Phase II pilot randomised controlled trial. ( Bland, M; Buckley, H; Chetter, I; Clark, L; Cook, L; Dumville, J; Fenner, C; Forsythe, R; Gabe, R; Harding, K; Hinchliffe, R; Layton, A; Lindsay, E; McDaid, C; Moffatt, C; Rolfe, D; Sbizzera, I; Stansby, G; Tilbrook, H; Torgerson, D; Vowden, P; Williams, L, 2018) |
| " We conducted network meta-analysis of sinusitis symptoms, heath-related quality of life, rescue oral corticosteroids and surgery, endoscopic and radiologic scores, and adverse events." | 2.82 | Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis. ( Bousquet, J; Brignardello-Petersen, R; Chu, DK; Kennedy, DW; Oykhman, P; Paramo, FA, 2022) |
| "Aspirin) was effective." | 2.82 | [Idiopathic recurrent pericarditis: review of the literature and the Geneva experience]. ( Dominati, A; Meyer, P; Seebach, JD, 2022) |
| " Adverse drug reactions may be renal, gastrointestinal, hematological, or immunologic." | 2.82 | Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years. ( Gorenflo, M; Saur, P; van den Anker, JN; van Dyk, M; Welzel, T; Ziesenitz, VC, 2022) |
| "In addition, treating chronic hypertension neither reduces nor increases fetal or newborn death or morbidity, regardless of the gestational age at which the antihypertensive treatment is started." | 2.82 | Toward personalized management of chronic hypertension in pregnancy. ( Kametas, N; Khalil, A; Magee, LA; von Dadelszen, P, 2022) |
| "Aspirin is an inexpensive, widely used medication but its safety and efficacy in the treatment of VLUs remains to be established." | 2.80 | Aspirin for Venous Ulcers: Randomised Trial (AVURT): study protocol for a randomised controlled trial. ( Bland, M; Buckley, H; Chetter, I; Clark, L; Cook, L; Dumville, J; Forsythe, RO; Gabe, R; Harding, K; Hinchliffe, RJ; Layton, A; Lindsay, E; McDaid, C; Moffatt, C; Phillips, C; Rolfe, D; Stansby, G; Tilbrook, H; Torgerson, D; Vowden, P; Williams, L, 2015) |
| "The rate of superimposed preeclampsia was 28." | 2.79 | Aspirin plus calcium supplementation to prevent superimposed preeclampsia: a randomized trial. ( Atallah, AN; Kulay, L; Santos, GM; Sass, N; Souza, EV; Torloni, MR, 2014) |
| "Whether low-dose aspirin prevents preeclampsia is unclear." | 2.69 | Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. ( Caritis, S; Hauth, J; Klebanoff, M; Landon, M; Lindheimer, MD; Meis, P; Miodovnik, M; Paul, R; Sibai, B; Thom, E; Thurnau, G; VanDorsten, P, 1998) |
| "Pregnancy-induced hypertension is a major cause of maternal and fetal morbidity and mortality." | 2.61 | Hypertension and Pregnancy: Management and Future Risks. ( Jim, B; Reddy, S, 2019) |
| "Aspirin is a generally well-tolerated drug that is now widely used in aged patients for its antithrombotic action." | 2.55 | Aspirin treatment for chronic wounds: Potential beneficial and inhibitory effects. ( Darby, IA; Weller, CD, 2017) |
| "Chronic rhinosinusitis is often associated with bronchial asthma." | 2.45 | [Chronic rhinosinusitis in morbus widal: clinical aspects and therapeutic options]. ( Jung, H, 2009) |
| "Rhinosinusitis is among the most common infectious complications of humoral immunodeficiency, and humoral immunodeficiency is not uncommon in patients with refractory chronic rhinosinusitis." | 2.44 | Diseases associated with chronic rhinosinusitis: what is the significance? ( Ryan, MW, 2008) |
| "Venous ulcers affect approximately 1% of the world's population, increasing healthcare expenditures and decreasing quality of life." | 2.43 | Venous ulcers: pathophysiology and treatment options. ( Eaglstein, WH; Falabella, A; Kirsner, RS; Trent, JT, 2005) |
| "Eosinophilia is frequently, but not exclusively, caused by immunoglobulin (Ig)E-mediated hypersensitivity and is dominated by the associated cytokine milieu of Th2 inflammation." | 2.43 | Differential diagnosis of eosinophilic chronic rhinosinusitis. ( Ferguson, BJ; Sok, JC, 2006) |
| "In the United States, pancreatic cancer is the 4(th) leading cause of cancer death, and in Europe it is the 6th." | 2.42 | Epidemiology of pancreatic cancer. ( Michaud, DS, 2004) |
| "The standard therapy in Crohn's disease and ulcerative colitis is based on corticosteroids and aminosalicylates." | 2.41 | [Therapy of chronic inflammatory bowel diseases]. ( Stange, EF, 2002) |
| "Colchicine treatment seems to be efficacious and can be used to stop steroid therapy." | 2.41 | [Is chronic or recurrent idiopathic pericarditis an autonomous inflammatory disease?]. ( Disdier, P; Ene, N; Granel, B; Habib, G; Mesana, T; Pache, X; Rey, J; Serratrice, J; Swiader, L; Weiller, PJ, 2001) |
| "An elderly woman with chronic ulcerative colitis who developed proximal muscle weakness, increased serum creatine phosphokinase activity, and histological and electromyographic abnormalities characteristic of polymyositis is described." | 2.38 | Polymyositis associated with ulcerative colitis. ( Chawla, YK; Chugh, S; Dang, N; Dilawari, JB; Radotra, BD; Sawhney, IM, 1993) |
| "The risk of early recurrence of embolism in the first 30 days ranges from 8 to 15%." | 2.38 | [Embolic complications of chronic atrial fibrillation]. ( Brechenmacher, C; Chauvin, M; Koenig, A; Théolade, R, 1992) |
| "Aspirin was also associated with significantly fewer reinfarctions and strokes." | 2.38 | Aspirin in chronic cardiovascular disease and acute myocardial infarction. ( Hennekens, CH, 1990) |
| "Paroxysmal atrial fibrillation is associated with a lower risk of thromboembolic complications than chronic atrial fibrillation." | 2.38 | Thromboembolic complications in atrial fibrillation. ( Petersen, P, 1990) |
| " This dose-response effect, evident in both endoscopic and microbleeding studies done after acute or short-term aspirin administration, is also associated with the risk of developing chronic gastric ulcer." | 2.37 | Aspirin and the stomach. ( Graham, DY; Smith, JL, 1986) |
| "Tyrosine kinase inhibitors (TKIs) used to treat chronic myeloid leukaemia (CML) can cause cardiovascular adverse events." | 1.72 | The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity. ( Alagna, G; Di Lisi, D; Madaudo, C; Novo, G; Rossetto, L; Santoro, M; Siragusa, S, 2022) |
| " Long-term administration of acetylsalicylic acid (ASA) after desensitization has been used to mitigate these sequelae, but the optimal dose and balancing symptom relief and side effects remain unsettled." | 1.56 | Symptom Control of Patients With Chronic Rhinosinusitis With Nasal Polyps Under Maintenance Therapy With Daily Acetylsalicylic Acid. ( Appel, H; Greve, J; Hahn, J; Hoffmann, TK; Lindemann, J; Petereit, F; Scheithauer, MO; Sommer, F; Veit, JA, 2020) |
| "Gallbladder stones (cholecystolithiasis) are the main risk factor for gallbladder cancer (GBC), a lethal biliary malignancy with poor survival rates worldwide." | 1.56 | Evaluation of the chemopreventive potentials of ezetimibe and aspirin in a novel mouse model of gallbladder preneoplasia. ( Arrese, M; Bizama, C; Espinoza, JA; Ferreccio, C; García, P; Gómez, N; González, X; Guevara, F; Kalergis, AM; Lobos-González, L; Miquel, JF; Muñoz-Durango, N; Roa, JC; Rosa, L; Saavedra, N; Villegas, J; Wichmann, IA, 2020) |
| "Aspirin sensitivity has a highly significant association with AFRS." | 1.48 | Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study. ( Ahmed, S; Almeyda, R; Anari, S; Carrie, S; Cathcart, R; Clark, A; Coombes, E; Erskine, S; Farboud, A; Hobson, J; Hopkins, C; Jervis, P; Kara, N; Khalil, H; Kumar, N; Mansell, N; Panesaar, J; Philpott, C; Philpott, CM; Prinsley, P; Ray, J; Robertson, A; Salam, M; Sunkaraneni, S; Sunkaraneni, V; Wilson, A; Woods, J, 2018) |
| "Severe thrombocytopenia was identified in 36 patients (36." | 1.48 | Safety of Diagnostic and Therapeutic Cardiac Catheterization in Cancer Patients With Acute Coronary Syndrome and Chronic Thrombocytopenia. ( Balanescu, DV; Cilingiroglu, M; Donisan, T; Durand, JB; Giza, DE; Iliescu, C; Kim, PY; Lopez-Mattei, JC; Marmagkiolis, K; Mouhayar, EN; Mukerji, SS; Muñoz Gonzalez, ED; Palaskas, N; Song, J, 2018) |
| "Thus treatment with aspirin in the chronic phase of Chagas' disease changes the natural history of the disease and raises the possibility of using it as a new therapeutic approach to the treatment of this aspect of Chagas' disease pathology." | 1.46 | Treatment with low doses of aspirin during chronic phase of experimental Chagas' disease increases oesophageal nitrergic neuronal subpopulation in mice. ( de Almeida Araújo, EJ; de Mello Gonçales Sant'ana, D; Marques de Araújo, S; Martins Moreira, N; Massocatto, CL; Muniz, E; Pinge-Filho, P; Rossi, RM, 2017) |
| "The rate of preeclampsia was much higher at quintile (Q) 5 of VAT depth (9." | 1.46 | Preeclampsia and Preterm Birth Associated With Visceral Adiposity in Early Pregnancy. ( Berger, H; Bujold, E; Connelly, PW; De Souza, LR; Park, AL; Ray, JG, 2017) |
| "Prednisone was the most common OCS prescribed." | 1.46 | Oral corticosteroid prescribing habits for rhinosinusitis: The American Rhinologic Society membership. ( Ernst, HM; Rotenberg, BW; Rudmik, L; Scott, JR; Sowerby, LJ, 2017) |
| "In aspirin-treated ACS patients, MRP-8/14 and 11-dehydro-TXB2 were lower versus those not receiving aspirin (P<0." | 1.40 | Circulating myeloid-related protein-8/14 is related to thromboxane-dependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment. ( Davì, G; Di Marco, M; Di Nicola, M; La Barba, S; Lattanzio, S; Liani, R; Mascellanti, M; Paloscia, L; Pascale, S; Santilli, F, 2014) |
| "Aspirin resistance was defined as the mean platelet aggregation of > or = 70% with 10 mM ADP and the mean platelet aggregation of > or = 20% with 0." | 1.39 | Aspirin resistance in Thai patients with chronic stable angina. ( Chinthammitr, Y; Chotinaiwattarakul, C; Karevee, D; Panchavinnin, P; Phankingthongkum, R; Sumalee, C; Tresukosol, D; Tungsubutra, W; Wongpraparut, N, 2013) |
| "Glucose metabolic changes in CM patients taking different dosage of analgesic during headache-free periods and clear distinctions in several brain regions were observed." | 1.39 | Overuse of paracetamol caffeine aspirin powders affects cerebral glucose metabolism in chronic migraine patients. ( Di, W; Fang, Y; Luo, N; Miao, J; Qi, W; Shi, X; Tao, Y; Xiao, Z; Yi, C; Zhang, A; Zhang, X; Zhu, Y, 2013) |
| "270 patients (93 with deep vein thrombosis (DVT) or pulmonary embolism (PE), and 177 with non-haemorrhagic stroke (cerebrovascular accident (CVA)) admitted between January 2006 and December 2010 with a discharge diagnosis of either DVT, PE or CVA, who had LAC and antiphospholipid antibodies measured within 6 months from their index admission." | 1.38 | High antiphospholipid antibody levels are associated with statin use and may reflect chronic endothelial damage in non-autoimmune thrombosis: cross-sectional study. ( Broder, A; Putterman, C; Tobin, JN, 2012) |
| "Aspirin use was associated with reduced risk of developing HCC and of death due to CLD whereas nonaspirin NSAID use was only associated with reduced risk of death due to CLD." | 1.38 | Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. ( Freedman, ND; Graubard, BI; Gunja, MZ; Hollenbeck, AR; McGlynn, KA; Park, Y; Sahasrabuddhe, VV; Schwartz, LM; Trabert, B, 2012) |
| "To discover analgesics for treating chronic pain 17 novel Schiff's bases, N,N'-(Z-allylidene-1,3-diyl)bisamino acid methyl esters were prepared from 1,1,3,3,-tetramethoxypropane and amino acid methyl esters." | 1.36 | A class of novel Schiff's bases: Synthesis, therapeutic action for chronic pain, anti-inflammation and 3D QSAR analysis. ( Li, C; Peng, L; Peng, S; Wu, J; Wu, Y; Zhao, M; Zheng, M; Zhou, Y, 2010) |
| "Overall, men who developed cancer were less likely to have had hypercholesterolemia (odds ratio (OR) = 0." | 1.36 | Chronic disease in men with newly diagnosed cancer: a nested case-control study. ( Driver, JA; Gaziano, JM; Kurth, T; Yung, R, 2010) |
| " Proved herein is the necessity of long-term administration of antiplatelet drugs in order to prevent vascular complications on the part of the heart, brain, and peripheral arteries, with a description of the drugs most commonly used for these purposes." | 1.36 | [Antiplatelet therapy in patients with chronic obliterating diseases of lower-limb arteries]. ( Dzhalilova, NS; Kuznetsov, MR; Sizarev, AV; Tepliakov, SA; Tugdumov, BV, 2010) |
| "Aspirin was given as 160 mg/day and clopidogrel as 300 mg loading dose followed by 75 mg/day." | 1.35 | Clopidogrel inhibits platelet aggregation in patients on aspirin with stable chronic angina pectoris. ( Agewall, S; Berglund, M; Gordon, A; Saha, S; Sylvén, C, 2008) |
| "The associations between colorectal cancer risk and several chronic illnesses, operations and various medications were examined in 715 colorectal cancer cases and 727 age- and sex-matched controls in data derived from a large, comprehensive population-based study of this cancer conducted in Melbourne, Australia." | 1.34 | Colorectal cancer risk, chronic illnesses, operations and medications: case control results from the Melbourne Colorectal Cancer Study. 1988. ( Kune, GA; Kune, S; Watson, LF, 2007) |
| "Chronic constipation is associated with use of acetaminophen, aspirin and non-steroidal anti-inflammatory drugs." | 1.34 | Risk factors for chronic constipation and a possible role of analgesics. ( Chang, JY; Locke, GR; Schleck, CD; Talley, NJ; Zinsmeister, AR, 2007) |
| "Overweight and obesity are well-established risk factors for cardiovascular disease and decline in kidney function in individuals with existing chronic kidney disease (CKD)." | 1.33 | Association between body mass index and CKD in apparently healthy men. ( Buring, JE; Gaziano, JM; Gelber, RP; Kausz, AT; Kurth, T; Levey, AS; Manson, JE, 2005) |
| "Though her hemoptysis improved, respiratory failure suddenly worsened." | 1.33 | [A case of acute exacerbation of chronic pulmonary thromboembolism with essential thrombocythemia during treatment for hemoptysis]. ( Abe, T; Haraguchi, M; Hayashi, M; Ito, K; Nakajima, H; Sakagami, T; Tsutsui, N, 2006) |
| "Colitis was induced in rats by an enema containing 2,4,6-trinitrobenzen sulfonic acid." | 1.32 | Decrease in non-selective, non-sustained attention induced by a chronic visceral inflammatory state as a new pain evaluation in rats. ( Ardid, D; Eschalier, A; Etienne, M; Jourdan, D; Millecamps, M, 2004) |
| "Aspirin was administered for vascular event prevention." | 1.32 | Aspirin withdrawal and acute lower limb ischemia. ( Albaladejo, P; Castier, Y; Francis, F; Geeraerts, T; Lesèche, G; Marty, J, 2004) |
| "In vehicle-treated rats, gastric ulcers healed progressively and at day 14 the healing was completed, accompanied by a significant rise in the GBF at ulcer margin." | 1.31 | Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers. ( Brzozowski, T; Drozdowicz, D; Hahn, EG; Konturek, PC; Konturek, SJ; Pajdo, R; Ptak, A; Sliwowski, Z, 2001) |
| "We describe a case of thoracic aortic aneurysm complicated by chronic disseminated intravascular coagulation (DIC)." | 1.31 | [Thoracic aortic aneurysm with chronic disseminated intravascular coagulation treated successfully with orally administered camostat mesilate, warfarin and aspirin]. ( Fukuda, N; Nakamori, Y; Oeda, E; Sato, Y; Shimohakamada, Y; Shinohara, K; Takahashi, T; Tominaga, T, 2002) |
| "Patients with chronic facial pain including those with facial arthromyalgia (TMJ dysfunction syndrome) were investigated for evidence of abnormal systemic and intra-articular free radical activity." | 1.30 | The role of oxygen free radicals in idiopathic facial pain. ( Aghabeigi, B; Haque, M; Harris, M; Henderson, B; Hodges, SJ; Wasil, M, 1997) |
| "Pulmonary edema was rare and acute renal failure did not develop in any women." | 1.30 | Safety of labor epidural anesthesia for women with severe hypertensive disease. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. ( Caritis, SN; Dombrowski, MP; Hauth, JC; Hogg, B; Klebanoff, M; Landon, M; Lindheimer, M; MacPherson, C; McNellis, D; Meis, PJ; Miodovnik, M; Paul, R; Roberts, JM; Sibai, BM; Thurnau, GR; Van Dorsten, JP, 1999) |
| " Incidence of side effects and toxicity may be reduced by choice of drug and modification of dosing regimen." | 1.28 | Nonnarcotic analgesics and tricyclic antidepressants for the treatment of chronic nonmalignant pain. ( Richlin, DM, 1991) |
| "An analysis of 100 consecutive cases of juvenile rheumatoid arthritis from South India revealed a male preponderance (62%), a lower incidence of the systemic onset variety (10%) and equal incidence of systemic features when compared with the West." | 1.28 | Pattern of rheumatic diseases in south India. IV. Clinical profile of juvenile rheumatoid arthritis. ( Chandrasekaran, AN; Krishnamurthy, V; Madhavan, R; Parthiban, M; Porkodi, R; Subramaniam, R, 1990) |
| "They found that in the course of treatment proteinuria did not change and glomerular filtration declined insignificantly." | 1.28 | [The effect of acetylsalicylic acid and dipyridamole on glomerular filtration and proteinuria in chronic glomerulonephritis]. ( Jáchymová, M; Knotková, V; Nĕmecek, K; Petrů, I, 1990) |
| "The purpose of the investigation was to evaluate the long-term administration of 100 mg acetylsalicylic acid in patients with chronic proliferative glomerulonephritis." | 1.28 | [Treatment of chronic glomerulonephritis with small doses of acetylsalicylic acid]. ( Jáchymová, M; Knotková, V; Nĕmecek, K; Petrů, I, 1990) |
| "), rioprostil prevents the acute effects of aspirin on the gastric mucosa of dogs, accelerates the healing of aspirin-induced gastric lesions, and heals preexisting aspirin-induced gastric lesions during chronic administration of aspiring." | 1.28 | Slow release delivery of rioprostil by an osmotic pump inhibits the formation of acute aspirin-induced gastric lesions in dogs and accelerates the healing of chronic lesions without incidence of side effects. ( Katz, LB; Shriver, DA, 1989) |
| " The side effects of antihistamines are minor, and the dosage of corticosteroid used and length of time it is given are small enough to avoid major side effects." | 1.27 | Chronic urticaria. Possible causes, suggested treatment alternatives. ( Kaplan, AP, 1983) |
| " Failures (22%) were due to such factors as insufficient dosage at the very beginning of our experience or severe depressive syndrome." | 1.27 | [Chronic refractory pain in cancer patients. Value of the spinal injection of lysine acetylsalicylate. 60 cases]. ( Abergel, A; Amiot, JF; Babinet, P; Boule, D; Glowinski, J; Hardy, F; Mechali, D; Palacci, JH; Pellerin, M; Wingtin, LN, 1987) |
| " Three weeks later these rats were orally dosed each day with aspirin (375 mg/kg) for six months." | 1.27 | Molecular weight of gastric mucus glycoprotein is a determinant of the degree of subsequent aspirin induced chronic gastric ulceration in the rat. ( Bagshaw, PF; Munster, DJ; Wilson, JG, 1987) |
| "In 97." | 1.26 | [Hypersensitivity to acetysal in bronchial asthma]. ( Kosturkov, G; Mileva, Zh; Staneva-Stoianova, M, 1980) |
| "Treatment with Verapamil or aspirin reduced both chronic hypoxic pulmonary hypertension and the hypertrophy of the right ventricle." | 1.26 | Effects of verapamil and aspirin on experimental chronic hypoxic pulmonary hypertension and right ventricular hypertrophy in rats. ( Kentera, D; Susić, D; Zdravković, M, 1979) |
| "The factors that determine the recurrence rate of chronic gastric ulcer were studied in 105 patients." | 1.25 | Factors relevant to the prognosis of chronic gastric ulcer. ( Coupland, GA; Greig, M; Hobbin, E; Piper, DW; Shinners, J, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 164 (28.47) | 18.7374 |
| 1990's | 83 (14.41) | 18.2507 |
| 2000's | 146 (25.35) | 29.6817 |
| 2010's | 118 (20.49) | 24.3611 |
| 2020's | 65 (11.28) | 2.80 |
| Authors | Studies |
|---|---|
| Franklin, PX | 1 |
| Pillai, AD | 1 |
| Rathod, PD | 1 |
| Yerande, S | 1 |
| Nivsarkar, M | 1 |
| Padh, H | 1 |
| Vasu, KK | 1 |
| Sudarsanam, V | 1 |
| Zhou, Y | 1 |
| Zhao, M | 1 |
| Wu, Y | 1 |
| Li, C | 1 |
| Wu, J | 1 |
| Zheng, M | 1 |
| Peng, L | 1 |
| Peng, S | 1 |
| Oykhman, P | 2 |
| Paramo, FA | 1 |
| Bousquet, J | 2 |
| Kennedy, DW | 2 |
| Brignardello-Petersen, R | 1 |
| Chu, DK | 3 |
| Wangberg, H | 2 |
| Spierling Bagsic, SR | 2 |
| Osuna, L | 1 |
| White, AA | 5 |
| Bertlich, M | 1 |
| Ihler, F | 1 |
| Bertlich, I | 1 |
| Weiss, BG | 1 |
| Gröger, M | 2 |
| Haubner, F | 1 |
| Quint, T | 3 |
| Dahm, V | 1 |
| Ramazanova, D | 1 |
| Arnoldner, MA | 1 |
| Kurz, H | 1 |
| Janik, S | 1 |
| Brunner, PM | 1 |
| Knerer-Schally, B | 1 |
| Weninger, W | 1 |
| Griss, J | 1 |
| Ristl, R | 1 |
| Schneider, S | 3 |
| Bangert, C | 3 |
| D'Souza, GE | 1 |
| Nwagu, U | 1 |
| Barton, B | 1 |
| Unsal, AA | 1 |
| Rabinowitz, MR | 1 |
| Rosen, MR | 1 |
| Nyquist, GG | 1 |
| Cohn, J | 1 |
| Most, J | 1 |
| Toskala, EM | 1 |
| Talat, R | 1 |
| Gengler, I | 1 |
| Phillips, KM | 1 |
| Caradonna, DS | 1 |
| Gray, ST | 1 |
| Sedaghat, AR | 1 |
| Idler, BM | 1 |
| Lal, D | 1 |
| Marino, MJ | 1 |
| Tripathi, SH | 1 |
| Kumar, A | 1 |
| Kohanski, MA | 2 |
| Palmer, JN | 1 |
| Adappa, ND | 1 |
| Bosso, JV | 2 |
| Wallace, DV | 1 |
| Wang, Y | 1 |
| Qu, P | 1 |
| Sun, Y | 1 |
| Li, Z | 1 |
| Liu, L | 1 |
| Yang, L | 1 |
| Laidlaw, TM | 6 |
| Stevens, WW | 5 |
| Miss Ozuna, L | 1 |
| Ryan, T | 2 |
| Bensko, JC | 3 |
| Buchheit, KM | 7 |
| Di Lisi, D | 1 |
| Madaudo, C | 1 |
| Alagna, G | 1 |
| Santoro, M | 1 |
| Rossetto, L | 1 |
| Siragusa, S | 1 |
| Novo, G | 1 |
| Dominati, A | 1 |
| Meyer, P | 1 |
| Seebach, JD | 1 |
| Villazala-Merino, S | 1 |
| Fahrenberger, M | 1 |
| Krausgruber, T | 1 |
| Bauer, WM | 1 |
| Stanek, V | 2 |
| Campion, NJ | 2 |
| Bartosik, T | 2 |
| Regelsberger, G | 1 |
| Niederberger-Leppin, V | 1 |
| Bock, C | 1 |
| Eckl-Dorna, J | 2 |
| Sohail, A | 1 |
| Hacker, J | 2 |
| Maurer, R | 3 |
| Gakpo, D | 1 |
| Taliaferro, F | 1 |
| Ordovas-Montanes, J | 1 |
| Ezquer, F | 2 |
| Quintanilla, ME | 2 |
| Morales, P | 2 |
| Santapau, D | 2 |
| Munita, JM | 1 |
| Moya-Flores, F | 1 |
| Ezquer, M | 2 |
| Herrera-Marschitz, M | 2 |
| Israel, Y | 2 |
| Ziesenitz, VC | 1 |
| Welzel, T | 1 |
| van Dyk, M | 1 |
| Saur, P | 1 |
| Gorenflo, M | 1 |
| van den Anker, JN | 1 |
| Aydin, Ö | 1 |
| Atmiş, EÖ | 1 |
| Anadolu, Y | 1 |
| Yorulmaz, İ | 1 |
| Çelik, GE | 1 |
| Walters, BK | 1 |
| Hagan, JB | 1 |
| Divekar, RD | 1 |
| Willson, TJ | 1 |
| Stokken, JK | 1 |
| Pinheiro-Neto, CD | 1 |
| O'Brien, EK | 1 |
| Choby, G | 1 |
| Esmaeilzadeh, H | 1 |
| Zare, M | 1 |
| Alyasin, S | 1 |
| Nabavizadeh, H | 1 |
| Mortazavi, N | 1 |
| Kanannejad, Z | 1 |
| Rank, MA | 2 |
| Bognanni, A | 1 |
| Bernstein, JA | 1 |
| Ellis, AK | 1 |
| Golden, DBK | 1 |
| Greenhawt, M | 1 |
| Horner, CC | 1 |
| Ledford, DK | 1 |
| Lieberman, J | 1 |
| Luong, AU | 1 |
| Orlandi, RR | 1 |
| Samant, SA | 1 |
| Shaker, MS | 1 |
| Soler, ZM | 2 |
| Stukus, DR | 1 |
| Wang, J | 3 |
| Peters, AT | 2 |
| Poglitsch, K | 1 |
| Morgenstern, C | 1 |
| Gangl, K | 1 |
| Sinz, C | 1 |
| Liu, DT | 1 |
| Landegger, LD | 1 |
| Tu, A | 1 |
| Rocha-Hasler, M | 1 |
| Cahill, KN | 3 |
| Alfallaj, R | 1 |
| Obaid, SB | 1 |
| Almousa, H | 1 |
| Ismail, D | 1 |
| Mahjoub, S | 1 |
| Alanazy, F | 1 |
| Dousary, SA | 1 |
| Alromaih, S | 1 |
| Aloulah, M | 1 |
| Alrasheed, A | 1 |
| Alroqi, AS | 1 |
| Alsaleh, S | 1 |
| Mullur, J | 1 |
| McGill, A | 1 |
| Supron, AD | 1 |
| Bergmark, RW | 2 |
| Roditi, RE | 1 |
| Adame, MJ | 1 |
| Raji, M | 1 |
| Shan, Y | 1 |
| Zhang, Y | 1 |
| Kuo, YF | 1 |
| Tripple, JW | 1 |
| Imam, KH | 1 |
| Woessner, KM | 3 |
| Kim, SL | 1 |
| Vukadinović, T | 1 |
| Vuksanović Božarić, A | 1 |
| Vukomanović Đurđević, B | 1 |
| Radunović, M | 1 |
| Perić, A | 2 |
| Kokkinidis, DG | 1 |
| Schizas, D | 1 |
| Pargaonkar, S | 1 |
| Karamanis, D | 1 |
| Mylonas, KS | 1 |
| Hasemaki, N | 1 |
| Palaiodimos, L | 1 |
| Varrias, D | 1 |
| Tzavellas, G | 1 |
| Siasos, G | 1 |
| Klonaris, C | 1 |
| Kharawala, A | 1 |
| Chlorogiannis, DD | 1 |
| Georgopoulos, S | 1 |
| Bakoyiannis, C | 1 |
| Lee, SE | 1 |
| Farquhar, DR | 1 |
| Adams, KN | 1 |
| Masood, MM | 1 |
| Senior, BA | 1 |
| Thorp, BD | 2 |
| Zanation, AM | 2 |
| Ebert, CS | 2 |
| Vanassche, T | 1 |
| Verhamme, P | 1 |
| Anand, SS | 2 |
| Shestakovska, O | 2 |
| Fox, KA | 1 |
| Bhatt, DL | 4 |
| Avezum, A | 2 |
| Alings, M | 1 |
| Aboyans, V | 1 |
| Maggioni, AP | 2 |
| Widimsky, P | 1 |
| Berkowitz, SD | 1 |
| Yusuf, S | 3 |
| Connolly, SJ | 3 |
| Eikelboom, JW | 4 |
| Bosch, J | 3 |
| San Nicoló, M | 1 |
| Högerle, C | 1 |
| Gellrich, D | 1 |
| Eder, K | 1 |
| Pfrogner, E | 1 |
| Welsh, RC | 1 |
| Peterson, ED | 1 |
| De Caterina, R | 1 |
| Bode, C | 1 |
| Gersh, B | 1 |
| Berríos-Cárcamo, P | 1 |
| Olivares, B | 1 |
| Lucchesi, A | 1 |
| Carloni, S | 1 |
| De Matteis, S | 1 |
| Ghetti, M | 1 |
| Musuraca, G | 1 |
| Poggiaspalla, M | 1 |
| Augello, AF | 1 |
| Giordano, G | 1 |
| Fattori, PP | 1 |
| Martinelli, G | 1 |
| Napolitano, R | 1 |
| Studer, MB | 1 |
| Roland, LT | 1 |
| Ochsner, MC | 1 |
| Cox, D | 1 |
| DelGaudio, JM | 1 |
| Wise, SK | 1 |
| Levy, JM | 4 |
| Springer, SP | 1 |
| Mor, MK | 1 |
| Sileanu, F | 1 |
| Zhao, X | 1 |
| Aspinall, SL | 1 |
| Ersek, M | 1 |
| Niznik, JD | 1 |
| Hanlon, JT | 2 |
| Hunnicutt, J | 1 |
| Gellad, WF | 1 |
| Schleiden, LJ | 1 |
| Thorpe, JM | 1 |
| Thorpe, CT | 1 |
| Hahn, J | 1 |
| Appel, H | 1 |
| Scheithauer, MO | 1 |
| Petereit, F | 1 |
| Greve, J | 1 |
| Lindemann, J | 1 |
| Hoffmann, TK | 1 |
| Veit, JA | 1 |
| Sommer, F | 1 |
| Alanin, MC | 1 |
| Laidlaw, T | 2 |
| Society, TS | 1 |
| Hopkins, C | 4 |
| McHugh, T | 1 |
| Levin, M | 1 |
| Snidvongs, K | 1 |
| Banglawala, SM | 1 |
| Sommer, DD | 1 |
| González-Juanatey, JR | 1 |
| Almendro-Delia, M | 1 |
| Cosín-Sales, J | 1 |
| Bellmunt-Montoya, S | 1 |
| Gómez-Doblas, JJ | 1 |
| Riambau, V | 1 |
| García-Moll, X | 1 |
| García-Alegría, J | 1 |
| Hernández, JL | 1 |
| Lozano, FS | 1 |
| Suarez Fernández, C | 1 |
| Grose, E | 1 |
| Lee, DJ | 1 |
| Yip, J | 1 |
| Cottrell, J | 1 |
| Sykes, J | 1 |
| Lee, JK | 1 |
| Lee, JM | 1 |
| Gelardi, M | 1 |
| Porro, G | 1 |
| Quaranta, V | 1 |
| Quaranta, N | 1 |
| Cassano, M | 1 |
| Ciprandi, G | 1 |
| Study Group On CRSwNP, I | 1 |
| Malfitano, MJ | 1 |
| Santarelli, GD | 1 |
| Gelpi, M | 1 |
| Brown, WC | 1 |
| Stepp, WH | 1 |
| Hernandez, S | 1 |
| Kimple, AJ | 1 |
| Magee, LA | 1 |
| Khalil, A | 1 |
| Kametas, N | 1 |
| von Dadelszen, P | 1 |
| Jacobsen, AP | 1 |
| Raber, I | 1 |
| McCarthy, CP | 1 |
| Blumenthal, RS | 1 |
| Cusack, RW | 1 |
| Serruys, PWJC | 1 |
| Wijns, W | 1 |
| McEvoy, JW | 1 |
| Mustafa, SS | 1 |
| Vadamalai, K | 1 |
| Scott, B | 1 |
| Ramsey, A | 1 |
| Simon, TG | 1 |
| Chan, AT | 1 |
| Booker, WA | 1 |
| Jerschow, E | 1 |
| Baptist, AP | 1 |
| Borish, L | 3 |
| Campo, P | 1 |
| Cho, SH | 1 |
| Keswani, A | 1 |
| Nanda, A | 1 |
| Palumbo, M | 1 |
| Rahman, S | 1 |
| Dominas, C | 1 |
| Roditi, R | 1 |
| Bhattacharyya, N | 1 |
| Maxfield, A | 1 |
| Rosa, L | 1 |
| Lobos-González, L | 1 |
| Muñoz-Durango, N | 1 |
| García, P | 1 |
| Bizama, C | 1 |
| Gómez, N | 1 |
| González, X | 1 |
| Wichmann, IA | 1 |
| Saavedra, N | 1 |
| Guevara, F | 1 |
| Villegas, J | 1 |
| Arrese, M | 1 |
| Ferreccio, C | 1 |
| Kalergis, AM | 1 |
| Miquel, JF | 1 |
| Espinoza, JA | 1 |
| Roa, JC | 1 |
| Espersen, J | 1 |
| Weber, U | 1 |
| Römer-Franz, A | 1 |
| Lenarz, T | 1 |
| Stolle, SRO | 1 |
| Warnecke, A | 1 |
| Cook, KA | 2 |
| Domissy, A | 1 |
| Simon, RA | 4 |
| Modena, BD | 1 |
| White, A | 1 |
| Dannenberg, L | 1 |
| M'Pembele, R | 1 |
| Mourikis, P | 1 |
| Helten, C | 1 |
| Zako, S | 1 |
| Ahlbrecht, S | 1 |
| Richter, H | 1 |
| Zikeli, D | 1 |
| Benkhoff, M | 1 |
| Huhn-Wientgen, R | 1 |
| Thienel, M | 1 |
| Levkau, B | 1 |
| Kelm, M | 1 |
| Petzold, T | 1 |
| Polzin, A | 1 |
| Shantsila, E | 2 |
| Kozieł, M | 1 |
| Lip, GY | 7 |
| Corbella, S | 1 |
| Calciolari, E | 1 |
| Alberti, A | 1 |
| Donos, N | 1 |
| Francetti, L | 1 |
| Arshi, S | 1 |
| Darougar, S | 1 |
| Nabavi, M | 1 |
| Bemanian, MH | 1 |
| Fallahpour, M | 1 |
| Shokri, S | 1 |
| Ahmadian, J | 1 |
| Molatefi, R | 1 |
| Rekabi, M | 1 |
| Moinfar, Z | 1 |
| Hashemitari, P | 1 |
| Eslami, N | 1 |
| Milton, S | 1 |
| McIntosh, J | 1 |
| Macrae, F | 1 |
| Chondros, P | 1 |
| Trevena, L | 1 |
| Jenkins, M | 1 |
| Walter, FM | 1 |
| Taylor, N | 1 |
| Boyd, L | 1 |
| Saya, S | 1 |
| Karnchanachari, N | 1 |
| Novy, K | 1 |
| Forbes, C | 1 |
| Gutierrez, JM | 1 |
| Broun, K | 1 |
| Whitburn, S | 1 |
| McGill, S | 1 |
| Fishman, G | 1 |
| Marker, J | 1 |
| Shub, M | 1 |
| Emery, J | 1 |
| Yong, M | 1 |
| Wu, YQ | 1 |
| Howlett, J | 1 |
| Ballreich, J | 1 |
| Walgama, E | 1 |
| Thamboo, A | 1 |
| Cohen, NA | 1 |
| Barrett, NA | 1 |
| Priyadharshini, VS | 1 |
| Jiménez-Chobillon, MA | 1 |
| de Graaf, J | 1 |
| Porras Gutiérrez de Velasco, R | 1 |
| Gratziou, C | 1 |
| Ramírez-Jiménez, F | 1 |
| Teran, LM | 1 |
| Rojanaworarit, C | 1 |
| Limsawan, S | 1 |
| Eccleston, C | 1 |
| Cooper, TE | 1 |
| Fisher, E | 1 |
| Anderson, B | 1 |
| Wilkinson, NM | 1 |
| Masuda, T | 1 |
| Yano, F | 1 |
| Omura, N | 1 |
| Tsuboi, K | 1 |
| Hoshino, M | 1 |
| Yamamoto, SR | 1 |
| Akimoto, S | 1 |
| Kashiwagi, H | 1 |
| Yanaga, K | 1 |
| Massocatto, CL | 3 |
| Martins Moreira, N | 1 |
| Muniz, E | 2 |
| Marques de Araújo, S | 1 |
| Pinge-Filho, P | 2 |
| Rossi, RM | 2 |
| de Almeida Araújo, EJ | 1 |
| de Mello Gonçales Sant'ana, D | 1 |
| Garfinkel, D | 1 |
| Ilin, N | 1 |
| Waller, A | 1 |
| Torkan-Zilberstein, A | 1 |
| Zilberstein, N | 1 |
| Gueta, I | 1 |
| Walters, KM | 1 |
| Waldram, JD | 2 |
| Xiao, X | 1 |
| Zhang, Z | 1 |
| Chang, ET | 1 |
| Liu, Z | 1 |
| Liu, Q | 1 |
| Cai, Y | 1 |
| Chen, G | 1 |
| Huang, QH | 1 |
| Xie, SH | 1 |
| Cao, SM | 1 |
| Shao, JY | 1 |
| Jia, WH | 1 |
| Zheng, Y | 1 |
| Liao, J | 1 |
| Chen, Y | 1 |
| Lin, L | 1 |
| Ernberg, I | 1 |
| Huang, G | 1 |
| Zeng, Y | 1 |
| Zeng, YX | 1 |
| Adami, HO | 1 |
| Ye, W | 1 |
| Fox, KAA | 2 |
| Harrington, RA | 1 |
| Steg, PG | 1 |
| Philpott, CM | 1 |
| Erskine, S | 2 |
| Kumar, N | 2 |
| Anari, S | 2 |
| Kara, N | 2 |
| Sunkaraneni, S | 1 |
| Ray, J | 2 |
| Clark, A | 2 |
| Wilson, A | 1 |
| Philpott, C | 1 |
| Robertson, A | 1 |
| Ahmed, S | 1 |
| Carrie, S | 1 |
| Sunkaraneni, V | 1 |
| Jervis, P | 1 |
| Panesaar, J | 1 |
| Farboud, A | 1 |
| Cathcart, R | 1 |
| Almeyda, R | 1 |
| Khalil, H | 1 |
| Prinsley, P | 1 |
| Mansell, N | 1 |
| Salam, M | 1 |
| Hobson, J | 1 |
| Woods, J | 1 |
| Coombes, E | 1 |
| Chahine, KM | 1 |
| Sibai, BM | 3 |
| Yamaguchi, T | 1 |
| Ishii, T | 2 |
| Yamamoto, K | 1 |
| Higashi, N | 2 |
| Taniguchi, M | 2 |
| Okamoto, M | 1 |
| Iliescu, C | 1 |
| Balanescu, DV | 1 |
| Donisan, T | 1 |
| Giza, DE | 1 |
| Muñoz Gonzalez, ED | 1 |
| Cilingiroglu, M | 1 |
| Song, J | 1 |
| Mukerji, SS | 1 |
| Lopez-Mattei, JC | 1 |
| Kim, PY | 1 |
| Palaskas, N | 1 |
| Mouhayar, EN | 1 |
| Durand, JB | 1 |
| Marmagkiolis, K | 1 |
| Weinstein, SF | 1 |
| Katial, RK | 4 |
| Bardin, P | 1 |
| Korn, S | 1 |
| McDonald, M | 1 |
| Garin, M | 1 |
| Bateman, ED | 1 |
| Hoyte, FCL | 1 |
| Germinaro, M | 1 |
| Tilbrook, H | 2 |
| Clark, L | 2 |
| Cook, L | 2 |
| Bland, M | 2 |
| Buckley, H | 2 |
| Chetter, I | 2 |
| Dumville, J | 2 |
| Fenner, C | 1 |
| Forsythe, R | 1 |
| Gabe, R | 2 |
| Harding, K | 2 |
| Layton, A | 2 |
| Lindsay, E | 2 |
| McDaid, C | 2 |
| Moffatt, C | 2 |
| Rolfe, D | 2 |
| Sbizzera, I | 1 |
| Stansby, G | 2 |
| Torgerson, D | 2 |
| Vowden, P | 2 |
| Williams, L | 2 |
| Hinchliffe, R | 1 |
| DeGregorio, GA | 1 |
| Singer, J | 1 |
| Kowalski, ML | 3 |
| Cooper, T | 1 |
| Greig, SR | 1 |
| Zhang, H | 1 |
| Seemann, R | 1 |
| Wright, ED | 1 |
| Vliagoftis, H | 1 |
| Côté, DWJ | 1 |
| Coppens, M | 1 |
| Weitz, JI | 1 |
| Eikelboom, JWA | 1 |
| Fröhlich, H | 1 |
| Rosenfeld, N | 1 |
| Täger, T | 1 |
| Goode, K | 1 |
| Kazmi, S | 1 |
| Hole, T | 1 |
| Katus, HA | 1 |
| Atar, D | 1 |
| Cleland, JGF | 2 |
| Agewall, S | 2 |
| Clark, AL | 1 |
| Frankenstein, L | 1 |
| Grundtvig, M | 1 |
| Leavitt, K | 1 |
| Običan, S | 1 |
| Yankowitz, J | 1 |
| Greenberg, B | 1 |
| Neaton, JD | 1 |
| Anker, SD | 2 |
| Byra, WM | 1 |
| Deng, H | 1 |
| Fu, M | 1 |
| La Police, DA | 1 |
| Lam, CSP | 1 |
| Mehra, MR | 1 |
| Nessel, CC | 1 |
| Spiro, TE | 1 |
| van Veldhuisen, DJ | 3 |
| Vanden Boom, CM | 1 |
| Zannad, F | 2 |
| Reddy, S | 1 |
| Jim, B | 1 |
| Kovačević, SV | 1 |
| Barać, A | 1 |
| Gaćeša, D | 1 |
| Perić, AV | 1 |
| Jožin, SM | 1 |
| Förster-Ruhrmann, U | 1 |
| Behrbohm, W | 1 |
| Pierchalla, G | 1 |
| Szczepek, AJ | 1 |
| Fluhr, JW | 1 |
| Olze, H | 1 |
| Souza, ND | 1 |
| Belin, BS | 1 |
| Araújo, SM | 1 |
| Sant'ana, DMG | 1 |
| Araújo, EJA | 1 |
| P Filho, P | 1 |
| Nihei, OK | 1 |
| Moreira, NM | 2 |
| Branch, KR | 1 |
| Probstfield, JL | 1 |
| Cheng, RK | 1 |
| Cleland, EJ | 1 |
| Bassiouni, A | 1 |
| Wormald, PJ | 1 |
| Phankingthongkum, R | 1 |
| Panchavinnin, P | 1 |
| Chinthammitr, Y | 1 |
| Tresukosol, D | 1 |
| Chotinaiwattarakul, C | 1 |
| Tungsubutra, W | 1 |
| Wongpraparut, N | 1 |
| Karevee, D | 1 |
| Sumalee, C | 1 |
| Molina-Berríos, A | 1 |
| Campos-Estrada, C | 1 |
| Lapier, M | 1 |
| Duaso, J | 1 |
| Kemmerling, U | 1 |
| Galanti, N | 1 |
| Ferreira, J | 1 |
| Morello, A | 1 |
| López-Muñoz, R | 1 |
| Maya, JD | 1 |
| Jang, DW | 1 |
| Comer, BT | 1 |
| Lachanas, VA | 1 |
| Kountakis, SE | 3 |
| Kutlu, A | 1 |
| Salihoglu, M | 1 |
| Haholu, A | 1 |
| Cesmeci, E | 1 |
| Cincik, H | 1 |
| Ozturk, S | 2 |
| Li, Q | 1 |
| Tian, Y | 1 |
| Wang, ZF | 1 |
| Liu, SB | 1 |
| Mi, WL | 1 |
| Ma, HJ | 1 |
| Wu, GC | 1 |
| Yu, J | 1 |
| Wang, YQ | 1 |
| Edward, JA | 1 |
| Sanyal, M | 1 |
| Ramakrishnan, VR | 2 |
| Le, W | 1 |
| Nguyen, AL | 1 |
| Kingdom, TT | 2 |
| Hwang, PH | 1 |
| Nayak, JV | 1 |
| Matsuo, H | 1 |
| Yokooji, T | 1 |
| Morita, H | 1 |
| Ooi, M | 1 |
| Urata, K | 1 |
| Ishii, K | 1 |
| Takahagi, S | 1 |
| Yanase, Y | 1 |
| Hiragun, T | 1 |
| Mihara, S | 1 |
| Hide, M | 1 |
| Schlosser, RJ | 1 |
| Schmedes, GW | 1 |
| Storck, K | 1 |
| Mulligan, JK | 1 |
| Reina-Couto, M | 1 |
| Carvalho, J | 1 |
| Valente, MJ | 1 |
| Vale, L | 1 |
| Afonso, J | 1 |
| Carvalho, F | 1 |
| Bettencourt, P | 1 |
| Sousa, T | 1 |
| Albino-Teixeira, A | 1 |
| Klimek, L | 2 |
| Dollner, R | 1 |
| Pfaar, O | 1 |
| Mullol, J | 1 |
| Parikh, A | 3 |
| Scadding, GK | 1 |
| Souza, EV | 1 |
| Torloni, MR | 1 |
| Atallah, AN | 1 |
| Santos, GM | 1 |
| Kulay, L | 1 |
| Sass, N | 1 |
| Świerczyńska-Krępa, M | 2 |
| Sanak, M | 4 |
| Bochenek, G | 1 |
| Stręk, P | 2 |
| Ćmiel, A | 1 |
| Gielicz, A | 1 |
| Plutecka, H | 1 |
| Szczeklik, A | 4 |
| Niżankowska-Mogilnicka, E | 2 |
| Santilli, F | 1 |
| Paloscia, L | 1 |
| Liani, R | 1 |
| Di Nicola, M | 1 |
| Di Marco, M | 1 |
| Lattanzio, S | 1 |
| La Barba, S | 1 |
| Pascale, S | 1 |
| Mascellanti, M | 1 |
| Davì, G | 1 |
| Palikhe, S | 1 |
| Palikhe, NS | 1 |
| Kim, SH | 6 |
| Yoo, HS | 1 |
| Shin, YS | 1 |
| Park, HS | 5 |
| Sánchez-Borges, M | 1 |
| Caballero-Fonseca, F | 1 |
| Capriles-Hulett, A | 1 |
| González-Aveledo, L | 1 |
| Cavkaytar, O | 1 |
| Arik Yilmaz, E | 1 |
| Buyuktiryaki, B | 1 |
| Sekerel, BE | 1 |
| Sackesen, C | 1 |
| Soyer, OU | 1 |
| Sethukumar, P | 1 |
| Heywood, R | 1 |
| Narula, A | 1 |
| Shi, L | 1 |
| Pu, J | 1 |
| Xu, L | 1 |
| Malaguit, J | 1 |
| Zhang, J | 1 |
| Chen, S | 1 |
| Matura, LA | 1 |
| Ventetuolo, CE | 1 |
| Palevsky, HI | 1 |
| Lederer, DJ | 1 |
| Horn, EM | 1 |
| Mathai, SC | 1 |
| Pinder, D | 1 |
| Archer-Chicko, C | 1 |
| Bagiella, E | 1 |
| Roberts, KE | 1 |
| Tracy, RP | 1 |
| Hassoun, PM | 1 |
| Girgis, RE | 1 |
| Kawut, SM | 1 |
| Dazy, KM | 1 |
| DeConde, AS | 1 |
| Suh, JD | 1 |
| Mace, JC | 1 |
| Alt, JA | 1 |
| Smith, TL | 3 |
| Makowska, J | 1 |
| Lewandowska-Polak, A | 1 |
| Wojtczak, A | 1 |
| Skrętkowicz, J | 1 |
| Szabó, K | 1 |
| Polyánka, H | 1 |
| Kiricsi, Á | 1 |
| Révész, M | 1 |
| Vóna, I | 1 |
| Szabó, Z | 1 |
| Bella, Z | 1 |
| Kadocsa, E | 1 |
| Kemény, L | 1 |
| Széll, M | 1 |
| Hirschberg, A | 1 |
| Barinov, EF | 1 |
| Mamedaliyeva, S | 1 |
| Tverdokhleb, TA | 1 |
| Forsythe, RO | 1 |
| Phillips, C | 1 |
| Hinchliffe, RJ | 1 |
| Pezato, R | 1 |
| Holtappels, G | 2 |
| De Ruyck, N | 1 |
| Derycke, L | 1 |
| Van Crombruggen, K | 1 |
| Bachert, C | 5 |
| Pérez-Novo, CA | 1 |
| Araújo, EJ | 1 |
| Sant'Ana, DM | 1 |
| Chin, KL | 1 |
| Collier, TJ | 1 |
| Pitt, B | 1 |
| McMurray, JJ | 2 |
| Swedberg, K | 1 |
| Pocock, SJ | 1 |
| Vincent, J | 1 |
| Turgonyi, E | 1 |
| Krum, H | 1 |
| Gitomer, SA | 1 |
| Fountain, CR | 1 |
| Getz, AE | 1 |
| Sillau, SH | 1 |
| Bartsch, E | 1 |
| Medcalf, KE | 1 |
| Park, AL | 2 |
| Ray, JG | 2 |
| Helou, A | 1 |
| Walker, S | 1 |
| Stewart, K | 1 |
| George, J | 1 |
| Dunn, NM | 1 |
| Porcaro, F | 1 |
| Di Marco, A | 1 |
| Cutrera, R | 1 |
| Schleimer, RP | 1 |
| Stevenson, DD | 2 |
| Gudziol, V | 2 |
| Michel, M | 1 |
| Sonnefeld, C | 1 |
| Koschel, D | 1 |
| Hummel, T | 2 |
| Darby, IA | 1 |
| Weller, CD | 1 |
| De Souza, LR | 1 |
| Connelly, PW | 1 |
| Bujold, E | 1 |
| Berger, H | 1 |
| Scott, JR | 1 |
| Ernst, HM | 1 |
| Rotenberg, BW | 1 |
| Rudmik, L | 1 |
| Sowerby, LJ | 1 |
| Gallagher, AM | 2 |
| Rietbrock, S | 2 |
| Plumb, J | 1 |
| van Staa, TP | 2 |
| Walter, T | 1 |
| Szabo, S | 2 |
| Kazmaier, S | 1 |
| Swoboda, S | 1 |
| Suselbeck, T | 1 |
| Brueckmann, M | 1 |
| Borggrefe, M | 1 |
| Beyer, ME | 1 |
| Hoffmeister, HM | 1 |
| Williams, AN | 1 |
| Grinshteĭn, IuI | 1 |
| Savchenko, AA | 1 |
| Grinshteĭn, IIu | 1 |
| Savchenko, EA | 1 |
| Schwartz, KA | 1 |
| Schwartz, DE | 1 |
| Barber, K | 1 |
| Reeves, M | 1 |
| De Franco, AC | 1 |
| Yoshimura, T | 1 |
| Yoshikawa, M | 1 |
| Otori, N | 1 |
| Haruna, S | 1 |
| Moriyama, H | 1 |
| Doucet, J | 1 |
| Gréboval-Furstenfeld, E | 1 |
| Tavildari, A | 1 |
| M'bello, L | 1 |
| Delaunay, O | 1 |
| Pesqué, T | 1 |
| Moirot, P | 1 |
| Mouton-Schleifer, D | 1 |
| Caversaccio, M | 1 |
| Häusler, R | 1 |
| Helbling, A | 1 |
| Ye, YM | 4 |
| Hur, GY | 3 |
| Park, HJ | 1 |
| Kim, HM | 1 |
| Das, S | 1 |
| Maeso, PA | 1 |
| Becker, AM | 1 |
| Prosser, JD | 1 |
| Adam, BL | 1 |
| Kang, YM | 1 |
| Cho, BY | 1 |
| Tay, KH | 1 |
| Lane, DA | 1 |
| Plumb, JM | 1 |
| Massie, BM | 2 |
| Collins, JF | 1 |
| Ammon, SE | 1 |
| Armstrong, PW | 1 |
| Cleland, JG | 1 |
| Ezekowitz, M | 1 |
| Jafri, SM | 1 |
| Krol, WF | 1 |
| O'Connor, CM | 1 |
| Schulman, KA | 1 |
| Teo, K | 1 |
| Warren, SR | 1 |
| Rodríguez, C | 1 |
| Medici, M | 1 |
| Rodríguez, AV | 1 |
| Mozzi, F | 1 |
| Font de Valdez, G | 1 |
| Günther, C | 1 |
| Meurer, M | 1 |
| Stein, A | 1 |
| Viehweg, A | 1 |
| Lee-Kirsch, MA | 1 |
| Platt, M | 1 |
| Metson, R | 2 |
| Stankovic, K | 1 |
| Buriachkovskaia, LI | 1 |
| Uchitel', IA | 1 |
| Sumarokov, AV | 1 |
| Popov, EG | 1 |
| Scher, AI | 1 |
| Lipton, RB | 1 |
| Stewart, WF | 1 |
| Bigal, M | 1 |
| Canonica, GW | 1 |
| Casale, TB | 1 |
| Cruz, AA | 1 |
| Lockey, RJ | 1 |
| Zuberbier, T | 1 |
| Cohen, M | 1 |
| Kan, LP | 1 |
| Chu, KM | 1 |
| Lin, GM | 1 |
| Jung, H | 1 |
| Naganawa, S | 1 |
| Ishihara, S | 1 |
| Iwano, S | 1 |
| Sone, M | 1 |
| Nakashima, T | 1 |
| Krupa, M | 1 |
| Moskała, M | 1 |
| Składzień, T | 1 |
| Grzywna, E | 1 |
| Donghi, D | 1 |
| Mainetti, C | 1 |
| Kaithwas, G | 1 |
| Majumdar, DK | 1 |
| Savoia, F | 1 |
| Gaddoni, G | 1 |
| Casadio, C | 1 |
| Patrizi, A | 1 |
| Spadola, G | 1 |
| Bassi, P | 1 |
| Albertini, F | 1 |
| Ballardini, G | 1 |
| Briganti, E | 1 |
| Casolari, S | 1 |
| De Donà, D | 1 |
| Menni, B | 1 |
| Zanotti, M | 1 |
| De Angelis, P | 1 |
| Ponikowski, P | 1 |
| Ronco, C | 1 |
| Wood, AJ | 1 |
| Douglas, RG | 1 |
| Fukunaga, A | 1 |
| Hatakeyama, M | 1 |
| Taguchi, K | 1 |
| Shimizu, H | 1 |
| Horikawa, T | 1 |
| Nishigori, C | 1 |
| Driver, JA | 1 |
| Yung, R | 1 |
| Gaziano, JM | 4 |
| Kurth, T | 3 |
| Kuznetsov, MR | 1 |
| Tepliakov, SA | 1 |
| Sizarev, AV | 1 |
| Tugdumov, BV | 1 |
| Dzhalilova, NS | 1 |
| Malekzadeh, F | 1 |
| Marshall, T | 1 |
| Pourshams, A | 1 |
| Gharravi, M | 1 |
| Aslani, A | 1 |
| Nateghi, A | 1 |
| Rastegarpanah, M | 1 |
| Khoshnia, M | 1 |
| Semnani, S | 1 |
| Salahi, R | 1 |
| Thomas, GN | 1 |
| Larijani, B | 1 |
| Cheng, KK | 1 |
| Malekzadeh, R | 1 |
| Strand, M | 1 |
| Prasertsuntarasai, T | 1 |
| Leung, R | 1 |
| Zheng, W | 1 |
| Alam, R | 1 |
| Jardine, MJ | 1 |
| Ninomiya, T | 1 |
| Perkovic, V | 1 |
| Cass, A | 1 |
| Turnbull, F | 1 |
| Gallagher, MP | 1 |
| Zoungas, S | 1 |
| Lambers Heerspink, HJ | 1 |
| Chalmers, J | 1 |
| Zanchetti, A | 1 |
| Wali, RK | 1 |
| Douglas, GC | 1 |
| Karkos, PD | 1 |
| Swift, AC | 1 |
| Gao, F | 1 |
| Zhou, YJ | 1 |
| Wang, ZJ | 1 |
| Yang, SW | 1 |
| Nie, B | 1 |
| Liu, XL | 1 |
| Jia, de A | 1 |
| Yan, ZX | 1 |
| Htun, P | 1 |
| Fateh-Moghadam, S | 1 |
| Bischofs, C | 1 |
| Banya, W | 1 |
| Müller, K | 1 |
| Bigalke, B | 1 |
| Stellos, K | 1 |
| May, AE | 1 |
| Flather, M | 1 |
| Gawaz, M | 1 |
| Geisler, T | 1 |
| Mukherjee, S | 1 |
| Machado, FS | 1 |
| Huang, H | 1 |
| Oz, HS | 1 |
| Jelicks, LA | 1 |
| Prado, CM | 1 |
| Koba, W | 1 |
| Fine, EJ | 1 |
| Zhao, D | 1 |
| Factor, SM | 1 |
| Collado, JE | 1 |
| Weiss, LM | 1 |
| Tanowitz, HB | 1 |
| Ashton, AW | 1 |
| Chávez, E | 1 |
| Castro-Sánchez, L | 1 |
| Shibayama, M | 1 |
| Tsutsumi, V | 1 |
| Pérez Salazar, E | 1 |
| Moreno, MG | 1 |
| Muriel, P | 1 |
| Yawn, BP | 1 |
| Martín de Argila de Prados, C | 1 |
| Rizk, H | 1 |
| Bech, FR | 1 |
| Chertow, GM | 1 |
| Dixon, BS | 1 |
| Beck, GJ | 1 |
| Dember, LM | 1 |
| Vazquez, MA | 1 |
| Greenberg, A | 1 |
| Delmez, JA | 1 |
| Allon, M | 2 |
| Himmelfarb, J | 1 |
| Hu, B | 1 |
| Greene, T | 1 |
| Radeva, MK | 1 |
| Davidson, IJ | 1 |
| Ikizler, TA | 1 |
| Braden, GL | 1 |
| Lawson, JH | 1 |
| Cotton, JR | 1 |
| Kusek, JW | 1 |
| Feldman, HI | 1 |
| Diener, HC | 1 |
| Weber, R | 1 |
| Weimar, C | 1 |
| Röther, J | 1 |
| Mascitelli, L | 1 |
| Goldstein, MR | 1 |
| Latthe, PM | 1 |
| Champaneria, R | 1 |
| Khan, KS | 1 |
| Hart, RG | 1 |
| Pearce, LA | 1 |
| Asinger, RW | 1 |
| Herzog, CA | 1 |
| Kozdağ, G | 1 |
| Yaymacı, M | 1 |
| Ertaş, G | 1 |
| Celikyurt, U | 1 |
| Sahin, T | 1 |
| Kılıç, T | 1 |
| Ural, D | 1 |
| Merkonidis, C | 1 |
| Cecchini, MP | 1 |
| Gerber, J | 1 |
| Seo, HS | 1 |
| Evans, CD | 1 |
| Eurich, DT | 1 |
| Remillard, AJ | 1 |
| Shevchuk, YM | 1 |
| Blackburn, D | 1 |
| Basra, SS | 1 |
| Tsai, P | 1 |
| Lakkis, NM | 1 |
| Zhang, L | 1 |
| Maya, ID | 1 |
| Bray, MS | 1 |
| Fernandez, JR | 1 |
| Broder, A | 1 |
| Tobin, JN | 1 |
| Putterman, C | 1 |
| del Río Solá, ML | 1 |
| Antonio, J | 1 |
| Fajardo, G | 1 |
| Vaquero Puerta, C | 1 |
| Niccoli, G | 1 |
| Giubilato, S | 1 |
| Leo, A | 1 |
| Cosentino, N | 1 |
| Fracassi, F | 1 |
| Cataneo, L | 1 |
| Porto, I | 1 |
| Leone, AM | 1 |
| Burzotta, F | 1 |
| Trani, C | 1 |
| Biasucci, LM | 1 |
| Narducci, ML | 1 |
| Pulcinelli, FM | 1 |
| Crea, F | 1 |
| Fruth, K | 1 |
| Goebel, G | 1 |
| Koutsimpelas, D | 1 |
| Gosepath, J | 2 |
| Schmidtmann, I | 1 |
| Mann, WJ | 2 |
| Brieger, J | 1 |
| Gokce, M | 1 |
| Altan, I | 1 |
| Unal, S | 1 |
| Kuskonmaz, B | 1 |
| Aytac, S | 1 |
| Cetin, M | 1 |
| Tuncer, M | 1 |
| Gumruk, F | 1 |
| Gurgey, A | 1 |
| Wrigley, BJ | 1 |
| Pisters, R | 1 |
| Azoulay, L | 1 |
| Dell'Aniello, S | 1 |
| Simon, TA | 1 |
| Langleben, D | 1 |
| Renoux, C | 1 |
| Suissa, S | 1 |
| Celejewska-Wójcik, N | 1 |
| Mastalerz, L | 3 |
| Wójcik, K | 1 |
| Nieckarz, R | 1 |
| Januszek, R | 1 |
| Hartwich, P | 1 |
| Szaleniec, J | 1 |
| Hydzik-Sobocińska, K | 1 |
| Oleś, K | 1 |
| Cybulska, A | 1 |
| Pattanaik, D | 1 |
| Lieberman, P | 1 |
| Das, P | 1 |
| Funosas, E | 1 |
| Feser, G | 1 |
| Escovich, L | 1 |
| Maestri, L | 1 |
| Di, W | 1 |
| Shi, X | 1 |
| Zhu, Y | 1 |
| Tao, Y | 1 |
| Qi, W | 1 |
| Luo, N | 1 |
| Xiao, Z | 1 |
| Yi, C | 1 |
| Miao, J | 1 |
| Zhang, A | 1 |
| Zhang, X | 1 |
| Fang, Y | 1 |
| Sahasrabuddhe, VV | 1 |
| Gunja, MZ | 1 |
| Graubard, BI | 1 |
| Trabert, B | 1 |
| Schwartz, LM | 1 |
| Park, Y | 1 |
| Hollenbeck, AR | 1 |
| Freedman, ND | 1 |
| McGlynn, KA | 1 |
| Kamath, S | 2 |
| Blann, AD | 3 |
| Chin, BS | 2 |
| Berde, CB | 1 |
| Sethna, NF | 1 |
| Berges-Gimeno, MP | 1 |
| Di Lorenzo, G | 2 |
| Pacor, ML | 2 |
| Vignola, AM | 1 |
| Profita, M | 1 |
| Esposito-Pellitteri, M | 1 |
| Biasi, D | 1 |
| Corrocher, R | 2 |
| Caruso, C | 1 |
| Stange, EF | 1 |
| Wepner, U | 1 |
| Rasmussen, A | 1 |
| Christensen, J | 1 |
| Clemmensen, PM | 1 |
| Dalsgaard, NJ | 1 |
| Dam, H | 1 |
| Hindberg, I | 1 |
| Lunde, M | 1 |
| Plenge, P | 1 |
| Mellerup, E | 1 |
| Brost, H | 1 |
| Ott, H | 1 |
| Pfannenstiel, C | 1 |
| Wenzl, TG | 1 |
| Heimann, G | 1 |
| Rossatto, ER | 1 |
| da Silva, LB | 1 |
| Pereira, GS | 1 |
| Bonan, CD | 1 |
| Battastini, AM | 1 |
| Ribeiro, JP | 1 |
| Sarkis, JJ | 1 |
| Stumpf, C | 1 |
| Lehner, C | 1 |
| Yilmaz, A | 1 |
| Daniel, WG | 1 |
| Garlichs, CD | 1 |
| Dare, WN | 1 |
| Noronha, CC | 1 |
| Kusemiju, OT | 1 |
| Okanlawon, OA | 1 |
| Kantarci, A | 1 |
| Van Dyke, TE | 1 |
| Kumana, CR | 1 |
| Leung, CS | 1 |
| Tam, KM | 1 |
| Meune, C | 1 |
| Mahé, I | 2 |
| Mourad, JJ | 1 |
| Cohen-Solal, A | 1 |
| Levy, B | 1 |
| Kevorkian, JP | 1 |
| Jondeau, G | 1 |
| Habib, A | 1 |
| Lebret, M | 1 |
| Knellwolf, AL | 1 |
| Simoneau, G | 1 |
| Caulin, C | 2 |
| Bergmann, JF | 2 |
| Guazzi, M | 1 |
| Brambilla, R | 1 |
| Reina, G | 1 |
| Tumminello, G | 1 |
| Guazzi, MD | 1 |
| Martin, DO | 1 |
| Losi, MA | 1 |
| Golino, P | 1 |
| Betocchi, S | 1 |
| Ragni, M | 1 |
| Aversa, M | 1 |
| Chiariello, M | 1 |
| Grenard, AS | 1 |
| WARIN, RP | 5 |
| ALEXANDER, S | 1 |
| BOYLE, RW | 1 |
| TABET, RC | 1 |
| WIGHTMAN, BK | 1 |
| Pods, R | 1 |
| Ross, D | 1 |
| van Hülst, S | 1 |
| Rudack, C | 1 |
| Maune, S | 1 |
| Morgan, G | 1 |
| Spivak, JL | 1 |
| Barosi, G | 1 |
| Tognoni, G | 1 |
| Barbui, T | 1 |
| Finazzi, G | 1 |
| Marchioli, R | 1 |
| Marchetti, M | 1 |
| Mita, H | 1 |
| Kawagishi, Y | 1 |
| Higashi, A | 1 |
| Osame, M | 1 |
| Akiyama, K | 1 |
| Gurbel, PA | 1 |
| Bliden, KP | 1 |
| Millecamps, M | 1 |
| Etienne, M | 1 |
| Jourdan, D | 1 |
| Eschalier, A | 1 |
| Ardid, D | 1 |
| Ferguson, BJ | 3 |
| Erbagci, Z | 1 |
| Blich, M | 1 |
| Gross, B | 1 |
| Michaud, DS | 1 |
| Albaladejo, P | 1 |
| Geeraerts, T | 1 |
| Francis, F | 1 |
| Castier, Y | 1 |
| Lesèche, G | 1 |
| Marty, J | 1 |
| Blassneck, K | 1 |
| Nusko, G | 1 |
| Niedobitek, G | 1 |
| Hahn, EG | 4 |
| Harsch, IA | 1 |
| Maeda, K | 1 |
| Sakai, T | 1 |
| Hira, K | 1 |
| Sato, TS | 1 |
| Bito, S | 1 |
| Asai, A | 1 |
| Hayano, K | 1 |
| Matsumura, S | 1 |
| Yamashiro, S | 1 |
| Fukui, T | 1 |
| Van Zele, T | 2 |
| Gevaert, P | 2 |
| Watelet, JB | 1 |
| Claeys, G | 1 |
| Claeys, C | 1 |
| van Cauwenberge, P | 2 |
| Preobrazhenskiĭ, DV | 1 |
| Sidorenko, BA | 1 |
| Kiktev, VG | 1 |
| Batyraliev, TA | 1 |
| Pershukov, IV | 1 |
| Löbner, K | 1 |
| Füchtenbusch, M | 1 |
| Pilotto, A | 1 |
| Franceschi, M | 1 |
| Leandro, G | 1 |
| Paris, F | 1 |
| Cascavilla, L | 1 |
| Longo, MG | 1 |
| Niro, V | 1 |
| Andriulli, A | 1 |
| Scarcelli, C | 1 |
| Di Mario, F | 1 |
| Brzozowska, I | 1 |
| Targosz, A | 1 |
| Sliwowski, Z | 2 |
| Kwiecien, S | 2 |
| Drozdowicz, D | 3 |
| Pajdo, R | 2 |
| Konturek, PC | 3 |
| Brzozowski, T | 3 |
| Pawlik, M | 1 |
| Konturek, SJ | 3 |
| Pawlik, WW | 2 |
| Amrol, D | 1 |
| Murray, JJ | 1 |
| Corrigan, C | 1 |
| Mallett, K | 1 |
| Ying, S | 2 |
| Roberts, D | 1 |
| Scadding, G | 2 |
| Lee, T | 1 |
| O'Brien, CL | 1 |
| Gage, BF | 1 |
| Baigent, C | 1 |
| Landray, M | 1 |
| Leaper, C | 1 |
| Altmann, P | 1 |
| Armitage, J | 1 |
| Baxter, A | 1 |
| Cairns, HS | 1 |
| Collins, R | 1 |
| Foley, RN | 1 |
| Frighi, V | 1 |
| Kourellias, K | 1 |
| Ratcliffe, PJ | 1 |
| Rogerson, M | 1 |
| Scoble, JE | 1 |
| Tomson, CR | 1 |
| Warwick, G | 1 |
| Wheeler, DC | 1 |
| Krane, V | 1 |
| Wanner, C | 1 |
| Park, SH | 1 |
| Park, DI | 1 |
| Kim, HJ | 1 |
| Cho, YK | 1 |
| Sung, IK | 1 |
| Sohn, CI | 1 |
| Jeon, WK | 1 |
| Kim, BI | 1 |
| Keum, DK | 1 |
| Joshi, SR | 1 |
| Zwolinska-Wcislo, M | 1 |
| Stachura, J | 1 |
| Budak, A | 1 |
| Bogdal, J | 1 |
| Setkowicz, M | 1 |
| Cormican, LJ | 1 |
| Farooque, S | 1 |
| Altmann, DR | 1 |
| Lee, TH | 2 |
| Mascia, K | 1 |
| Patrie, J | 1 |
| Hunt, J | 1 |
| Phillips, CD | 1 |
| Steinke, JW | 1 |
| Jochmann, N | 1 |
| Stangl, K | 1 |
| Garbe, E | 1 |
| Baumann, G | 1 |
| Stangl, V | 1 |
| Koga, T | 1 |
| Oshita, Y | 1 |
| Kamimura, T | 1 |
| Koga, H | 1 |
| Aizawa, H | 1 |
| Trent, JT | 1 |
| Falabella, A | 1 |
| Eaglstein, WH | 1 |
| Kirsner, RS | 1 |
| Karaayvaz, M | 1 |
| Caliskaner, Z | 1 |
| Gulec, M | 1 |
| Kannan, S | 1 |
| Gelber, RP | 2 |
| Kausz, AT | 1 |
| Manson, JE | 2 |
| Buring, JE | 2 |
| Levey, AS | 1 |
| Oates, JA | 1 |
| Lovett, JK | 1 |
| Gutowski, NJ | 1 |
| de Weck, A | 1 |
| Sanz, ML | 1 |
| Gamboa, P | 1 |
| Meng, Q | 1 |
| Corrigan, CJ | 1 |
| Wise, J | 1 |
| Watala, C | 1 |
| Ulicna, O | 1 |
| Golanski, J | 1 |
| Nocun, M | 1 |
| Waczulíková, I | 1 |
| Markuszewski, L | 1 |
| Drzewoski, J | 1 |
| Piepoli, MF | 2 |
| Lee, JY | 1 |
| Sok, JC | 2 |
| Schmidt, M | 1 |
| Brömsen, J | 1 |
| Blumenstein, M | 1 |
| Manoharan, A | 1 |
| Gemmell, R | 1 |
| Hartwell, T | 1 |
| Serebruany, VL | 1 |
| Midei, MG | 1 |
| Meilman, H | 1 |
| Malinin, AI | 1 |
| Lowry, DR | 1 |
| Lindblad, CI | 1 |
| Gross, CR | 1 |
| Sloane, RJ | 1 |
| Pieper, CF | 1 |
| Hajjar, ER | 1 |
| Ruby, CM | 1 |
| Schmader, KE | 1 |
| Frishman, WH | 1 |
| Veresh, M | 1 |
| Schlocker, SJ | 1 |
| Tejani, N | 1 |
| Abe, T | 1 |
| Hayashi, M | 1 |
| Sakagami, T | 1 |
| Tsutsui, N | 1 |
| Ito, K | 2 |
| Nakajima, H | 1 |
| Haraguchi, M | 1 |
| Garcia-Donaire, JA | 1 |
| Ruilope, LM | 1 |
| Bae, JS | 1 |
| Yoon, HJ | 1 |
| Suh, CH | 1 |
| Nahm, DH | 1 |
| Bernardo, E | 1 |
| Angiolillo, DJ | 1 |
| Ramírez, C | 1 |
| Cavallari, U | 1 |
| Trabetti, E | 1 |
| Sabaté, M | 1 |
| Hernández, R | 1 |
| Moreno, R | 1 |
| Escaned, J | 1 |
| Alfonso, F | 1 |
| Bañuelos, C | 1 |
| Costa, MA | 1 |
| Bass, TA | 1 |
| Pignatti, PF | 1 |
| Macaya, C | 1 |
| Fernandez-Ortiz, A | 1 |
| Turchin, I | 1 |
| Barankin, B | 1 |
| Saha, S | 1 |
| Berglund, M | 1 |
| Sylvén, C | 1 |
| Gordon, A | 1 |
| Ducros, A | 1 |
| Robinson, JL | 1 |
| Griest, S | 1 |
| James, KE | 1 |
| Zhang, N | 1 |
| Patou, J | 1 |
| Patane', S | 1 |
| Marte, F | 1 |
| Di Bella, G | 1 |
| Chiribiri, A | 1 |
| von Pape, KW | 1 |
| Dzijan-Horn, M | 1 |
| Bohner, J | 1 |
| Spannagl, M | 1 |
| Weisser, H | 1 |
| Calatzis, A | 1 |
| Kim, JE | 1 |
| Agrawal, A | 1 |
| Joharapurkar, SR | 1 |
| Gharde, P | 1 |
| Merritt, MA | 1 |
| Green, AC | 1 |
| Nagle, CM | 1 |
| Webb, PM | 1 |
| Browne, JP | 1 |
| Slack, R | 1 |
| Lund, V | 1 |
| Brown, P | 1 |
| Kune, GA | 1 |
| Kune, S | 1 |
| Watson, LF | 1 |
| Schaeffner, ES | 1 |
| Bowman, TS | 1 |
| Chang, JY | 1 |
| Locke, GR | 1 |
| Schleck, CD | 1 |
| Zinsmeister, AR | 1 |
| Talley, NJ | 2 |
| Friedewald, VE | 1 |
| King, SB | 1 |
| Pepine, CJ | 1 |
| Vetrovec, GW | 1 |
| Roberts, WC | 1 |
| Thomas, MC | 1 |
| Choi, SJ | 1 |
| Shin, SY | 1 |
| Han, JH | 1 |
| Sechtem, U | 1 |
| Joe, SA | 1 |
| Thakkar, K | 1 |
| Stankovic, KM | 1 |
| Goldsztein, H | 1 |
| Reh, DD | 1 |
| Platt, MP | 1 |
| Grevers, G | 1 |
| Ryan, MW | 1 |
| Moore-Robinson, M | 1 |
| Kaplan, AP | 1 |
| Lacouture, PG | 1 |
| Gaudreault, P | 1 |
| Lovejoy, FH | 1 |
| Krilis, S | 1 |
| Gregson, RP | 1 |
| Basten, A | 1 |
| Baldo, BA | 1 |
| Kirk, RM | 1 |
| Stambaugh, JE | 2 |
| Wüthrich, B | 1 |
| Pinals, RS | 1 |
| Vargha von Szeged, A | 1 |
| Michos, N | 1 |
| Falliers, CJ | 2 |
| Novak, EJ | 1 |
| Viau, C | 1 |
| Bernard, A | 1 |
| Lauwerys, R | 1 |
| Maldague, P | 1 |
| Lundeberg, TC | 1 |
| Gendeleka, GF | 1 |
| Gruzina, EA | 1 |
| Scherrer, M | 1 |
| Zeller, C | 1 |
| Berger, M | 1 |
| Towns, SJ | 1 |
| Mellis, CM | 1 |
| Boughton, BJ | 1 |
| Jerrome, DW | 1 |
| Rychetnik, M | 1 |
| Mancinella, A | 1 |
| Ortolani, C | 1 |
| Cornelli, U | 1 |
| Bellani, M | 1 |
| Pastorello, E | 1 |
| Zanussi, C | 1 |
| Binderup, L | 1 |
| Bramm, E | 1 |
| Arrigoni-Martelli, E | 1 |
| Valles, J | 1 |
| Aznar, J | 1 |
| Santos, MT | 1 |
| Fernandez, MA | 1 |
| Schaub, RG | 1 |
| Keith, JC | 1 |
| Rawlings, CA | 1 |
| Glavinskaia, TA | 1 |
| Novikov, AI | 1 |
| Pavlova, LT | 1 |
| Settipane, GA | 2 |
| Treadwell, BL | 1 |
| Rane, A | 1 |
| Säwe, J | 1 |
| Dahlström, B | 1 |
| Paalzow, L | 1 |
| Kager, L | 1 |
| Geller, LI | 1 |
| Alekseenko, SA | 1 |
| Bessonova, GA | 1 |
| Bartolucci, L | 1 |
| Canini, F | 1 |
| Fioroni, E | 1 |
| Pinchi, G | 1 |
| Carosi, M | 2 |
| Bonaduce, D | 1 |
| Postiglione, M | 1 |
| Ferrara, N | 1 |
| Petretta, M | 1 |
| De Caprio, L | 1 |
| Rengo, F | 1 |
| Carpinteri, F | 1 |
| Caltagirone, S | 1 |
| Vagliasindi, M | 1 |
| Palermo, F | 1 |
| Di Maria, GU | 1 |
| Crimi, N | 1 |
| Cusmano, F | 1 |
| Marvulli, G | 1 |
| Partipilo, N | 1 |
| Zanierato, G | 1 |
| Ranghino, E | 1 |
| Negri, L | 1 |
| Morandini, GC | 1 |
| Zuccali, G | 1 |
| Gherson, G | 1 |
| Parenti, M | 1 |
| Tarlo, SM | 1 |
| Broder, I | 1 |
| Pfeiffer, HM | 1 |
| Valverde, E | 1 |
| Vich, JM | 1 |
| García-Calderón, JV | 1 |
| García-Calderón, PA | 1 |
| Calabro, JJ | 1 |
| Sidorova, LD | 1 |
| Arkhipov, BF | 1 |
| Degtiareva, MM | 1 |
| Barkagan, LZ | 1 |
| Dormandy, JA | 1 |
| Maruta, T | 1 |
| Swanson, DW | 1 |
| Kosturkov, G | 1 |
| Staneva-Stoianova, M | 1 |
| Mileva, Zh | 1 |
| Dudka, PF | 1 |
| Lehman, CW | 1 |
| Simoons, ML | 1 |
| Deckers, JW | 1 |
| van Wijngaarden, J | 1 |
| Smit, AJ | 1 |
| de Graeff, PA | 1 |
| van Gilst, WH | 1 |
| van der Broek, SA | 1 |
| Lie, KI | 1 |
| Wesseling, H | 1 |
| Grossman, CM | 1 |
| Rienhardt, GW | 1 |
| Steyn, PS | 1 |
| Odendaal, HJ | 1 |
| Koskinen, P | 1 |
| Kupari, M | 1 |
| Halinen, MO | 1 |
| Poungvarin, N | 1 |
| Opartkiattikul, N | 1 |
| Chaithiraphan, S | 1 |
| Viriyavejakul, A | 1 |
| Newton, W | 1 |
| Ruckley, CV | 1 |
| Prescott, RJ | 1 |
| Buzás, G | 1 |
| Layton, AM | 1 |
| Ibbotson, SH | 1 |
| Davies, JA | 1 |
| Goodfield, MJ | 1 |
| Smith, RJ | 2 |
| Burton, JL | 1 |
| Marshall, RE | 1 |
| Tyrrell, MR | 1 |
| Sizykh, TP | 1 |
| Efimova, NIu | 1 |
| Kohriyama, T | 1 |
| Tanaka, E | 1 |
| Katayama, S | 1 |
| Yamamura, Y | 1 |
| Nakamura, S | 1 |
| Knotková, V | 5 |
| Nĕmecek, K | 5 |
| Ramsay, LE | 1 |
| Yip, L | 1 |
| Dart, RC | 1 |
| Gabow, PA | 1 |
| Duclos, J | 1 |
| Rogov, VA | 1 |
| Tareeva, IE | 1 |
| Sidorova, IS | 1 |
| Androsova, SO | 1 |
| Katamadze, KT | 1 |
| Nikiforova, OV | 1 |
| Homberg, M | 1 |
| Tschöpe, D | 1 |
| Greber, H | 1 |
| Hackländer, T | 1 |
| Schwippert, B | 1 |
| Gries, FA | 1 |
| Mödder, U | 1 |
| Chugh, S | 1 |
| Dilawari, JB | 1 |
| Sawhney, IM | 1 |
| Dang, N | 1 |
| Radotra, BD | 1 |
| Chawla, YK | 1 |
| Andersson, R | 1 |
| McCowan, LM | 1 |
| Buist, RG | 1 |
| North, RA | 1 |
| Gamble, G | 1 |
| Chalasani, N | 1 |
| Roman, J | 1 |
| Jurado, RL | 1 |
| Song, JY | 1 |
| Choi, JY | 1 |
| Ko, JT | 1 |
| Bae, EJ | 1 |
| Kim, HS | 1 |
| Noh, CI | 1 |
| Yoon, YS | 1 |
| Connelly, SJ | 1 |
| Turpie, AG | 1 |
| Greenberg, PD | 1 |
| Cello, JP | 1 |
| Rockey, DC | 1 |
| Stroobandt, G | 1 |
| Fransen, P | 1 |
| Thauvoy, C | 1 |
| Menard, E | 1 |
| Carlsson, J | 1 |
| Tebbe, U | 1 |
| McFadden, EA | 2 |
| Woodson, BT | 1 |
| Massaro, BM | 1 |
| Toohill, RJ | 2 |
| Leslie, GI | 1 |
| Gallery, ED | 1 |
| Arnold, JD | 1 |
| Ross, MR | 1 |
| Gyory, AZ | 1 |
| Greenberg, ML | 1 |
| Malenka, DJ | 1 |
| Disch, DL | 1 |
| Guzzini, F | 1 |
| Ceppi, M | 1 |
| Gasparini, P | 1 |
| Sali, L | 1 |
| Vecchi, C | 1 |
| Davies, RJ | 1 |
| Abdelaziz, MM | 1 |
| Calderon, MA | 1 |
| Khair, O | 1 |
| Devalia, JL | 1 |
| Rusznak, C | 1 |
| Marroni, NP | 1 |
| Marroni, CA | 1 |
| Esser, T | 1 |
| Brugnara, L | 1 |
| Casadevall, M | 1 |
| Piqué, JM | 1 |
| Prach, AT | 1 |
| Senior, BW | 1 |
| Hopwood, D | 1 |
| McBride, PD | 1 |
| MacDonald, TM | 1 |
| Kerr, MA | 1 |
| Murray, FE | 1 |
| Tharion, G | 1 |
| Bhattacharji, S | 1 |
| Aghabeigi, B | 1 |
| Haque, M | 1 |
| Wasil, M | 1 |
| Hodges, SJ | 1 |
| Henderson, B | 1 |
| Harris, M | 1 |
| Kantachuvesiri, S | 1 |
| Kaojarern, S | 1 |
| Kitayaporn, D | 1 |
| Phanichphant, S | 1 |
| Sumethkul, V | 1 |
| Wananukul, W | 1 |
| Pongskul, C | 1 |
| Arkaravichien, W | 1 |
| Jankriengkri, S | 1 |
| Chanchairujira, T | 1 |
| Milewski, M | 1 |
| Duplaga, M | 1 |
| Nizankowska, E | 1 |
| Anzuini, A | 1 |
| Rosanio, S | 1 |
| Legrand, V | 1 |
| Tocchi, M | 1 |
| Coppi, R | 1 |
| Marazzi, G | 1 |
| Vicedomini, G | 1 |
| Pagnotta, P | 1 |
| Montorfano, M | 1 |
| Bonnier, H | 1 |
| Sheiban, I | 1 |
| Kulbertus, HE | 1 |
| Chierchia, SL | 1 |
| Lyss, AP | 1 |
| Portenoy, RK | 1 |
| Wheeldon, NM | 1 |
| Caritis, S | 1 |
| Sibai, B | 1 |
| Hauth, J | 1 |
| Lindheimer, MD | 1 |
| Klebanoff, M | 2 |
| Thom, E | 1 |
| VanDorsten, P | 1 |
| Landon, M | 2 |
| Paul, R | 2 |
| Miodovnik, M | 2 |
| Meis, P | 1 |
| Thurnau, G | 1 |
| Ohnishi-Inoue, Y | 1 |
| Mitsuya, K | 1 |
| Horio, T | 1 |
| Kolosova, OA | 1 |
| Ellis, MH | 1 |
| Dibuz, M | 1 |
| Szabó, T | 1 |
| Monoki, E | 1 |
| Nagymélykuti, L | 1 |
| Illyés, M | 1 |
| Varga, E | 1 |
| Csípö, L | 1 |
| Weightman, WM | 1 |
| Gibbs, NM | 1 |
| Sheminant, MR | 1 |
| Whitford, EG | 1 |
| Mahon, BD | 1 |
| Newman, MA | 1 |
| Aronow, WS | 1 |
| Ahn, C | 1 |
| Kronzon, I | 1 |
| Gutstein, H | 1 |
| Witlin, AG | 1 |
| Rodríguez, D | 1 |
| Agustí, A | 1 |
| van Kooten, F | 1 |
| Ciabattoni, G | 1 |
| Koudstaal, PJ | 1 |
| Grobbee, DE | 1 |
| Kluft, C | 1 |
| Patrono, C | 1 |
| Bellelli, G | 1 |
| Barbisoni, P | 1 |
| Gusmeri, A | 1 |
| Sabatini, T | 1 |
| Rozzini, R | 1 |
| Trabucchi, M | 1 |
| Atamuradov, MA | 1 |
| Garaev, TA | 1 |
| Ikonomidis, I | 1 |
| Andreotti, F | 1 |
| Economou, E | 1 |
| Stefanadis, C | 1 |
| Toutouzas, P | 1 |
| Nihoyannopoulos, P | 1 |
| Nakamura, H | 1 |
| Kawasaki, M | 1 |
| Higuchi, Y | 1 |
| Takahashi, S | 1 |
| Haddad, B | 1 |
| Hogg, B | 1 |
| Hauth, JC | 1 |
| Caritis, SN | 1 |
| Lindheimer, M | 1 |
| Van Dorsten, JP | 1 |
| MacPherson, C | 1 |
| Meis, PJ | 1 |
| Thurnau, GR | 1 |
| Dombrowski, MP | 1 |
| McNellis, D | 1 |
| Roberts, JM | 1 |
| Sturtevant, J | 1 |
| Amar, YG | 1 |
| Frenkiel, S | 1 |
| Sobol, SE | 1 |
| Li-Saw-Hee, FL | 1 |
| Cohen, N | 1 |
| Almoznino-Sarafian, D | 1 |
| Alon, I | 1 |
| Gorelik, O | 1 |
| Koopfer, M | 1 |
| Chachashvily, S | 1 |
| Shteinshnaider, M | 1 |
| Litvinjuk, V | 1 |
| Modai, D | 1 |
| Stern, S | 1 |
| Altkorn, D | 1 |
| Levinson, W | 1 |
| Thun, MJ | 1 |
| Padeh, S | 1 |
| Passwell, JH | 1 |
| Kordek, P | 1 |
| Studniarek, M | 1 |
| Kośny, B | 1 |
| Bieńkiewicz, B | 1 |
| Hosemann, W | 1 |
| Murphy, GJ | 1 |
| Taha, R | 1 |
| Windmill, DC | 1 |
| Metcalfe, M | 1 |
| Nicholson, ML | 1 |
| Backues, KA | 1 |
| Hoover, JP | 1 |
| Bahr, RJ | 1 |
| Confer, AW | 1 |
| Chalman, JA | 1 |
| Larry, ML | 1 |
| Jhund, PS | 1 |
| Davie, AP | 1 |
| Ptak, A | 1 |
| Jackson, SL | 1 |
| Peterson, GM | 1 |
| Vial, JH | 1 |
| Daud, R | 1 |
| Ang, SY | 1 |
| Mardiney, M | 1 |
| Fihn, SD | 1 |
| Williams, SV | 1 |
| Daley, J | 1 |
| Gibbons, RJ | 1 |
| Elwood, PC | 1 |
| Granel, B | 1 |
| Serratrice, J | 1 |
| Rey, J | 1 |
| Pache, X | 1 |
| Swiader, L | 1 |
| Habib, G | 1 |
| Mesana, T | 1 |
| Ene, N | 1 |
| Disdier, P | 1 |
| Weiller, PJ | 1 |
| Fukuda, N | 1 |
| Shimohakamada, Y | 1 |
| Nakamori, Y | 1 |
| Tominaga, T | 1 |
| Shinohara, K | 1 |
| Takahashi, T | 1 |
| Oeda, E | 1 |
| Sato, Y | 1 |
| Caine, GJ | 1 |
| Gurney, D | 1 |
| Strain, WD | 1 |
| Lye, M | 1 |
| Biedermann, T | 1 |
| Hartmann, K | 1 |
| Sing, A | 1 |
| Przybilla, B | 1 |
| Scott, AC | 1 |
| Wensel, R | 1 |
| Davos, CH | 1 |
| Kemp, M | 1 |
| Kaczmarek, A | 1 |
| Hooper, J | 1 |
| Coats, AJ | 1 |
| Krebs, A | 1 |
| Roduner, J | 1 |
| Franco, D | 1 |
| Durandy, Y | 1 |
| Deporte, A | 1 |
| Bismuth, H | 1 |
| Dougherty, JH | 1 |
| Levy, DE | 1 |
| Weksler, BB | 1 |
| Erlings, M | 1 |
| Jongedijk-Brondsted, H | 1 |
| Kentera, D | 1 |
| Susić, D | 1 |
| Zdravković, M | 1 |
| Sheffer, AL | 1 |
| Bazyka, DA | 1 |
| Vedanthan, PK | 1 |
| Menon, MM | 1 |
| Bell, TD | 1 |
| Bergin, D | 1 |
| Bowie, EJ | 1 |
| Owen, CA | 1 |
| Doss, M | 1 |
| Moran, H | 1 |
| Hanna, DB | 1 |
| Ansell, BM | 2 |
| Hall, M | 1 |
| Engler, C | 1 |
| Hoffmann, C | 1 |
| Petzoldt, D | 1 |
| Laplante, L | 1 |
| Beaudry, C | 1 |
| Fisherman, EW | 2 |
| Cohen, GN | 2 |
| Takeuchi, K | 3 |
| Okabe, S | 4 |
| Takagi, K | 3 |
| Umeda, N | 1 |
| Kaaber, K | 1 |
| Dorofeev, GI | 1 |
| Ivashkin, VT | 1 |
| Kuznetsov, VV | 1 |
| Tkachenko, EI | 1 |
| Tabata, K | 1 |
| Ishihara, Y | 1 |
| Kunimi, H | 1 |
| Izumi, K | 1 |
| Uchida, N | 1 |
| Done, AK | 1 |
| Chafee, FH | 1 |
| Postman, IM | 1 |
| Levine, MI | 1 |
| Saker, JH | 1 |
| Barrick, RH | 1 |
| Nicholas, SS | 1 |
| Schwartz, HJ | 1 |
| Honsinger, RW | 1 |
| Klein, DE | 1 |
| Sjaastad, O | 1 |
| Dale, I | 1 |
| Miyoshi, A | 1 |
| Katona, G | 1 |
| Illig, L | 2 |
| Doeglas, HM | 3 |
| Stillman, RM | 1 |
| Chapa, L | 1 |
| Stark, ML | 1 |
| Malik, LN | 1 |
| Keates, JR | 1 |
| Sawyer, PN | 1 |
| Sofia, RD | 1 |
| Honda, K | 1 |
| Takata, Y | 1 |
| Naganuma, T | 1 |
| Barkin, JS | 1 |
| Giménez Camarasa, JM | 1 |
| Braaf, MM | 1 |
| Rosne, RS | 1 |
| Athreya, BH | 1 |
| Borns, P | 1 |
| Rosenlund, ML | 1 |
| Cameron, AJ | 1 |
| Stuart, MJ | 1 |
| Murphy, S | 1 |
| Oski, FA | 1 |
| Piper, DW | 3 |
| Greig, M | 1 |
| Coupland, GA | 1 |
| Hobbin, E | 1 |
| Shinners, J | 1 |
| Adamska-Dyniewska, H | 1 |
| Goch, JH | 1 |
| Bala, T | 1 |
| Chojnacki, J | 1 |
| Chojnowska-Jezierska, J | 1 |
| Tkaczewski, W | 1 |
| Bock, OA | 2 |
| Hall, D | 1 |
| Zeitler, H | 1 |
| Rudolph, W | 1 |
| Kahn, JK | 1 |
| Koenig, A | 1 |
| Théolade, R | 1 |
| Chauvin, M | 1 |
| Brechenmacher, C | 1 |
| Oosting, E | 1 |
| Kardaun, SH | 1 |
| Los, P | 1 |
| de Monchy, JG | 1 |
| Petrů, I | 4 |
| Jáchymová, M | 4 |
| Bulbena, O | 1 |
| Escolar, G | 1 |
| Bravo, ML | 1 |
| Navarro, C | 1 |
| Nensey, YM | 1 |
| Schubert, TT | 1 |
| Bologna, SD | 1 |
| Ma, CK | 1 |
| Richlin, DM | 1 |
| Matuschak, GM | 1 |
| Yasuda, K | 1 |
| Matsui, Y | 1 |
| Goda, T | 1 |
| Sakuma, M | 1 |
| Go, K | 1 |
| Ridker, PM | 1 |
| Hennekens, CH | 2 |
| Rubin, P | 1 |
| Yee, JP | 1 |
| Ruoff, G | 1 |
| Porkodi, R | 1 |
| Subramaniam, R | 1 |
| Krishnamurthy, V | 1 |
| Madhavan, R | 1 |
| Parthiban, M | 1 |
| Chandrasekaran, AN | 1 |
| Kany, RJ | 1 |
| Fink, JN | 1 |
| Kaltenbach, M | 1 |
| Vallbracht, C | 1 |
| Goodman, DL | 1 |
| McDonnell, JT | 1 |
| Nelson, HS | 1 |
| Vaughan, TR | 1 |
| Weber, RW | 1 |
| Petersen, P | 2 |
| Cieslar, P | 1 |
| Pelèska, J | 1 |
| Pick, P | 1 |
| Tomasy, M | 1 |
| Katz, LB | 1 |
| Shriver, DA | 1 |
| Paganini-Hill, A | 1 |
| Chao, A | 1 |
| Ross, RK | 1 |
| Henderson, BE | 1 |
| Boysen, G | 1 |
| Godtfredsen, J | 1 |
| Andersen, ED | 1 |
| Andersen, B | 1 |
| Satta, MA | 1 |
| Scoppola, A | 1 |
| Melina, D | 1 |
| Guerrera, G | 2 |
| Capaldi, L | 1 |
| Folli, G | 1 |
| Minotti, V | 1 |
| Patoia, L | 1 |
| Roila, F | 1 |
| Basurto, C | 1 |
| Tonato, M | 1 |
| Pasqualucci, V | 1 |
| Maresca, V | 1 |
| Del Favero, A | 1 |
| Sandler, DP | 1 |
| Smith, JC | 1 |
| Weinberg, CR | 1 |
| Buckalew, VM | 1 |
| Dennis, VW | 1 |
| Blythe, WB | 1 |
| Burgess, WP | 1 |
| Gogoll, L | 1 |
| Bentsen, P | 1 |
| Hochrein, H | 1 |
| Pellerin, M | 1 |
| Hardy, F | 1 |
| Abergel, A | 1 |
| Boule, D | 1 |
| Palacci, JH | 1 |
| Babinet, P | 1 |
| Wingtin, LN | 1 |
| Glowinski, J | 1 |
| Amiot, JF | 1 |
| Mechali, D | 1 |
| Finiguerra, M | 1 |
| Conti, P | 1 |
| Morandini, G | 1 |
| Laugner, B | 1 |
| Muller, A | 1 |
| Thiébaut, JB | 1 |
| Farcot, JM | 1 |
| Obara, A | 1 |
| Płachta, H | 1 |
| Maruszyński, M | 1 |
| Bober, S | 1 |
| Zero, E | 1 |
| De Castro-Costa, M | 1 |
| Gybels, J | 1 |
| Kupers, R | 1 |
| Van Hees, J | 1 |
| Rogers, C | 1 |
| Brown, A | 1 |
| Valsecchi, R | 1 |
| Tribbia, G | 1 |
| Rossi, A | 1 |
| Perego, GB | 1 |
| Cainelli, T | 1 |
| Semble, EL | 1 |
| Wu, WC | 1 |
| McNeil, D | 1 |
| King, RB | 1 |
| Graham, DY | 1 |
| Smith, JL | 1 |
| Bhettay, E | 1 |
| Warrington, RJ | 1 |
| Sauder, PJ | 1 |
| McPhillips, S | 1 |
| Bagshaw, PF | 1 |
| Munster, DJ | 1 |
| Wilson, JG | 1 |
| Pöllmann, W | 1 |
| Pfaffenrath, V | 1 |
| Dupont, C | 1 |
| Rasmussen, BK | 1 |
| Larsen, JJ | 1 |
| Arnt, J | 1 |
| English, GM | 1 |
| Skiendzielewski, JJ | 1 |
| Parrish, G | 1 |
| Harrington, TM | 1 |
| McIntosh, JH | 1 |
| Byth, K | 1 |
| Kemp, AS | 1 |
| Schembri, G | 1 |
| Inatomi, N | 1 |
| Hirata, T | 1 |
| Inada, I | 1 |
| Satoh, H | 1 |
| Sino, A | 1 |
| Maki, Y | 1 |
| Hart, FD | 1 |
| Huskisson, EC | 1 |
| Michaëlsson, G | 1 |
| Schlumberger, HD | 1 |
| Löbbecke, EA | 1 |
| Kallós, P | 1 |
| Crifò, S | 1 |
| Di Feliciantonio, D | 1 |
| Di Francesco, G | 1 |
| Sidoli, A | 1 |
| Wright, R | 1 |
| Reynolds, KW | 1 |
| Gormsen, J | 1 |
| Andersen, LA | 1 |
| Lightdale, CJ | 1 |
| Kurtz, RC | 1 |
| Boyle, CC | 1 |
| Sherlock, P | 1 |
| Winawer, SJ | 2 |
| Smagin, VG | 1 |
| Sokolov, LK | 1 |
| Gavrilenko, IaV | 1 |
| Ivanov, VF | 1 |
| Terent'ev, NM | 1 |
| Raaflaub, J | 1 |
| Dubach, UC | 1 |
| Ward, JR | 1 |
| Nanra, RS | 1 |
| Kincaid-Smith, P | 1 |
| Trygstad, CW | 1 |
| Bang, NU | 1 |
| Heidenreich, RO | 1 |
| Csiscko, BM | 1 |
| Rodda, B | 1 |
| Desbaillets, LG | 1 |
| Schnetzer, GW | 1 |
| Penner, JA | 1 |
| MacDonald, WC | 1 |
| St John, DJ | 1 |
| Yeomans, ND | 1 |
| De Boer, WG | 1 |
| Goldenfarb, PB | 1 |
| Finch, SC | 1 |
| Seaman, WE | 1 |
| Ishak, KG | 1 |
| Plotz, PH | 1 |
| Chamberlain, MA | 1 |
| Yamagata, S | 1 |
| Ishimori, A | 1 |
| Horák, J | 1 |
| Hyde, JS | 1 |
| Floro, LD | 1 |
| Vithayasai, V | 1 |
| Bossa, G | 1 |
| Giordano, M | 1 |
| Grant, NH | 1 |
| Rosenthale, ME | 1 |
| Alburn, HE | 1 |
| Singer, AC | 1 |
| Dalessio, DJ | 1 |
| Stoia, I | 1 |
| Walther, J | 1 |
| Cooke, AR | 1 |
| Bejar, J | 1 |
| McCray, RS | 1 |
| Zamcheck, N | 1 |
| Lorber, J | 1 |
| James, J | 1 |
| Oka, S | 1 |
| Kodama, T | 1 |
| Lience, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424] | Phase 3 | 27,395 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Moving Towards PREcision Medicine In United Airways Disease: Unraveling inflaMmatory Patterns in Asthmatic Patients With or Without Nasal Polyps (PREMIUM) - a Descriptive Pilot Study[NCT05009758] | 30 participants (Anticipated) | Interventional | 2021-09-01 | Recruiting | |||
| A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma[NCT01287039] | Phase 3 | 489 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma[NCT01285323] | Phase 3 | 464 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Aspirin for Venous Ulcers: Randomised Trial (AVURT)[NCT02333123] | Phase 2 | 26 participants (Actual) | Interventional | 2015-07-10 | Terminated (stopped due to Recruitment halted following TSC meeting due to poor recruitment and study unlikely to complete. Funders withdrew continued support) | ||
| Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial[NCT04696120] | Phase 2 | 200 participants (Anticipated) | Interventional | 2021-03-02 | Not yet recruiting | ||
| A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban With Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects With Heart Failure and Significant Coronary Artery Diseas[NCT01877915] | Phase 3 | 5,081 participants (Actual) | Interventional | 2013-09-10 | Completed | ||
| Dupilumab as add-on Therapy for Aspirin-exacerbated Respiratory Disease (AERD)[NCT03595488] | Phase 2 | 11 participants (Actual) | Interventional | 2018-09-05 | Completed | ||
| A Clinical Trial of Aspirin and Simvastatin in Pulmonary Arterial Hypertension[NCT00384865] | Phase 2 | 64 participants (Actual) | Interventional | 2006-09-30 | Terminated | ||
| Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial[NCT04855513] | 414 participants (Anticipated) | Interventional | 2022-03-24 | Not yet recruiting | |||
| Assessment of the Cardiovascular Risk Profile of Infants Exposed to Pre-eclampsia in Utero[NCT05091827] | 234 participants (Anticipated) | Observational | 2021-11-30 | Not yet recruiting | |||
| Randomized Evaluation of Decision Support Interventions for Atrial Fibrillation[NCT04357288] | 1,200 participants (Anticipated) | Interventional | 2020-12-16 | Active, not recruiting | |||
| Improving Patient Care Via Proteomics Based, Microbe-Specific Detection of Chronic Rhinosinusitis[NCT00962689] | 38 participants (Actual) | Observational | 2009-08-31 | Completed | |||
| CSP #442 - Warfarin and Antiplatelet Therapy Study in Patients With Congestive Heart Failure (WATCH)[NCT00007683] | Phase 3 | 1,587 participants (Anticipated) | Interventional | 1998-10-31 | Completed | ||
| "Real Life Proof-of-Concept Study to Assess the Effect of Methylcellulose as add-on Seal to the In-season Pharmacologic Rescue Treatment in Subjects With Allergic Rhinitis"[NCT02557269] | Phase 4 | 60 participants (Actual) | Interventional | 2015-05-31 | Active, not recruiting | ||
| Fixed Combination for Lipid and Blood Pressure Control. Randomized Cross-over Study[NCT03047538] | Phase 4 | 0 participants (Actual) | Interventional | 2017-09-01 | Withdrawn (stopped due to Insufficient funds) | ||
| Effectiveness of Polypill for Primary Prevention of Cardiovascular Disease (PolyPars): Study Design and Rationale for a Pragmatic Cluster Randomized Controlled Trial[NCT03459560] | Phase 3 | 4,415 participants (Actual) | Interventional | 2015-12-20 | Active, not recruiting | ||
| Fixed-dose Combination Therapy (PolyPill) in Primary and Secondary Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians[NCT01271985] | Phase 3 | 8,410 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases[NCT01867281] | Phase 4 | 32 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial[NCT02942407] | Phase 4 | 154 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| Evaluation of Platelet Aggregation and Adenosine Levels in Patients With Coronary Artery Disease and Chronic Kidney Dysfunction Taking Dual Antiplatelet Therapy With Aspirin and Clopidogrel or Ticagrelor[NCT03039205] | Phase 2 | 90 participants (Actual) | Interventional | 2017-11-07 | Completed | ||
| Personalizing Perioperative Morphine Analgesia for Adolescents Undergoing Major Spine Surgeries[NCT01839461] | 137 participants (Actual) | Observational | 2009-07-31 | Completed | |||
| A Randomized, Double-Blinded, Placebo Controlled Trial Using Single Dose Dexmedetomidine In The Treatment Of Pain In Patients Undergoing Cleft Palate Repair[NCT02915042] | Phase 4 | 0 participants (Actual) | Interventional | 2017-12-31 | Withdrawn (stopped due to Recruitment concerns) | ||
| Genetic, Epigenetic, Psychosocial, and Biological Determinants of Post-surgical Pain After Pectus or Spine Surgery[NCT04031716] | 600 participants (Anticipated) | Interventional | 2018-07-06 | Enrolling by invitation | |||
| Predicting Perioperative Opioid Adverse Effects and Personalizing Analgesia in Children: A Multicenter Pharmacogenetic Study[NCT01495611] | 1,000 participants (Actual) | Observational | 2010-11-30 | Completed | |||
| Pilot Study of the Effect of Omalizumab on Basophil and Mast Responses to Intranasal Cat Allergen Challenge[NCT00604786] | 18 participants (Actual) | Interventional | 2007-07-31 | Completed | |||
| Role of Doxycycline in the Management of Patients With Chronic Rhinosinusitis With Nasal Polyps[NCT05157412] | Phase 3 | 60 participants (Anticipated) | Interventional | 2022-03-01 | Not yet recruiting | ||
| Study of Heart and Renal Protection (SHARP): The Effects of Lowering LDL-cholesterol With Simvastatin 20mg Plus Ezetimibe 10mg in Patients With Chronic Kidney Disease: a Randomized Placebo-controlled Trial[NCT00125593] | Phase 4 | 9,438 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Retrospective Review on Patients With Recurrent Asthmatic Attacks Requiring Hospitalizations[NCT04479501] | 2,280 participants (Actual) | Observational | 2017-12-01 | Completed | |||
| A 3 Year Longitudinal Study of the Level of Asthma Control and Treatment of Asthma Patients in Hong Kong[NCT03239431] | 400 participants (Anticipated) | Observational [Patient Registry] | 2017-09-15 | Recruiting | |||
| Non-invasive Measurement of Microvascular Blood Flow During Mild External Compression of the Leg[NCT01804478] | 20 participants (Actual) | Interventional | 2005-05-31 | Completed | |||
| Improving Equitable Acces and Adherence to Secondary Prevention Therapy With a Fixed-Dose Combination Drug[NCT01321255] | Phase 3 | 2,118 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| SPIDER: A Structured Process Informed by Data, Evidence and Research - A Research and Quality Improvement Collaboration Supporting Practices in Improving Care for Complex Elderly Patients[NCT03689049] | 104 participants (Anticipated) | Interventional | 2018-03-26 | Enrolling by invitation | |||
| Determinants of Surgical Outcomes in Chronic Sinusitis[NCT00799097] | 516 participants (Actual) | Observational | 2004-07-31 | Completed | |||
| Effects of Edoxaban on Platelet Aggregation in Patients With Stable Coronary Artery Disease[NCT05122455] | Phase 2/Phase 3 | 70 participants (Anticipated) | Interventional | 2021-09-14 | Recruiting | ||
| Effect of Low Dose of Colchicine on Platelet Reactivty in Patients With Chronic Coronary Disease[NCT05956145] | Phase 3 | 80 participants (Anticipated) | Interventional | 2021-06-17 | Recruiting | ||
| Effect of Thymoquinone and Olive Oil on Wound Healing After Endoscopic Sinus Surgery in Patients With Nasal Polyposis[NCT06070311] | 50 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | |||
| Role of Short Term Systemic Corticosteroid Therapy in the Management of Chronic Rhinosinusitis Without Nasal Polyps[NCT01676415] | Phase 4 | 9 participants (Actual) | Interventional | 2012-08-31 | Terminated (stopped due to participants are no longer receiving intervention due to clinical logistics) | ||
| Gel-Sinuplasty for Chronic Rhinosinusitis With and Without Nasal Polyposis[NCT03472144] | Phase 3 | 60 participants (Anticipated) | Interventional | 2017-07-07 | Recruiting | ||
| High Volume Saline Irrigation in the Post-operative Management of Chronic Rhinosinusitis: A Multicenter Randomized Single-Blind Controlled Trial[NCT02636959] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | ||
| Role of Epithelial Barrier Integrity in Biologic Treatment Response of Severe Asthmatics With/Out Chronic Rhinosinusitis With Nasal Polyps (CRSwNP). Can Shedding of Epithelial Barrier Proteins be Used as Biomarker in Severe Asthma With/Out CRSwNP Manageme[NCT05365841] | 85 participants (Anticipated) | Observational | 2022-05-15 | Not yet recruiting | |||
| Ideal Frequency of Postoperative High Volume Saline Irrigations Following Endoscopic Sinus Surgery[NCT01680705] | 75 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| Comparison of Handheld Vibrator to Topical Eye Drops as Anesthesia for Intravitreal Injections[NCT03079713] | 110 participants (Actual) | Interventional | 2017-04-12 | Completed | |||
| A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation in High Risk Primary Prevention (Patients With Metabolic Syndrome)[NCT00272311] | Phase 4 | 70 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation & Endothelial Function in Secondary Prevention (Pts w/Chronic Stable Coronary Disease)[NCT00272337] | Phase 4 | 37 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Comparison of Fetal Hemodynamic Measurements Between Pregnant Women Taking Anti-hypertensive Medication and Controls[NCT00759278] | 0 participants (Actual) | Observational | 2008-08-31 | Withdrawn (stopped due to No participants) | |||
| Heart Rate Lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease[NCT01365286] | Phase 4 | 40 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| A Sequential Phase I - Phase II Pilot Study to Compare Cardiac Imaging Capabilities of ICE With TEE Followed by a Randomized Comparison of ICE Guided Cardioversion With Conventional Cardioversion Strategy in Patients With Atrial Fibrillation[NCT00281073] | Phase 1/Phase 2 | 95 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 313 |
| Rivaroxaban 5mg + Aspirin Placebo | 366 |
| Rivaroxaban Placebo + Aspirin 100mg | 378 |
Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 282 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 389 |
| Rivaroxaban 5mg + Aspirin Placebo | 453 |
| Rivaroxaban Placebo + Aspirin 100mg | 516 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 329 |
| Rivaroxaban 5mg + Aspirin Placebo | 397 |
| Rivaroxaban Placebo + Aspirin 100mg | 450 |
Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 379 |
| Rivaroxaban 5mg + Aspirin Placebo | 448 |
| Rivaroxaban Placebo + Aspirin 100mg | 496 |
Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 353 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 288 |
| Rivaroxaban 5mg + Aspirin Placebo | 255 |
| Rivaroxaban Placebo + Aspirin 100mg | 170 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 138 |
"The ACQ is a 7-item instrument that measures asthma control (Juniper et al 1999). Six questions are self-assessments; the seventh item, completed by a member of the study staff, is the result of the patient's FEV1 measurement. Each item has 7 possible answers on a scale of 0 to 6, and the total score is the mean of all responses (the total scale is therefore 0-6). A higher score is an indication of poorer asthma control. The during treatment (Weeks 4, 8, 12 and 16) average ACQ was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline scores indicate improvement in asthma control." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.676 |
| Reslizumab 3.0 mg/kg | -0.941 |
"The AQLQ is a 32-item instrument administered as a self-assessment (Juniper et al 1992). The questionnaire is divided into 4 domains: activity limitation, symptoms, emotional function, and environmental stimuli. Patients were asked to recall their experiences during the last 2 weeks and to respond to each question on a 7-point scale (1=severe impairment, 7=no impairment). The overall AQLQ score is the mean of all 32 responses. Five of the activity questions were patient-specific, which means that each patient identified and scored 5 activities in which the patient was limited by asthma; these 5 activities were identified at the first visit and retained for all subsequent follow-up visits.~Positive change from baseline scores indicate improvement in quality of life." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Week 16
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.695 |
| Reslizumab 3.0 mg/kg | 0.933 |
"The ASUI is an 11-item instrument designed to assess the frequency and severity of asthma symptoms and side effects, weighted by patient preferences (Revicki et al 1998). ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control; info obtained from questionnaire about asthma symptoms.~The during treatment (Weeks 4, 8, 12 and 16) average ASUI was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Positive change from baseline values indicate improvement in asthma symptoms. Information was obtained from questionnaire about asthma symptoms." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.109 |
| Reslizumab 3.0 mg/kg | 0.167 |
"FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained from pulmonary function tests. It is the volume of air expired in the first second of a forced expiration using a spirometer. Positive change from baseline scores indicate improvement in asthma control.~The during treatment (Weeks 4, 8, 12 and 16) average FEV1 was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16
| Intervention | liters (Least Squares Mean) |
|---|---|
| Placebo | 0.110 |
| Reslizumab 3.0 mg/kg | 0.248 |
"SABA are used for quick relief of asthma symptoms. To measure SABA use, at each clinical visit patients were asked to recall their usage of SABA therapy within the last 3 days of the scheduled visit. If usage was confirmed, the number of puffs used was recorded. For the purpose of summaries, an average daily usage was evaluated by dividing the total number of puffs recorded over 3 days by 3.~The during treatment (Weeks 4, 8, 12 and 16) SABA use was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline scores indicate improvement in asthma control." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16
| Intervention | puffs/day (Least Squares Mean) |
|---|---|
| Placebo | -0.36 |
| Reslizumab 3.0 mg/kg | -0.64 |
"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization CAEs were adjudicated by committee to assure consistency.~Adjusted CAE rate and confidence intervals were based on Negative Binomial regression model adjusted for stratification factors.~Results are offered as adjusted means." (NCT01287039)
Timeframe: Day 1 to Week 52
| Intervention | CAEs in 52 weeks (Mean) |
|---|---|
| Placebo | 1.804 |
| Reslizumab 3.0 mg/kg | 0.904 |
"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization.~CAEs were adjudicated by committee to assure consistency. The distributions were compared by a log rank test stratified by baseline usage of oral corticosteroid (yes or no) and geographical region (US or other)." (NCT01287039)
Timeframe: Day 1 to Day 478 (longest treatment time plus 2 weeks)
| Intervention | weeks (Median) |
|---|---|
| Placebo | 34.9 |
| Reslizumab 3.0 mg/kg | NA |
The immunogenicity of reslizumab was assessed by measuring for the presence of anti-reslizumab antibodies at baseline, weeks 16, 32, 48, and 52 or early withdrawal. Blood samples for anti-reslizumab antibodies assessment were also obtained from all patients (inside or outside of the US) experiencing a serious adverse event, an adverse event leading to withdrawal, or an exacerbation of asthma symptoms. (NCT01287039)
Timeframe: Weeks 16, 32, 48 and 52
| Intervention | participants (Number) |
|---|---|
| Reslizumab 3.0 mg/kg | 8 |
"Blood eosinophil counts were measured using a standard complete blood count (CBC) with differential blood test at each scheduled visit, and from all patients experiencing a serious adverse event, an adverse event leading to withdrawal, or an exacerbation of asthma symptoms.~The during treatment average eosinophil counts were estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline values correlate to reduced asthma severity." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 or early withdrawal
| Intervention | 10^9 blood eosinophil/L (Least Squares Mean) | |
|---|---|---|
| Over first 16 weeks | Over 52 weeks | |
| Placebo | -0.118 | -0.127 |
| Reslizumab 3.0 mg/kg | -0.584 | -0.582 |
"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization.~CAEs were adjudicated by committee to assure consistency. Adjusted CAE rate and confidence intervals for the two criteria were based on Negative Binomial regression model adjusted for stratification factors.~Results are offered as adjusted means." (NCT01287039)
Timeframe: Day 1 to Week 52
| Intervention | CAEs in 52 weeks (Mean) | |
|---|---|---|
| Requiring systemic corticosterioids >3 days | Requiring hospitalization or ER visit | |
| Placebo | 1.604 | 0.207 |
| Reslizumab 3.0 mg/kg | 0.722 | 0.137 |
An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. (NCT01287039)
Timeframe: Day 1 (post-dose) to Week 65. The last postbaseline value for approximately 20 patients in each
| Intervention | participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| At least 1 AE | Mild severity AE | Moderate severity AE | Severe AE | Treatment-related AE | Treatment-related mild AE | Treatment-related moderate AE | Treatment-related severe AE | AE causing patient discontinuation | Serious AE | Deaths | |
| Placebo | 206 | 41 | 133 | 32 | 36 | 23 | 13 | 0 | 8 | 34 | 1 |
| Reslizumab 3.0 mg/kg | 197 | 68 | 107 | 22 | 36 | 24 | 9 | 3 | 4 | 24 | 0 |
"Data represents participants with potentially clinically significant (PCS) abnormal serum chemistry, hematology, and urinalysis values.~Significance criteria:~Blood urea nitrogen: >=10.71 mmol/L~Uric acid: M>=625, F>=506 μmol/L~Aspartate aminotransferase: >=3*upper limit of normal (ULN). Normal range is 10-43 U/L~Alanine aminotransferase: >=3*ULN. Normal range is 10-40 U/L~GGT = gamma-glutamyl transpeptidase: >= 3*ULN. Normal range is 5-49 U/L.~Bilirubin: >=34.2 μmol/L~White blood cells: <=3.0 or >20 10^9/L~Hemoglobin: M<=115, F<=95 g/dL~Hematocrit: M<0.37, F<0.32 L/L~Neutrophils: <=1.0 10^9/L~Eosinophils: >10.0 %~Platelets: <75 or >=700 10^9/L~Urinalysis: blood, glucose, ketones and total protein: >=2 unit increase from baseline" (NCT01287039)
Timeframe: Week 4 to Week 65. The last postbaseline value for approximately 20 patients in each
| Intervention | participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blood urea nitrogen | Uric acid | Aspartate aminotransferase | Alanine aminotransferase | Gamma-glutamyl transpeptidase | Bilirubin | White blood cells - low | White blood cells - high | Hemoglobin | Hematocrit | Neutrophils | Eosinophils | Platelets - low | Platelets - high | Urinalysis - Blood (hemoglobin) | Urinalysis - Ketones | Urinalysis - Glucose | Urinalysis - Protein | |
| Placebo | 9 | 9 | 1 | 3 | 12 | 2 | 6 | 5 | 7 | 9 | 8 | 135 | 1 | 2 | 32 | 4 | 11 | 32 |
| Reslizumab 3.0 mg/kg | 8 | 6 | 1 | 5 | 12 | 1 | 6 | 3 | 4 | 6 | 6 | 3 | 2 | 0 | 21 | 5 | 14 | 34 |
"Data represents participants with potentially clinically significant (PCS) vital sign values.~Significance criteria~Sitting pulse - high 12-17 yr: >100 and increase of >= 30 beats/minute (bpm)~Sitting pulse - low >=18 yr: <50 and decrease of >=30 bpm~Sitting pulse - high >=18 yr: >100 and increase of >=30 bpm~Sitting systolic blood pressure - low >=18 yr: <90 and decrease of >=30 mmHg~Sitting systolic blood pressure - high >=18 yr: >160 and increase of >=30 mmHg~Sitting diastolic blood pressure - low 12-17 yr: <55 and decrease of >=12 mmHg~Sitting diastolic blood pressure - low >=18 yr: <50 and decrease of >=12 mmHg~Sitting diastolic blood pressure - high >=18 yr: >100 and increase of >=12 mmHg~Respiratory rate >=18 yr: >24 and increase of >=10 breaths/minute~Body temperature - low 12-17 yr: <96.5° Fahrenheit or <35.8° Celsius~Body temp - low >=18 yr: <96.5° F or <35.8° C~Body temp - high >=18 yr: >100.5° Fahrenheit" (NCT01287039)
Timeframe: Week 4 to Week 65. The last postbaseline value for approximately 20 patients in each
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sitting pulse - high 12-17 yr | Sitting pulse - low >=18 yr | Sitting pulse - high >=18 yr | Sitting systolic blood pressure - low >=18 yr | Sitting systolic blood pressure - high >=18 yr | Sitting diastolic blood pressure - low 12-17 yr | Sitting diastolic blood pressure - low >=18 yr | Sitting diastolic blood pressure - high >=18 yr | Respiratory rate >=18 yr | Body temperature - low 12-17 yr | Body temperature - low >=18 yr | Body temperature - high >=18 yr | |
| Placebo | 1 | 1 | 5 | 2 | 7 | 1 | 0 | 10 | 3 | 1 | 54 | 0 |
| Reslizumab 3.0 mg/kg | 1 | 0 | 7 | 5 | 7 | 0 | 1 | 5 | 2 | 1 | 49 | 1 |
"The ACQ is a 7-item instrument that measures asthma control (Juniper et al 1999). Six questions are self-assessments; the seventh item, completed by a member of the study staff, is the result of the patient's FEV1 measurement. Each item has 7 possible answers on a scale of 0 to 6, and the total score is the mean of all responses (the total scale is therefore 0-6). A higher score is an indication of poorer asthma control. The during treatment (Weeks 4, 8, 12 and 16) average ACQ was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline scores indicate improvement in asthma control." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.660 |
| Reslizumab 3.0 mg/kg | -0.857 |
"The AQLQ is a 32-item instrument administered as a self-assessment (Juniper et al 1992). The questionnaire is divided into 4 domains: activity limitation, symptoms, emotional function, and environmental stimuli. Patients were asked to recall their experiences during the last 2 weeks and to respond to each question on a 7-point scale (1=severe impairment, 7=no impairment). The overall AQLQ score is the mean of all 32 responses. Five of the activity questions were patient-specific, which means that each patient identified and scored 5 activities in which the patient was limited by asthma; these 5 activities were identified at the first visit and retained for all subsequent follow-up visits.~Positive change from baseline scores indicate improvement in quality of life." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Week 16
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.777 |
| Reslizumab 3.0 mg/kg | 0.987 |
"The ASUI is an 11-item instrument designed to assess the frequency and severity of asthma symptoms and side effects, weighted by patient preferences (Revicki et al 1998). ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control; info obtained from questionnaire about asthma symptoms.~The during treatment (Weeks 4, 8, 12 and 16) average ASUI was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Positive change from baseline values indicate improvement in asthma symptoms. Information was obtained from questionnaire about asthma symptoms." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.080 |
| Reslizumab 3.0 mg/kg | 0.115 |
"FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained from pulmonary function tests. It is the volume of air expired in the first second of a forced expiration using a spirometer.~Positive change from baseline scores indicate improvement in asthma control." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Week 16
| Intervention | liters (Least Squares Mean) |
|---|---|
| Placebo | 0.122 |
| Reslizumab 3.0 mg/kg | 0.223 |
"FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained from pulmonary function tests. It is the volume of air expired in the first second of a forced expiration using a spirometer. During study (Weeks 4, 8, 12 and 16) average value used a mixed effect model for repeated measures (MMRM) with treatment group, visit, treatment and visit interaction, and stratification factors as fixed effects and participant as a random effect. Covariates for baseline values were also included in the model; for pulmonary function test analyses, covariates for height and sex were included as well.~Positive change from baseline scores indicate improvement in asthma control." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16
| Intervention | liters (Least Squares Mean) |
|---|---|
| Placebo | 0.094 |
| Reslizumab 3.0 mg/kg | 0.187 |
"SABA are used for quick relief of asthma symptoms. To measure SABA use, at each clinical visit patients were asked to recall their usage of SABA therapy within the last 3 days of the scheduled visit. If usage was confirmed, the number of puffs used was recorded. For the purpose of summaries, an average daily usage was evaluated by dividing the total number of puffs recorded over 3 days by 3.~The during treatment (Weeks 4, 8, 12 and 16) average SABA use was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline scores indicate improvement in asthma control." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16
| Intervention | SABA puffs per day (Least Squares Mean) |
|---|---|
| Placebo | -0.44 |
| Reslizumab 3.0 mg/kg | -0.50 |
"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization.~CAEs were adjudicated by committee to assure consistency. Adjusted CAE rate and confidence intervals were based on Negative Binomial regression model adjusted for stratification factors.~Results are offered as adjusted means." (NCT01285323)
Timeframe: Day 1 to Month 12
| Intervention | CAEs in 52 weeks (Mean) |
|---|---|
| Placebo | 2.115 |
| Reslizumab 3.0 mg/kg | 0.859 |
"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization.~CAEs were adjudicated by committee to assure consistency. The distributions were compared by a log rank test stratified by baseline usage of oral corticosteroid (yes or no) and geographical region (US or other)." (NCT01285323)
Timeframe: Day 1 to Day 526 (longest treatment time plus 2 weeks)
| Intervention | weeks (Median) |
|---|---|
| Placebo | NA |
| Reslizumab 3.0 mg/kg | NA |
"The blood eosinophil counts were measured using a standard complete blood count (CBC) with differential blood test. Results of all differential blood tests conducted after randomization were blinded.~The during treatment average eosinophil count was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements. The 'over 16 weeks' value used data from Weeks 4, 8, 12 and 16. The 'over 52 weeks' value used all the during study time points listed in the Time Frame field.~Negative change from baseline values correlate to reduced asthma severity." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 or early withdrawal
| Intervention | 10^9 blood eosinophil/L (Least Squares Mean) | |
|---|---|---|
| Over first 16 weeks | Over 52 weeks | |
| Placebo | -0.076 | -0.076 |
| Reslizumab 3.0 mg/kg | -0.555 | -0.565 |
"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization CAEs were adjudicated by committee to assure consistency.~Adjusted CAE rate and confidence intervals for the two criteria were based on Negative Binomial regression model adjusted for stratification factors.~Results are offered as adjusted means." (NCT01285323)
Timeframe: Day 1 to Month 12
| Intervention | CAEs in 52 weeks (Mean) | |
|---|---|---|
| Requiring systemic corticosterioids >3 days | Requiring hospitalization or ER visit | |
| Placebo | 1.660 | 0.047 |
| Reslizumab 3.0 mg/kg | 0.646 | 0.033 |
Counts of participants with a positive anti-drug antibody (ADA) response during treatment is offered for the experimental treatment arm. Blood samples were collected for determination of ADAs before study drug infusion. (NCT01285323)
Timeframe: Baseline visit (prior to reslizumab exposure), Weeks 16, 32, 48 and 52
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Baseline | Week 16 | Week 32 | Week 48 | Week 52 | >=1 positive test result | |
| Reslizumab 3.0 mg/kg | 10 | 10 | 10 | 10 | 10 | 15 |
An adverse event (AE) was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. (NCT01285323)
Timeframe: Day 1 (post-dose) to Week 65. The endpoint for adverse events was the last postbaseline observation, which included the 90 day follow-up visit.
| Intervention | participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Any TEAE | Mild TEAE | Moderate TEAE | Severe TEAE | Treatment-related AE | Mild treatment-related AE | Moderate treatment-related AE | Severe treatment-related AE | TEAE causing patient discontinuation | Deaths | Serious AEs | |
| Placebo | 201 | 36 | 140 | 25 | 27 | 14 | 13 | 0 | 9 | 0 | 23 |
| Reslizumab 3.0 mg/kg | 177 | 67 | 98 | 12 | 34 | 22 | 11 | 1 | 8 | 0 | 18 |
"Data represents participants with potentially clinically significant (PCS) abnormal serum chemistry, hematology (except for eosinophil values), and urinalysis values.~Significance criteria:~Blood urea nitrogen: >=10.71 mmol/L~Creatinine: >=177 μmol/L~Urate: M>=625, F>=506 μmol/L~Aspartate aminotransferase (AST): >=3*upper limit of normal (ULN)~Alanine aminotransferase (ALT): >=3*ULN~GGT = gamma-glutamyl transpeptidase: >= 3*ULN~Total bilirubin: >=34.2 μmol/L~White blood cells (low): <=3.0*10^9/L~White blood cells (high): >=20*10^9/L~Hemoglobin (age >=18 years): M<=115, F<=95 g/dL~Hematocrit (age >=18 years): M<0.37, F<0.32 L/L~Eosinophils/leukocytes: >=10.0%~Platelets: <=75*10^9/L~Neutrophils: <=1.0*10^9/L~Urinalysis: blood, ketones, glucose, and protein: >=2 unit increase from baseline" (NCT01285323)
Timeframe: Week 4 to Week 52
| Intervention | participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blood urea nitrogen | Creatinine | Urate | AST | ALT | GGT | Bilirubin | Leukocytes (low) | Leukocytes (high) | Hemoglobin | Hematocrit | Eosinophils/leukocytes | Platelets | Neutrophils | Urine blood (hemoglobin) | Urine ketones | Urine glucose | Urine protein | |
| Placebo | 5 | 0 | 5 | 3 | 7 | 11 | 3 | 3 | 0 | 5 | 10 | 168 | 1 | 14 | 28 | 6 | 9 | 28 |
| Reslizumab 3.0 mg/kg | 4 | 1 | 2 | 2 | 3 | 9 | 3 | 10 | 1 | 6 | 8 | 10 | 1 | 9 | 12 | 1 | 7 | 28 |
"Data represents participants with potentially clinically significant (PCS) vital sign values.~Significance criteria~Sitting pulse (high): >100 and increase of >= 30 beats/minute~Sitting systolic blood pressure (low): <90 and decrease of >= 30 mmHg~Sitting systolic blood pressure (high): >160 and increase of >= 30 mmHg~Sitting diastolic blood pressure (low): <50 and decrease of >=12 mmHg (if 12-17 years old: <55 and decrease of >=12 mmHg 0~Sitting diastolic blood pressure (high): >100 and increase of >=12 mmHg~Respiratory rate (low): <6 breaths/minute~Respiratory rate (high): >24 and increase of >=10 breaths/minute~Body temperature (low): <35.8° Celsius~Body temperature (high): >=38.1 and increase of >=1.1° Celsius" (NCT01285323)
Timeframe: Week 4 to Week 52
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| >=1 postbaseline vital sign abnormality | Sitting pulse (high) | Sitting systolic blood pressure (low) | Sitting systolic blood pressure (high) | Sitting diastolic blood pressure (low) | Sitting diastolic blood pressure (high) | Respiratory rate (low) | Respiratory rate (high) | Body temperature (low) | Body temperature (high) | |
| Placebo | 58 | 6 | 2 | 0 | 4 | 3 | 0 | 4 | 50 | 1 |
| Reslizumab 3.0 mg/kg | 49 | 6 | 1 | 1 | 3 | 4 | 1 | 5 | 39 | 0 |
Event rate of all-Cause Mortality (ACM) or re-Hospitalization for worsening heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 24.84 |
| Placebo | 24.57 |
Event Rate of all-cause mortality (ACM), MI, or stroke were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 patient [pt]-year [yr]) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 13.44 |
| Placebo | 14.27 |
Event rate of bleeding events and required Hospitalization were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to 227 Weeks
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 1.52 |
| Placebo | 1.16 |
Event rate of cardio vascular death were assessed. CV death included deaths due to spontaneous bleeding, MI, stroke, worsening HF and arrhythmias, death due to CV procedures and sudden death. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 9.46 |
| Placebo | 9.96 |
Event rate of cardio vascular (CV) death or re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 23.32 |
| Placebo | 23.46 |
Event rate of ISTH major bleeding event were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to 227 Weeks
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 2.04 |
| Placebo | 1.21 |
Event rate due to cardio vascular events were assessed. Hospitalization for a CV Event required that participants be hospitalized (in-patient or emergency department) for greater than 24 hours and must have met the following criterion:Discharge summary with primary reason for admission listed as CV in nature (example, bleeding, arrhythmia, ACS, MI) other than HF which was captured in the HF re-hospitalization. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 13.30 |
| Placebo | 14.04 |
Event rate of re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
| Intervention | Event rate per 100 patient-year (Number) |
|---|---|
| Rivaroxaban | 17.24 |
| Placebo | 17.45 |
Event rate of either fatal bleeding or bleeding into critical space with potential for permanent disability were assessed. Fatal bleeding event was death within 7 days after a bleeding event which required hospitalization or met International Society on Thrombosis and Haemostasis(ISTH) major bleeding definition criteria. Fatal bleeding events included those met criteria in 3 categories: 1: Any ISTH major bleeding event consider primary cause of death by investigator; 2: Any ISTH major bleeding event not considered to be primary cause of death by investigator but resulted in death within 7 days;3: Any bleeding event resulted in hospital stay and death within 7 days. Bleeding into critical space with potential for permanent disability included 7 critical spaces: intracranial, intraspinal, intraocular. Event rate estimated based on time to first occurrence of event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to 227 Weeks
| Intervention | Event rate per 100 patient-year (Number) | |
|---|---|---|
| Fatal Bleeding | Critical Space Bleeding with Permanent Disability | |
| Placebo | 0.22 | 0.48 |
| Rivaroxaban | 0.22 | 0.32 |
Please refer to the Adverse Event Tables for specific information (NCT00384865)
Timeframe: Measured at 6 months
| Intervention | events (Number) |
|---|---|
| Aspirin 81 mg | 59 |
| Aspirin Placebo | 66 |
| Simvastatin 40 mg | 66 |
| Simvastatin Placebo | 58 |
(NCT00384865)
Timeframe: Measured at 6 months
| Intervention | meters (Least Squares Mean) |
|---|---|
| Aspirin 81 mg | 438.0 |
| Aspirin Placebo | 438.5 |
| Simvastatin 40 mg | 425.0 |
| Simvastatin Placebo | 452.7 |
Defined by the addition of new PAH therapies or dose increases in previously stable PAH therapy, hospitalization for right-sided heart failure, lung transplantation, atrial septostomy, and cardiovascular and all-cause death. (NCT00384865)
Timeframe: Measured at 6 months
| Intervention | events (Number) |
|---|---|
| Aspirin 81 mg | 2 |
| Aspirin Placebo | 6 |
| Simvastatin 40 mg | 4 |
| Simvastatin Placebo | 4 |
Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0-12 hours after the dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Apixaban 2.5 mg | 59.7 |
| Apixaban 5 mg | 97.9 |
Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0-12 hours after the dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Apixaban 2.5 mg | 28.2 |
| Apixaban 5mg | 49.7 |
Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0 to 12 hours after dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose
| Intervention | ng*h/mL (Geometric Mean) |
|---|---|
| Apixaban 2.5 mg | 507 |
| Apixaban 5mg | 868 |
"Assess the safety of apixaban versus warfarin regarding ISTH major bleeding or clinically relevant non-major bleeding events in patients with NVAF (nonvalvular atrial fibrillation) and ESRD (end-stage renal disease) on hemodialysis.~Major bleeding event is defined as:Acute clinically overt bleeding (including access site related bleeding) accompanied by 1 or more of the following: Decrease in Hgb of 2g/dL or more with overt bleeding; Transfusion of 2 or more units of packed RBCs in the setting of an overt bleeding event; Bleeding within a critical site. Hemorrhagic stroke (primary or infarction with hemorrhagic conversion) were classified as major bleeds.~Non-major bleeding event is defined as: Acute or sub-acute clinically overt bleeding (including access site related bleeding) that does not meet criteria for major bleeding & results in Hospital admission for bleeding, physician guided medical or surgical treatment for bleeding, or change in antithrombotic therapy" (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 21 |
| Warfarin | 16 |
Evaluate mortality rates for those participants randomized to warfarin and apixaban in patients with NVAF and ESRD on hemodialysis (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 21 |
| Warfarin | 13 |
"Adjudcated stroke defined as a new, non-traumatic episode of focal or global neurological dysfunction of sudden onset caused by central nervous system (CNS) vascular injury as a result of hemorrhage or infarction and not due to a readily identifiable non-vascular cause (i.e. brain tumor). CNS includes brain, spinal cord and retina. The required duration of the deficit is ≥ 24 hours.~Events with neurologic deficit lasting for < 24 hours and an imaging modality showing evidence of an acute stroke will be counted as stroke as well.~A retinal ischemic event (embolism, infarction) will be considered a stroke" (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 2 |
| Warfarin | 2 |
Number of participants experiencing adjudicated stroke or systemic embolism. (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 2 |
| Warfarin | 2 |
"Evaluate those experiencing stroke, systemic embolism, ISTH major bleeding, or all-cause mortality for those randomized to warfarin and apixaban in patients with NVAF and ESRD on hemodialysis~Definitions of stroke and systemic embolism are provided under the measurement description of the secondary outcomes for each individual event. Definition of major bleed is provided in outcome measurement description of the primary outcome measure." (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 27 |
| Warfarin | 29 |
"Adjudicated diagnosis of systemic arterial embolism (Non-pulmonary, non-cranial events) will require a positive clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), which is supported by evidence of embolism/thrombosis from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.~Clinical presentation would include:~Abrupt development of pain, absent pulses, pallor, and/or paresis in an extremity (at least an entire digit) without previous severe claudication or findings of severe peripheral vascular disease.~Renal embolism will be diagnosed when sudden flank pain or a change in renal laboratory findings occurred.~Abdominal vascular/visceral embolism was considered definite if acute abdominal symptoms or referred symptoms developed along with a change in abdominal examination or appropriate laboratory values." (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 0 |
| Warfarin | 0 |
Evaluate days between time from initiation to discontinuation of randomized therapy. (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Days (Mean) |
|---|---|
| Apixaban | 304.4 |
| Warfarin | 279.6 |
"Flow cytometry in mean fluorescence units.~100%*[(3.5 month value minus baseline value)/baseline value]" (NCT00604786)
Timeframe: Change from baseline to 3.5 months
| Intervention | percentage of basophil surface IgE (Mean) |
|---|---|
| Omalizumab Subcutaneous | -95 |
| Placebo Subcutaneous | -10 |
Revascularization included any arterial revascularization procedure, whether surgical or percutaneous, but excluded revascularization performed for hemodialysis vascular access (e.g. fistuloplasty) or to the donor kidney transplant artery. Revascularization included amputations for vascular disease (rather than for trauma or infection). All potential revascularization events (including angiography) were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 284 |
| Placebo | 352 |
End-stage renal disease was defined as initiation of maintenance dialysis or renal transplantation. Temporary dialysis was excluded. All potential dialysis and transplant events were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 1057 |
| Placebo | 1084 |
Major atherosclerotic events defined as non-fatal myocardial infarction or coronary death, non-hemorrhagic stroke, or any arterial revascularization procedure (excluding dialysis access procedures). Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 526 |
| Placebo | 619 |
Major coronary events defined as coronary death or non-fatal myocardial infarction. Myocardial infarction adjudicated based on the presence of serial changes in cardiac biomarkers (e.g. troponin, creatine kinase), typical ECG changes and typical cardiac symptoms. If myocardial infarction was fatal and post-mortem examination findings were available, this information was also assessed. All potential coronary events were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 213 |
| Placebo | 230 |
Major vascular events defined as non-fatal myocardial infarction or cardiac death, any stroke, or any arterial revascularization procedure (excluding dialysis access procedures). Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 701 |
| Placebo | 814 |
Major vascular events defined as non-fatal myocardial infarction or cardiac death, any stroke, or any arterial revascularization procedure (excluding dialysis access procedures). Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 639 |
| Placebo | 749 |
Stroke was defined as rapid onset of focal or global neurological deficit, with duration greater than 24 hours. Clinical notes and brain imaging were sought to determine the stroke etiology, and if the stroke was fatal and post-mortem examination findings were available, this information was also assessed. All potential stroke events (including transient ischemic attack and intracerebral hemorrhage) were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 131 |
| Placebo | 174 |
The medication side-effect and compliance inventory is a questionnaire to evaluate the frequency and severity of common side effects associated with the medications used in this study. (NCT01676415)
Timeframe: 4-6 weeks and 3 months after initiation of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisone | 0 |
| Topical Mometasone | 0 |
Change from baseline in individual symptom severity. The taskforce symptom inventory is a visual analog scale of the severity of the 4 major symptoms making up the clinical diagnostic criteria of CRS. (NCT01676415)
Timeframe: 4-6 weeks and 3 months after initiation of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisone | 0 |
| Topical Mometasone | 0 |
"The Sino-nasal Outcome Test-22 is a validated questionnaire that measures 22 nasal and quality of life symptoms (nasal obstruction and loss of smell and taste) ranked from 0 (not a problem) to 5 (problem as bad as it can be).~Min score= 0, Max score= 110 (worst possible problem on all symptoms)~Change from baseline of the SNOT-22 score. The SNOT-22 questionnaire is a 22-item disease-specific health related quality of life instrument validated for use in chronic rhinosinusitis." (NCT01676415)
Timeframe: 4-6 weeks and 3 months after initiation of treatment
| Intervention | units on a scale (Mean) | |
|---|---|---|
| 4-6 WEEKS | 3 MONTHS | |
| Prednisone | 45.75 | 49 |
| Topical Mometasone | 34.4 | 34.4 |
Changes in Heme oxygenase (HO-1) a downstream target of nitric oxide (NO) formation. (NCT00272311)
Timeframe: Baseline to 3 Months (90-97 days)
| Intervention | ng/mL (Mean) |
|---|---|
| Arm 1 of 5 Randomized Treatment Arms | 27.6 |
| Arm 2 of 5 Randomized Treatment Arms | 27.0 |
| Arm 3 of 5 Randomized Treatment Arms | 31.4 |
| Arm 4 of 5 Randomized Treatment Arms | 25.7 |
| Arm 5 of 5 Randomized Treatment Arms | 28.3 |
Heme oxygenase a downstream target of nitric oxide formation (NCT00272337)
Timeframe: Baseline to 3 Months (90-97 days)
| Intervention | ng/mL (Mean) |
|---|---|
| 1 of 5 Randomized Treatment Arms | 10.0 |
| 2 of 5 Randomized Treatment Arms | 11.2 |
| 3 of 5 Randomized Treatment Arms | 10.0 |
| 4 of 5 Randomized Treatment Arms | 11.0 |
| 5 of 5 Randomized Treatment Arms | 9.6 |
108 reviews available for aspirin and Chronic Disease
| Article | Year |
|---|---|
Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Aspirin; Chronic Disease; Humans; Nasa | 2022 |
Treatment options for chronic rhinosinusitis with nasal polyps.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Aspirin; Asthma; Biological Products; Chronic Diseas | 2021 |
Controversies in Allergy: Aspirin Desensitization or Biologics for Aspirin-Exacerbated Respiratory Disease-How to Choose.
Topics: Aspirin; Asthma, Aspirin-Induced; Biological Products; Chronic Disease; Desensitization, Immunologic | 2022 |
[Idiopathic recurrent pericarditis: review of the literature and the Geneva experience].
Topics: Aspirin; Chronic Disease; Colchicine; Humans; Pericarditis; Recurrence | 2022 |
Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years.
Topics: Adolescent; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; C | 2022 |
Aspirin-Exacerbated Respiratory Disease and the Unified Airway: A Contemporary Review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-Induced; Chronic Disease; | 2023 |
A Review of Aspirin-exacerbated Respiratory Diseases and Immunological Efficacy of Aspirin Desensitization.
Topics: Aspirin; Asthma; Asthma, Aspirin-Induced; Chronic Disease; Desensitization, Immunologic; Humans; Nas | 2022 |
Aspirin-exacerbated respiratory disease: Updates in the era of biologics.
Topics: Aspirin; Asthma; Asthma, Aspirin-Induced; Biological Products; Chronic Disease; Humans; Nasal Polyps | 2023 |
Nonsteroidal anti-inflammatory drug-exacerbated respiratory disease: diagnosis and current management.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease; Humans; Nasal Poly | 2023 |
The chronic rhinosinusitis practice parameter.
Topics: Advisory Committees; Aspirin; Asthma, Aspirin-Induced; Biological Products; Chronic Disease; Humans; | 2023 |
Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Chronic Disease; Coronary Artery Dis | 2019 |
Comorbidities associated with eosinophilic chronic rhinosinusitis: A systematic review and meta-analysis.
Topics: Aspirin; Asthma; Chronic Disease; Comorbidity; Eosinophilia; Humans; Nasal Polyps; Rhinitis; Severit | 2020 |
Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition.
Topics: Aspirin; Chronic Disease; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; | 2020 |
Toward personalized management of chronic hypertension in pregnancy.
Topics: Antihypertensive Agents; Aspirin; Blood Pressure Monitoring, Ambulatory; Calcium; Chronic Disease; C | 2022 |
Lifelong Aspirin for All in the Secondary Prevention of Chronic Coronary Syndrome: Still Sacrosanct or Is Reappraisal Warranted?
Topics: Acute Coronary Syndrome; Aspirin; Chronic Disease; Humans; Middle Aged; Platelet Aggregation Inhibit | 2020 |
Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma.
Topics: Alcohol Drinking; Aspirin; Carcinoma, Hepatocellular; Chronic Disease; Diabetes Mellitus, Type 2; Di | 2020 |
Hypertensive Disorders of Pregnancy.
Topics: Anticonvulsants; Antihypertensive Agents; Aspirin; Chronic Disease; Delivery, Obstetric; Eclampsia; | 2020 |
The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy,
Topics: Administration, Oral; Algorithms; Allergens; Animals; Anti-Inflammatory Agents; Aspirin; Asthma, Asp | 2021 |
Anticoagulation versus placebo for heart failure in sinus rhythm.
Topics: Administration, Oral; Anticoagulants; Aspirin; Cardiomyopathy, Dilated; Chronic Disease; Heart Failu | 2021 |
Systematic review and meta-analysis on the adjunctive use of host immune modulators in non-surgical periodontal treatment in healthy and systemically compromised patients.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspirin; Chronic Disea | 2021 |
Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Arthritis, Rheumatoid; Asp | 2017 |
Heterogeneity of NSAID-Exacerbated Respiratory Disease: has the time come for subphenotyping?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Biomarkers; Chronic Disea | 2019 |
Treatment and Prevention of Hypertensive Disorders During Pregnancy.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Calcium Channel Blockers; Chronic Dis | 2019 |
Hypertension and Pregnancy: Management and Future Risks.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Chronic Disease; Diuretics; Female; Human | 2019 |
Anticoagulation versus placebo for heart failure in sinus rhythm.
Topics: Administration, Oral; Anticoagulants; Aspirin; Cardiomyopathy, Dilated; Chronic Disease; Heart Failu | 2014 |
Topical nasal lysine aspirin in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis with nasal polyposis.
Topics: Administration, Intranasal; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Human | 2014 |
The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population--an updated meta-analysis.
Topics: Acute Disease; Asian People; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Chronic Disease; Cil | 2014 |
Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Desensitization, Immunologic; Hum | 2015 |
Hypersensitivity to Aspirin and other NSAIDs: Diagnostic Approach in Patients with Chronic Rhinosinusitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Drug Hypersensitivity; Humans; Rh | 2015 |
[Hypersensitivity to acetylsalicylic acid].
Topics: Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Humans; Incidence; Nasal Polyps; Rhinitis; | 2015 |
Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies.
Topics: Aspirin; Body Mass Index; Chronic Disease; Cohort Studies; Early Diagnosis; Female; Humans; Hyperten | 2016 |
Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies.
Topics: Aspirin; Body Mass Index; Chronic Disease; Cohort Studies; Early Diagnosis; Female; Humans; Hyperten | 2016 |
Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies.
Topics: Aspirin; Body Mass Index; Chronic Disease; Cohort Studies; Early Diagnosis; Female; Humans; Hyperten | 2016 |
Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies.
Topics: Aspirin; Body Mass Index; Chronic Disease; Cohort Studies; Early Diagnosis; Female; Humans; Hyperten | 2016 |
Chronic Rhinosinusitis and Aspirin-Exacerbated Respiratory Disease.
Topics: Allergens; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease; Disease Progre | 2016 |
Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Humans; Respiratory Tract Disease | 2016 |
Is aspirin desensitization indicated for the treatment recalcitrant chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease?
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Desensitization, Immunologic; Humans; Nasal Polyp | 2017 |
Current complications and treatment of aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Desensit | 2016 |
Aspirin treatment for chronic wounds: Potential beneficial and inhibitory effects.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Cyclooxygenase Inhibitor | 2017 |
The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis.
Topics: Administration, Oral; Aspirin; Chronic Disease; Desensitization, Immunologic; Humans; Lysine; Nasal | 2008 |
Gene-expression signatures of nasal polyps associated with chronic rhinosinusitis and aspirin-sensitive asthma.
Topics: Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Gene Expression Profiling; Humans; Nasal Po | 2009 |
Oral antiplatelet therapy for acute and chronic management of NSTE ACS: residual ischemic risk and opportunities for improvement.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Chronic Disease; Hemorrhage; Humans; Platele | 2009 |
[Chronic rhinosinusitis in morbus widal: clinical aspects and therapeutic options].
Topics: Adrenal Cortex Hormones; Aspirin; Asthma; Chronic Disease; Desensitization, Immunologic; Drug Hypers | 2009 |
Pathogenesis and treatment of chronic rhinosinusitis.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bi | 2010 |
Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Chronic Disease; Clinical Trials as Topic; Clopidogre | 2011 |
Role of aspirin desensitization in the management of chronic rhinosinusitis.
Topics: Aspirin; Chronic Disease; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Nasal Polyps; | 2011 |
Secondary prevention in the acute and early chronic phase after ischaemic stroke and transient ischaemic attacks with antiplatelet drugs--is antiplatelet monotherapy still reasonable?
Topics: Abciximab; Acute Disease; Antibodies, Monoclonal; Aspirin; Chronic Disease; Clopidogrel; Delayed-Act | 2011 |
Dysmenorrhoea.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Denervation; Dysme | 2011 |
Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chronic Disease; Clinical Trials as Topic; Clopidogrel; | 2011 |
Anticoagulation versus placebo for heart failure in sinus rhythm.
Topics: Administration, Oral; Anticoagulants; Aspirin; Chronic Disease; Heart Failure; Heart Rate; Humans; P | 2012 |
Analgesics for the treatment of pain in children.
Topics: Acetaminophen; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Anesthesia, General; A | 2002 |
Analgesics for the treatment of pain in children.
Topics: Acetaminophen; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Anesthesia, General; A | 2002 |
Analgesics for the treatment of pain in children.
Topics: Acetaminophen; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Anesthesia, General; A | 2002 |
Analgesics for the treatment of pain in children.
Topics: Acetaminophen; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Anesthesia, General; A | 2002 |
Analgesics for the treatment of pain in children.
Topics: Acetaminophen; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Anesthesia, General; A | 2002 |
Analgesics for the treatment of pain in children.
Topics: Acetaminophen; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Anesthesia, General; A | 2002 |
Analgesics for the treatment of pain in children.
Topics: Acetaminophen; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Anesthesia, General; A | 2002 |
Analgesics for the treatment of pain in children.
Topics: Acetaminophen; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Anesthesia, General; A | 2002 |
Analgesics for the treatment of pain in children.
Topics: Acetaminophen; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Anesthesia, General; A | 2002 |
Analgesics for the treatment of pain in children.
Topics: Acetaminophen; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Anesthesia, General; A | 2002 |
Analgesics for the treatment of pain in children.
Topics: Acetaminophen; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Anesthesia, General; A | 2002 |
Analgesics for the treatment of pain in children.
Topics: Acetaminophen; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Anesthesia, General; A | 2002 |
Analgesics for the treatment of pain in children.
Topics: Acetaminophen; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Anesthesia, General; A | 2002 |
Analgesics for the treatment of pain in children.
Topics: Acetaminophen; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Anesthesia, General; A | 2002 |
Analgesics for the treatment of pain in children.
Topics: Acetaminophen; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Anesthesia, General; A | 2002 |
Analgesics for the treatment of pain in children.
Topics: Acetaminophen; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Anesthesia, General; A | 2002 |
[Therapy of chronic inflammatory bowel diseases].
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2002 |
Lipoxins in chronic inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Eicosanoids; Humans; Hyd | 2003 |
Managing chronic atrial fibrillation: strategies to control symptoms and prevent embolism.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Echocardiogra | 2003 |
[Which antithrombotic treatment should be used in the treatment of an elderly patient with chronic atrial fibrillation?].
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibril | 2003 |
Chronic myeloproliferative disorders.
Topics: Antineoplastic Agents; Aspirin; Cardiovascular Diseases; Chronic Disease; Hematopoietic Stem Cell Tr | 2003 |
Categorization of eosinophilic chronic rhinosinusitis.
Topics: Aspergillosis, Allergic Bronchopulmonary; Aspirin; Child; Chronic Disease; Eosinophilia; Eosinophils | 2004 |
Epidemiology of pancreatic cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cholecystectomy; Cholelithiasis; Chronic Disease; | 2004 |
[Inflammation and diabetes].
Topics: Adiponectin; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Arte | 2004 |
Alternative medical treatment strategies for chronic hyperplastic eosinophilic sinusitis.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Antifungal Agents; Aspirin; Chronic Disease; Eosino | 2005 |
Current concepts in therapy of chronic rhinosinusitis and nasal polyposis.
Topics: Anti-Bacterial Agents; Antifungal Agents; Aspirin; Chronic Disease; Endoscopy; Eosinophilia; Histami | 2005 |
Mechanism of chronic urticaria exacerbation by aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Cyclooxygenase Inhibitors; Drug H | 2005 |
Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Aspir | 2005 |
Venous ulcers: pathophysiology and treatment options.
Topics: Anti-Inflammatory Agents; Aspirin; Bandages; Chronic Disease; Debridement; Diosmin; Growth Substance | 2005 |
Exercise rehabilitation in heart disease: the real "polypill" for primary and secondary prevention.
Topics: Aspirin; Chronic Disease; Coronary Disease; Diabetes Mellitus; Diabetes Mellitus, Type 2; Exercise; | 2005 |
Differential diagnosis of eosinophilic chronic rhinosinusitis.
Topics: Animals; Aspirin; Chronic Disease; Diagnosis, Differential; Eosinophilia; Fungi; Humans; Hypersensit | 2006 |
[Prevention of thromboembolism in patients with atrial fibrillation].
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disea | 2006 |
Pathophysiology and medical management of systemic hypertension and pre-eclampsia in pregnancy.
Topics: Adult; Antihypertensive Agents; Aspirin; Blood Pressure Determination; Calcium, Dietary; Chronic Dis | 2006 |
Spotlight on renin: cardiovascular outcomes in chronic kidney disease and suppression of the renin-angiotensin system.
Topics: Albuminuria; Aspirin; Cardiovascular Diseases; Chronic Disease; Glomerular Filtration Rate; Humans; | 2006 |
Differential diagnosis of eosinophilic chronic rhinosinusitis.
Topics: Aspirin; Chronic Disease; Diagnosis, Differential; Eosinophilia; Eosinophils; Humans; Mycoses; Rhini | 2007 |
[Acute and chronic headaches].
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspir | 2006 |
Staphylococcus aureus enterotoxins as immune stimulants in chronic rhinosinusitis.
Topics: Animals; Aspirin; Chronic Disease; Enterotoxins; Humans; Immunoglobulin E; Mice; Nasal Mucosa; Nasal | 2007 |
[Therapy of chronic stable angina].
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Aspirin; | 2008 |
Chronic rhinosinusitis and asthma.
Topics: Aspirin; Asthma; Chronic Disease; Comorbidity; Drug Hypersensitivity; Humans; Lymphocytes; Nasal Muc | 2008 |
Diseases associated with chronic rhinosinusitis: what is the significance?
Topics: Aspirin; Chronic Disease; Cystic Fibrosis; Humans; Hypersensitivity; Immunocompromised Host; Inciden | 2008 |
Chronic pain of childhood: a pharmacologic approach.
Topics: Acetaminophen; Adrenal Cortex Hormones; Analgesics; Analgesics, Opioid; Anti-Anxiety Agents; Anticon | 1984 |
[Allergic and pseudoallergic skin reactions to drugs and food additives].
Topics: Aspirin; Chronic Disease; Dermatitis, Contact; Drug Hypersensitivity; Drug Tolerance; Female; Food A | 1983 |
Approaches to rheumatoid arthritis and osteoarthritis: an overview.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Chronic Disease; Clinical Trials as Topic; | 1983 |
Analgesic-antipyretic choices for children with asthma: a review of safety and risk of common preparations.
Topics: Acetaminophen; Adolescent; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Br | 1984 |
[Current levels of cadmium in living organisma: physiopathological, clinical and therapeutic considerations].
Topics: Aspirin; Cadmium; Cadmium Poisoning; Chronic Disease; Dimercaprol; Edetic Acid; Environmental Pollut | 1981 |
New directions in anticoagulant and antiplatelet treatment.
Topics: Angina, Unstable; Aspirin; Chronic Disease; Drug Therapy, Combination; Humans; Myocardial Infarction | 1995 |
[Antithrombotic treatment in chronic nonrheumatic atrial fibrillation].
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebral Infarction; Chronic Disease; Clinica | 1993 |
[Growth factors in experimental ulcer].
Topics: Animals; Aspirin; Chronic Disease; Duodenal Ulcer; Epidermal Growth Factor; Ethanol; Fibroblast Grow | 1994 |
Concepts and controversies in salicylate toxicity.
Topics: Adult; Aspirin; Child; Chronic Disease; Decontamination; Humans; Male; Poisoning | 1994 |
Polymyositis associated with ulcerative colitis.
Topics: Aged; Aspirin; Chronic Disease; Colitis, Ulcerative; Colon; Drug Therapy, Combination; Female; Human | 1993 |
[Antithrombotic treatment of atrial fibrillation].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Clinical Trials as Topic; Fibrinolyti | 1996 |
Therapeutic strategies for atrial fibrillation. The value of decision analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; D | 1996 |
[Primary thrombocythemia in a female carrier of IgA deficiency].
Topics: Aged; Aspirin; Bacterial Vaccines; Biopsy; Bone Marrow; Chronic Disease; Combined Modality Therapy; | 1996 |
New insights into the understanding of asthma.
Topics: Air Pollutants; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchi; Chronic Disease; | 1997 |
Strategies for limiting the side effects of cancer pain therapy.
Topics: Age Factors; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemotherapy, Adjuvant; C | 1997 |
[Gastric and duodenal intramural hematoma: report of two cases].
Topics: Adult; Aspirin; Chronic Disease; Duodenal Diseases; Gastric Mucosa; Hematoma; Humans; Intestinal Muc | 1998 |
Counseling for women with preeclampsia or eclampsia.
Topics: Aspirin; Calcium; Chronic Disease; Counseling; Eclampsia; Female; HELLP Syndrome; Humans; Hypertensi | 1999 |
Chronic hypertension in pregnancy.
Topics: Abruptio Placentae; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin | 1999 |
Genetic mechanisms in aspirin-induced asthma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease; Eosinophilia; Female; Hum | 2000 |
Surgical treatment of nasal polyposis in patients with aspirin intolerance.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Cyclooxygenase Inhibitors; Humans | 2000 |
Reducing the risk: heart disease, stroke and aspirin.
Topics: Acute Disease; Aspirin; Blood Platelets; Chronic Disease; Cost-Benefit Analysis; Drug Costs; Heart D | 2001 |
[Is chronic or recurrent idiopathic pericarditis an autonomous inflammatory disease?].
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; As | 2001 |
Urticaria and angioedems.
Topics: Adrenal Cortex Hormones; Anaphylaxis; Angioedema; Aspirin; Chronic Disease; Cold Temperature; Diet T | 1975 |
Hemostatic failure in clinical medicine.
Topics: Acute Disease; Amyloidosis; Anticoagulants; Aspirin; Blood Platelet Disorders; Blood Vessels; Chroni | 1977 |
[A recent view of chronic gastritis (author's transl)].
Topics: Alcoholism; Aspirin; Bile; Chronic Disease; Follow-Up Studies; Gastric Juice; Gastritis; Humans | 1976 |
Anticoagulant therapy for atrial fibrillation. Recommendations from major studies.
Topics: Acute Disease; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Chronic Disease; Electric Co | 1992 |
[Embolic complications of chronic atrial fibrillation].
Topics: Aspirin; Atrial Fibrillation; Chronic Disease; Heart Valve Diseases; Humans; Primary Prevention; Pro | 1992 |
Aspirin in chronic cardiovascular disease and acute myocardial infarction.
Topics: Acute Disease; Aspirin; Cardiovascular Diseases; Chronic Disease; Humans; Myocardial Infarction; Pla | 1990 |
Thromboembolic complications in atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebral Infarction; Chronic Disease; Female; Fo | 1990 |
NSAID-induced gastric mucosal damage.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Female; Gastric Mucosa; Ga | 1987 |
Aspirin and the stomach.
Topics: Acute Disease; Adaptation, Physiological; Anemia; Animals; Aspirin; Buffers; Chronic Disease; Dose-R | 1986 |
[Pathogenesis of chronic interstitial nephritis following prolonged analgesic abuse].
Topics: Analgesics; Aniline Compounds; Animals; Aspirin; Chronic Disease; Dogs; Drug Hypersensitivity; Ethyl | 1972 |
Chronic effect of analgesics on the kidney.
Topics: Aminopyrine; Analgesics; Animals; Antipyrine; Aspirin; Caffeine; Chronic Disease; Drug Combinations; | 1972 |
Gastric mucosal injury by anti-inflammatory drugs.
Topics: Acute Disease; Anti-Inflammatory Agents; Aspirin; Chronic Disease; Epithelial Cells; Epithelium; Gas | 1974 |
[Chronic gastritis caused by exogenous factors].
Topics: Adolescent; Adult; Age Factors; Alcohol Drinking; Aspirin; Carcinogens; Chronic Disease; Female; Flu | 1968 |
[Bronchial asthma. A review for postgraduate medical education].
Topics: Adolescent; Adult; Aged; Aspirin; Asthma; Child; Chronic Disease; Czechoslovakia; Diagnosis, Differe | 1971 |
84 trials available for aspirin and Chronic Disease
| Article | Year |
|---|---|
Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial.
Topics: Aged; Anticoagulants; Aspirin; Chronic Disease; Coronary Artery Disease; Double-Blind Method; Drug T | 2020 |
Dupilumab as Add-on Therapy for Chronic Rhinosinusitis With Nasal Polyposis in Aspirin Exacerbated Respiratory Disease.
Topics: Antibodies, Monoclonal, Humanized; Aspirin; Chronic Disease; Humans; Nasal Polyps; Quality of Life; | 2021 |
The Effect of Aspirin on Moderate to Severe Asthmatic Patients with Aspirin Hypersensitivity, Chronic Rhinosinusitis, and Nasal Polyposis.
Topics: Adult; Anti-Asthmatic Agents; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Double-Blind Method | 2021 |
An RCT of a decision aid to support informed choices about taking aspirin to prevent colorectal cancer and other chronic diseases: a study protocol for the SITA (Should I Take Aspirin?) trial.
Topics: Aged; Aspirin; Chronic Disease; Colorectal Neoplasms; Decision Support Techniques; Humans; Middle Ag | 2021 |
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2019 |
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2019 |
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2019 |
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2019 |
AVURT: aspirin versus placebo for the treatment of venous leg ulcers - a Phase II pilot randomised controlled trial.
Topics: Aged; Aspirin; Chronic Disease; Compression Bandages; Double-Blind Method; Female; Humans; Male; Mid | 2018 |
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Chronic Disease; Corona | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Efficacy of hypertonic (2.3%) sea water in patients with aspirin-induced chronic rhinosinusitis following endoscopic sinus surgery.
Topics: Adult; Aspirin; China; Chronic Disease; Double-Blind Method; Endoscopy; Female; Humans; Male; Middle | 2019 |
Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combinat | 2019 |
Aspirin plus calcium supplementation to prevent superimposed preeclampsia: a randomized trial.
Topics: Adult; Aspirin; Brazil; Calcium, Dietary; Chronic Disease; Double-Blind Method; Drug Combinations; F | 2014 |
Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study.
Topics: Administration, Oral; Adult; Aged; Allergens; Aspirin; Asthma; Asthma, Aspirin-Induced; Chronic Dise | 2014 |
Interleukin-6 and tumor necrosis factor-α are associated with quality of life-related symptoms in pulmonary arterial hypertension.
Topics: Administration, Oral; Aspirin; Biomarkers; Chronic Disease; Dose-Response Relationship, Drug; Double | 2015 |
Aspirin for Venous Ulcers: Randomised Trial (AVURT): study protocol for a randomised controlled trial.
Topics: Aspirin; Chronic Disease; Clinical Protocols; Combined Modality Therapy; Compression Bandages; Doubl | 2015 |
Systemic expression of inflammatory mediators in patients with chronic rhinosinusitis and nasal polyps with and without Aspirin Exacerbated Respiratory Disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; C | 2016 |
Effect of clopidogrel on adhesion molecules, hemostasis, and fibrinolysis in coronary heart disease.
Topics: Aged; Angina Pectoris; Aspirin; Cell Adhesion Molecules; Chronic Disease; Clopidogrel; Double-Blind | 2008 |
Which parameters differ in very old patients with chronic atrial fibrillation treated by anticoagulant or aspirin? Antithrombotic treatment of atrial fibrillation in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; | 2008 |
Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chronic Disease; Clopidogrel; Death; Double-Blind Method; F | 2009 |
[Difficulties in evaluating the efficacy of antiplatelet therapy in clinical practice].
Topics: Adult; Aspirin; Chronic Disease; Clopidogrel; Data Interpretation, Statistical; Drug Resistance; Dru | 2009 |
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Card | 2010 |
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Card | 2010 |
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Card | 2010 |
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Card | 2010 |
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Card | 2010 |
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Card | 2010 |
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Card | 2010 |
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Card | 2010 |
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Card | 2010 |
The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Biomarkers; Chronic Disease; | 2010 |
Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Chronic Disease; Creatinine; Female; Glom | 2010 |
Use of aspirin associates with longer primary patency of hemodialysis grafts.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Aspirin; Aspirin, Dipyridamole Drug Combination; Chronic | 2011 |
Warfarin in atrial fibrillation patients with moderate chronic kidney disease.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Coagulation; Canada; Chi-Square Distributi | 2011 |
Association of factor V gene polymorphism with arteriovenous graft failure.
Topics: Adult; Aged; Aspirin; Chronic Disease; Dipyridamole; DNA; Double-Blind Method; Factor V; Female; Fol | 2012 |
Influence of aspirin therapy in the ulcer associated with chronic venous insufficiency.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Bandages, Hydrocolloid; Cardiovascular Agents; Chi-Square D | 2012 |
Alteration of hemostasis in patients treated with subgingival NSAIDs during periodontal therapy.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; G | 2012 |
A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Clopidogrel; | 2002 |
Platelet serotonin transporter in stroke patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Binding, Competitive; Biomarkers; Blood Plat | 2003 |
The stratification of platelet reactivity and activation in patients with stable coronary artery disease on aspirin therapy.
Topics: Aspirin; Biomarkers; Chronic Disease; Coronary Artery Disease; Humans; P-Selectin; Platelet Activati | 2003 |
First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.
Topics: Adult; Aged; Alanine Transaminase; Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Chronic Disea | 2005 |
Effect of high-dose aspirin on Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aspirin; Chronic Disease; Clarithromyc | 2005 |
Lack of association between gene sequence variations of platelet membrane receptors and aspirin responsiveness detected by the PFA-100 system in patients with coronary artery disease.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Female; Fibrinolytic Agents; Humans; Male; | 2006 |
Blood pressure measures and risk of chronic kidney disease in men.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; beta Carotene; Blood Pressure; Blood | 2008 |
Approaches to rheumatoid arthritis and osteoarthritis: an overview.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Chronic Disease; Clinical Trials as Topic; | 1983 |
[Experience with suprofen for acute and chronic pain in neurologic practice].
Topics: Acute Disease; Adult; Aspirin; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Drug | 1983 |
Vibratory stimulation for the alleviation of chronic pain.
Topics: Adolescent; Adult; Aged; Aspirin; Chronic Disease; Cryotherapy; Electric Stimulation Therapy; Female | 1983 |
Sodium cromoglycate and provocation tests in chronic urticaria.
Topics: Adult; Aspirin; Bleeding Time; Chronic Disease; Cromolyn Sodium; Female; Humans; Male; Middle Aged; | 1982 |
[Clinical evaluation of the therapeutic effectiveness of a new drug with anti-inflammatory-balsamic action, guacetisal, in respiratory tract diseases].
Topics: Adolescent; Adult; Aged; Aspirin; Bronchitis; Bronchopneumonia; Chronic Disease; Clinical Trials as | 1981 |
[Effects of guaiacolic ester of acetylsalicylic acid on spirometric and plethysmographic parameters in subjects with chronic obstructive bronchopneumopathy].
Topics: Aged; Aspirin; Bronchitis; Chronic Disease; Clinical Trials as Topic; Female; Humans; Lung Diseases, | 1981 |
[Guacetisal in the treatment of acute and chronic bronchopneumopathy].
Topics: Acute Disease; Aged; Anti-Bacterial Agents; Aspirin; Asthma; Bronchitis; Bronchodilator Agents; Bron | 1981 |
[Controlled clinical study of the treatment of chronic bronchitis with guacetisal].
Topics: Adult; Aged; Aspirin; Bromhexine; Bronchitis; Chronic Disease; Clinical Trials as Topic; Cough; Fema | 1981 |
[Preliminary study of guacetisal in chronic bronchitis].
Topics: Aged; Aspirin; Bronchitis; Chronic Disease; Clinical Trials as Topic; Cough; Dyspnea; Humans; Male; | 1981 |
[Treatment of bronchial inflammatory disorders with guacetisal].
Topics: Acute Disease; Aspirin; Bromhexine; Bronchitis; Carbonates; Chronic Disease; Clinical Trials as Topi | 1981 |
[Clinical trials of a new preparation in chronic bronchopneumopathies].
Topics: Adult; Aged; Aspirin; Asthma; Bronchitis; Chronic Disease; Clinical Trials as Topic; Cough; Female; | 1981 |
Effects of acetylsalicylic acid on peripheral hemodynamics in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Arm; Aspirin; Blood Pressure; Captopril; Chro | 1994 |
A comparative study of coumadin and aspirin for primary cardioembolic stroke and thromboembolic preventions of chronic rheumatic mitral stenosis with atrial fibrillation.
Topics: Adolescent; Adult; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Chi-Square Distribution; | 1994 |
Randomised trial of oral aspirin for chronic venous leg ulcers.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Bandages; Chronic Disease; Combined Modality | 1994 |
[Antiplatelet therapy in patients with cerebral thrombosis at the chronic phase--assessment of its effect on coagulation and fibrinolytic parameters].
Topics: Aged; Aspirin; Blood Coagulation; Cerebrovascular Disorders; Chronic Disease; Fibrinolysis; Humans; | 1994 |
[Acetylsalicylic acid and kurantil in the prevention of pregnancy complications in glomerulonephritis and hypertension].
Topics: Abortion, Spontaneous; Analysis of Variance; Aspirin; Chronic Disease; Dipyridamole; Drug Therapy, C | 1993 |
Neonatal outcome in a randomized, controlled trial of low-dose aspirin in high-risk pregnancies.
Topics: Aspirin; Chronic Disease; Double-Blind Method; Female; Humans; Hypertension; Infant, Newborn; Kidney | 1995 |
Aspirin in chloroform as an effective adjuvant in the management of chronic neurogenic pain.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemotherapy, Adjuvant; Chloroform; Chronic | 1997 |
Intranasal fluticasone propionate for chronic eosinophilic rhinitis in patients with aspirin-induced asthma.
Topics: Administration, Intranasal; Adult; Androstadienes; Anti-Allergic Agents; Aspirin; Asthma; Chronic Di | 1997 |
[Immediate and long-term clinical and angiographic results of the Wiktor stent in the treatment of chronic coronary occlusions].
Topics: Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Chronic Disease; Coro | 1997 |
Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units.
Topics: Adult; Aspirin; Chronic Disease; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Humans; Hyp | 1998 |
Increased thromboxane biosynthesis is associated with poststroke dementia.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Cerebral Hemorrhage; Chronic Disease; Co | 1999 |
Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin.
Topics: Adult; Aged; Angina Pectoris; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C-Reactive Protein; | 1999 |
Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin.
Topics: Adult; Aged; Angina Pectoris; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C-Reactive Protein; | 1999 |
Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin.
Topics: Adult; Aged; Angina Pectoris; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C-Reactive Protein; | 1999 |
Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin.
Topics: Adult; Aged; Angina Pectoris; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C-Reactive Protein; | 1999 |
Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Dose-Response Relationship, Dru | 2000 |
[Point scale quantification of changes in computed tomography of chronic hyperplastic rhinosinusitis].
Topics: Adult; Aspirin; Chronic Disease; Humans; Image Processing, Computer-Assisted; Middle Aged; Paranasal | 2000 |
Aspirin inhibits the acute venodilator response to furosemide in patients with chronic heart failure.
Topics: Aged; Aspirin; Chronic Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind M | 2001 |
Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid.
Topics: Acetates; Adolescent; Adult; Aged; Aspirin; Cetirizine; Chronic Disease; Cyclopropanes; Double-Blind | 2001 |
Platelet P-selectin levels in relation to plasma soluble P-selectin and beta-thromboglobulin levels in atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; beta-Thromboglobulin; Blood Platelets; Cell Coun | 2002 |
[Comparative results of treating lichen ruber planus by various methods].
Topics: Adolescent; Adult; Aged; Aspirin; Bismuth; Child; Child, Preschool; Chloroquine; Chronic Disease; Cl | 1977 |
Aspirin and tartrazine oral challenge: incidence of adverse response in chronic childhood asthma.
Topics: Adolescent; Aspirin; Asthma; Azo Compounds; Blood Pressure; Child; Chronic Disease; Clinical Trials | 1977 |
Naproxen in juvenile chronic polyarthritis.
Topics: Adolescent; Arthritis; Aspirin; Child; Child, Preschool; Chronic Disease; Clinical Trials as Topic; | 1979 |
Significance of tartrazine sensitivity in chronic urticaria of unknown etiology.
Topics: Adult; Aspirin; Azo Compounds; Benzenesulfonates; Chronic Disease; Clinical Trials as Topic; Eosinop | 1976 |
A new (?) Clinical headache entity "chronic paroxysmal hemicrania" 2.
Topics: Affective Symptoms; Aspirin; Cerebrovascular Circulation; Chronic Disease; Clinical Trials as Topic; | 1976 |
Clinical and objective assessments of naproxen through 5 years of clinical experience.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Arthritis, Rheumatoid; Aspirin; Chronic Disease; C | 1975 |
Reactions to aspirin and food additives in patients with chronic urticaria, including the physical urticarias.
Topics: Aspirin; Chronic Disease; Clinical Trials as Topic; Complement C3; Complement C4; Drug Hypersensitiv | 1975 |
Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure.
Topics: Adult; Aged; Aspirin; Chi-Square Distribution; Chronic Disease; Coronary Disease; Double-Blind Metho | 1992 |
Increased urinary excretion of the histamine metabolite N tau-methylhistamine during acetylsalicylic acid provocation in chronic urticaria patients.
Topics: Adult; Aged; Aspirin; Chronic Disease; Female; Histamine Release; Humans; Male; Methylhistamines; Mi | 1990 |
Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; beta Carotene; Cardiovascular Diseases; Ca | 1991 |
Comparison of long-term safety of ketorolac tromethamine and aspirin in the treatment of chronic pain.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; D | 1990 |
Chronic urticaria exacerbated by the antioxidant food preservatives, butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT).
Topics: Acetaminophen; Adult; Antioxidants; Aspirin; Butylated Hydroxyanisole; Butylated Hydroxytoluene; Chr | 1990 |
Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Chronic Disease; Clinical Trials as To | 1989 |
Warfarin to prevent thromboembolism in chronic atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Chronic Disease; Clinical Trials as Topic; Humans; Thromboembolism; Wa | 1989 |
Double-blind evaluation of analgesic efficacy of orally administered diclofenac, nefopam, and acetylsalicylic acid (ASA) plus codeine in chronic cancer pain.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Aspirin; Chronic Disea | 1989 |
Analgesic use and chronic renal disease.
Topics: Acetaminophen; Adult; Aged; Analgesics; Arthritis; Aspirin; Chronic Disease; Dose-Response Relations | 1989 |
[Action of methoxybutropate in chronic bronchitis. Comparison with guacetisal].
Topics: Adult; Aged; Aspirin; Bronchitis; Chronic Disease; Clinical Trials as Topic; Expectorants; Female; G | 1987 |
[Evaluation of the effect of polopirin S on platelet adhesiveness in chronic peripheral circulatory failure in arteriosclerosis].
Topics: Adult; Aged; Arteriosclerosis; Aspirin; Chronic Disease; Clinical Trials as Topic; Humans; Ischemia; | 1988 |
Double-blind study of sulindac and aspirin in juvenile chronic arthritis.
Topics: Adolescent; Adult; Arthritis, Juvenile; Aspirin; Child; Child, Preschool; Chronic Disease; Clinical | 1986 |
The clinical evaluation of anti-arthritic drugs.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Chronic Disease; Clinical Trials as Topic; | 1972 |
A controlled trial of aspirin in childhood glomerular disorders.
Topics: Adolescent; Age Factors; Aspirin; Blood Cell Count; Blood Platelets; Child; Child, Preschool; Chroni | 1973 |
A new form of aspirin--"Catalgix Forte". Its acceptability and effectiveness.
Topics: Analgesia; Arthritis; Arthritis, Rheumatoid; Aspirin; Bicarbonates; Chronic Disease; Clinical Trials | 1968 |
385 other studies available for aspirin and Chronic Disease
| Article | Year |
|---|---|
2-Amino-5-thiazolyl motif: a novel scaffold for designing anti-inflammatory agents of diverse structures.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Chronic Disease; Cyclooxygenase Inhib | 2008 |
A class of novel Schiff's bases: Synthesis, therapeutic action for chronic pain, anti-inflammation and 3D QSAR analysis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Chronic Disease; Disease Models, Animal; Ea | 2010 |
Appraisal of the Real-World Effectiveness of Biologic Therapies in Aspirin-Exacerbated Respiratory Disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Biological Therapy; Chronic Disease; Humans; Nasal Polyps; Pilot P | 2022 |
Management of chronic rhinosinusitis with nasal polyps in Samter triad by low-dose ASA desensitization or dupilumab.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Aspirin; Chronic Dis | 2021 |
Omalizumab-Induced Aspirin Tolerance in Nonsteroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease Patients Is Independent of Atopic Sensitization.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Humans; Nasal Polyps; Omalizumab; | 2022 |
Outcomes of aspirin exacerbated respiratory disease patients treated with aspirin desensitization and biologics.
Topics: Aspirin; Asthma, Aspirin-Induced; Biological Products; Chronic Disease; Desensitization, Immunologic | 2022 |
Chronic Rhinosinusitis Outcomes of Patients With Aspirin-Exacerbated Respiratory Disease Treated With Budesonide Irrigations: A Case Series.
Topics: Adrenal Cortex Hormones; Aspirin; Asthma, Aspirin-Induced; Budesonide; Chronic Disease; Humans; Nasa | 2022 |
Urinary leukotriene E4 is a biomarker for chronic rhinosinusitis associated with leukotriene dysregulation irrespective of aspirin sensitivity status.
Topics: Aspirin; Biomarkers; Chronic Disease; Humans; Leukotriene E4; Leukotrienes; Sinusitis | 2022 |
Comparison of aspirin desensitization outcomes between men and women with AERD.
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Desensitization, Immunologic; Female; Humans; Mal | 2022 |
Association between increased inflammatory cytokine expression in the lateral habenular nucleus and depressive-like behavior induced by unpredictable chronic stress in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Cytokines; Depression; H | 2022 |
Dupilumab-associated arthralgia in patients with aspirin-exacerbated respiratory disease.
Topics: Antibodies, Monoclonal, Humanized; Arthralgia; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Hu | 2022 |
The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity.
Topics: Adult; Aged; Aspirin; Cardiotoxicity; Chronic Disease; Female; Heart Failure; Humans; Inducible T-Ce | 2022 |
Comprehensive Analysis of Nasal Polyps Reveals a More Pronounced Type 2 Transcriptomic Profile of Epithelial Cells and Mast Cells in Aspirin-Exacerbated Respiratory Disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Eosinophilia; Epithelial Cells; Humans; Inflammat | 2022 |
Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Eicosanoids; Humans; Nasal Polyps; Prostaglandins | 2022 |
A dual treatment blocks alcohol binge-drinking relapse: Microbiota as a new player.
Topics: Acetylcysteine; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Animals; Aspirin; Chronic D | 2022 |
Aspirin desensitization following endoscopic sinus surgery is effective in patients with nonsteroidal antiinflammatory drug exacerbated respiratory disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-Induced; Chronic Di | 2023 |
The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis.
Topics: Administration, Intranasal; Adrenal Cortex Hormones; Aspirin; Biological Products; Chronic Disease; | 2023 |
Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease; Humans; Nasal Poly | 2023 |
Mechanistic and clinical updates in AERD: 2021-2022.
Topics: Adult; Aspirin; Asthma; Asthma, Aspirin-Induced; Chronic Disease; Humans; Nasal Polyps; Rhinitis | 2023 |
Demographic and clinical profile of patients with chronic rhinosinusitis in Saudi Arabia.
Topics: Aspirin; Asthma; Chronic Disease; Cross-Sectional Studies; Female; Humans; Male; Nasal Polyps; Preva | 2023 |
Co-treatment of non-steroidal anti-inflammatory drug-exacerbated respiratory disease with dupilumab and aspirin therapy after desensitization.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Aspirin; Asthma, Aspirin | 2023 |
Perioperative mepolizumab in aspirin-exacerbated respiratory disease does not prevent nasal polyp regrowth.
Topics: Antibodies, Monoclonal, Humanized; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Humans; Nasal | 2023 |
Association Between Aspirin-Exacerbated Respiratory Disease and Atherosclerotic Cardiovascular Disease: A Retrospective Review of US Claims Data.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-Induced; Cardiovascular Di | 2023 |
Angiogenesis and eosinophilia in the nasal mucosa of patients with different clinical phenotypes of chronic rhinosinusitis.
Topics: Aspirin; Chronic Disease; Cross-Sectional Studies; Eosinophilia; Humans; Nasal Mucosa; Nasal Polyps; | 2023 |
Differences between Lower Extremity Arterial Occlusion vs. Stenosis and Predictors of Successful Endovascular Interventions.
Topics: Arterial Occlusive Diseases; Aspirin; Chronic Disease; Constriction, Pathologic; Endovascular Proced | 2023 |
Effect of Zileuton Treatment on Sinonasal Quality of Life in Patients with Aspirin-Exacerbated Respiratory Disease.
Topics: Adult; Aged; Allergens; Anti-Asthmatic Agents; Arachidonate 5-Lipoxygenase; Aspirin; Asthma, Aspirin | 2019 |
The time course of nasal cytokine secretion in patients with aspirin-exacerbated respiratory disease (AERD) undergoing aspirin desensitization: preliminary data.
Topics: Adult; Aspirin; Asthma, Aspirin-Induced; Bodily Secretions; Chronic Disease; Cytokines; Desensitizat | 2020 |
Aspirin and N-acetylcysteine co-administration markedly inhibit chronic ethanol intake and block relapse binge drinking: Role of neuroinflammation-oxidative stress self-perpetuation.
Topics: Acetylcysteine; Alcohol Drinking; Alcoholism; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspi | 2021 |
Unexpected low expression of platelet fibrinogen receptor in patients with chronic myeloproliferative neoplasms: how does it change with aspirin?
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Chronic Disease; Fibrinogen; Humans; Middl | 2020 |
Aspirin-Exacerbated Respiratory Disease With Allergic Fungal Rhinosinusitis: A Case Series of Overlapping Sinonasal Endotypes.
Topics: Allergens; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Desensitization, Immunologic; Female; | 2020 |
Incidence and Predictors of Aspirin Discontinuation in Older Adult Veteran Nursing Home Residents at End of Life.
Topics: Aged; Aged, 80 and over; Aspirin; Chronic Disease; Dementia; Deprescriptions; Female; Heart Disease | 2020 |
Symptom Control of Patients With Chronic Rhinosinusitis With Nasal Polyps Under Maintenance Therapy With Daily Acetylsalicylic Acid.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Desensit | 2020 |
The Burden of Non-steroidal anti-inflammatory exacerbated respiratory disease from the patient's perspective - a qualitative analysis of posts from the Samter's Society.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Cost of Illness; Drug Hypersensit | 2020 |
Surgical outcomes in aspirin-exacerbated respiratory disease without aspirin desensitization.
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Endoscopy; Humans; Nasal Polyps; Retrospective St | 2020 |
Clinical-Cytological-Grading and phenotyping in patients with chronic rhinosinusitis with nasal polyps: the relevance in clinical practice.
Topics: Adult; Aspirin; Asthma; Cell Biology; Chronic Disease; Comorbidity; Cross-Sectional Studies; Female; | 2020 |
A Comparison of Sphenoid Sinus Osteoneogenesis in Aspirin-Exacerbated Respiratory Disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Humans; Nasal Polyps; Retrospective Studies; Rhin | 2021 |
Aspirin-Exacerbated Respiratory Disease: Association Between Patient-Reported Sinus and Asthma Morbidity.
Topics: Adult; Aspirin; Asthma; Chronic Disease; Female; Humans; Male; Middle Aged; Morbidity; Rhinitis | 2021 |
Evaluation of the chemopreventive potentials of ezetimibe and aspirin in a novel mouse model of gallbladder preneoplasia.
Topics: Animals; Aspirin; Chemoprevention; Cholecystolithiasis; Cholesterol; Cholesterol, Dietary; Chronic D | 2020 |
Level of sex hormones and their association with acetylsalicylic acid intolerance and nasal polyposis.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chronic Disease; Cone-Beam Computed Tomography; Drug Hypers | 2020 |
Dysbiosis in aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Dysbiosi | 2021 |
Perioperative management and perceived risks of sinus surgery in patients with aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Humans; Nasal Polyps; Rhinitis; Sinusitis | 2021 |
Rivaroxaban reduces thromboxane induced platelet aggregation - the forgotten compass arm?
Topics: Aspirin; Chronic Disease; Drug Therapy, Combination; Heart Diseases; Humans; Platelet Aggregation; P | 2021 |
Cost-effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease.
Topics: Antibodies, Monoclonal, Humanized; Aspirin; Chronic Disease; Cost-Benefit Analysis; Desensitization, | 2021 |
Epithelial dysregulation in chronic rhinosinusitis with nasal polyposis (CRSwNP) and aspirin-exacerbated respiratory disease (AERD).
Topics: Aspirin; Biomarkers; Chronic Disease; Disease Progression; Disease Susceptibility; Humans; Nasal Pol | 2021 |
Transcriptome Analysis Identifies Doublesex and Mab-3 Related Transcription Factor (DMRT3) in Nasal Polyp Epithelial Cells of Patients Suffering from Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease (AERD).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; E | 2021 |
Risk of Hemorrhage Attributed to Underlying Chronic Diseases and Uninterrupted Aspirin Therapy of Patients Undergoing Minor Oral Surgical Procedures: A Retrospective Cohort Study.
Topics: Adult; Aged; Anticoagulants; Aspirin; Chronic Disease; Female; Hemorrhage; Humans; Male; Middle Aged | 2017 |
Effect of Low-Dose Aspirin on Chronic Acid Reflux Esophagitis in Rats.
Topics: Administration, Oral; Animals; Aspirin; Body Weight; Chronic Disease; Dose-Response Relationship, Dr | 2018 |
Treatment with low doses of aspirin during chronic phase of experimental Chagas' disease increases oesophageal nitrergic neuronal subpopulation in mice.
Topics: Animals; Aspirin; Chagas Disease; Chronic Disease; Colon; Disease Models, Animal; Esophagus; Male; M | 2017 |
Inappropriate medication use and polypharmacy in end-stage cancer patients: Isn't it the family doctor's role to de-prescribe much earlier?
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Chronic Disease; Female; Hospice Care; Hu | 2018 |
Long-term Clinical Outcomes of Aspirin Desensitization With Continuous Daily Aspirin Therapy in Aspirin-exacerbated Respiratory Disease.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-In | 2018 |
Medical History, Medication Use, and Risk of Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Aspirin; Case-Control Studies; China; Chronic Disease; Female; Humans; Logistic Models; | 2018 |
Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?
Topics: Aspirin; Atherosclerosis; Chronic Disease; Clinical Trials as Topic; Death; Drug Therapy, Combinatio | 2019 |
Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study.
Topics: Administration, Inhalation; Aspirin; Asthma; Case-Control Studies; Chronic Disease; Cross-Sectional | 2018 |
Chronic Hypertension in Pregnancy: New Concepts for Classification and Management.
Topics: Adult; Antihypertensive Agents; Aspirin; Chronic Disease; Female; Humans; Hypertension; Hypertension | 2019 |
Differences in urinary leukotriene E4 levels and distribution of eosinophils between chronic rhinosinusitis patients with aspirin-intolerant and-tolerant asthma.
Topics: Aspirin; Asthma; Chronic Disease; Drug Tolerance; Eosinophils; Humans; Leukotriene E4; Rhinitis; Sin | 2016 |
Safety of Diagnostic and Therapeutic Cardiac Catheterization in Cancer Patients With Acute Coronary Syndrome and Chronic Thrombocytopenia.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Cardiac Catheterization; Chronic D | 2018 |
A 1-Day, 90-Minute Aspirin Challenge and Desensitization Protocol in Aspirin-Exacerbated Respiratory Disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Cyclooxygenase Inhibitors; Desensitization, Immun | 2019 |
Objective and subjective sinonasal and pulmonary outcomes in aspirin desensitization therapy: A prospective cohort study.
Topics: Aged; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Cohort Studies; Desensitization, Immunologi | 2019 |
Epidemiology and long-term outcome in outpatients with chronic heart failure in Northwestern Europe.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin Receptor Antagonists; Angiotensin-Conver | 2019 |
[Nasal provocation with increased ASA dose: improved "non-steroidal anti-inflammatory drugs (NSAIDs)-exacerbated disease" (N‑ERD) detection rate in chronic rhinosinusitis patients].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Humans; | 2019 |
Effect of acetylsalicylic acid on total myenteric neurons in mice experimentally infected with Trypanosoma cruzi.
Topics: Animals; Aspirin; Chagas Disease; Chronic Disease; Disease Models, Animal; Male; Mice; Myenteric Ple | 2019 |
The bacteriology of chronic rhinosinusitis and the pre-eminence of Staphylococcus aureus in revision patients.
Topics: Adult; Aged; Aspirin; Asthma; Chronic Disease; Female; Humans; Male; Middle Aged; Nasal Polyps; Pseu | 2013 |
Aspirin resistance in Thai patients with chronic stable angina.
Topics: Aged; Angina Pectoris; Asian People; Aspirin; Chronic Disease; Drug Resistance; Female; Humans; Male | 2013 |
Protection of vascular endothelium by aspirin in a murine model of chronic Chagas' disease.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Chagas Cardiomyopathy; Chronic Disease; Disease Models, | 2013 |
Aspirin sensitivity does not compromise quality-of-life outcomes in patients with Samter's triad.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease; | 2014 |
Short-term beneficial effect of aspirin in patient with chronic rhinosinusitis and tolerant to acetylsalicylic acid.
Topics: Adult; Aspirin; Chronic Disease; Humans; Male; Rhinitis; Sinusitis | 2013 |
Involvement of the spinal NALP1 inflammasome in neuropathic pain and aspirin-triggered-15-epi-lipoxin A4 induced analgesia.
Topics: Analgesia; Animals; Aspirin; Chronic Disease; Drug Therapy, Combination; Inflammasomes; Injections, | 2013 |
Systemic prednisone administration selectively alters granulocyte subsets in nasal polyps from aspirin-exacerbated respiratory disease and chronic rhinosinusitis patients.
Topics: Adult; Aged; Aspirin; Chronic Disease; Ethmoid Sinus; Female; Flow Cytometry; Glucocorticoids; Granu | 2013 |
Aspirin augments IgE-mediated histamine release from human peripheral basophils via Syk kinase activation.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Exercise-Induced; Basop | 2013 |
Impact of vitamin D deficiency upon clinical presentation in nasal polyposis.
Topics: Age Factors; Allergens; Antigens, Fungal; Aspirin; Black or African American; Cholecalciferol; Chron | 2014 |
Impaired resolution of inflammation in human chronic heart failure.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Cardiovascular Diseases; Chronic | 2014 |
Aspirin desensitization: useful treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in aspirin-exacerbated respiratory disease (AERD)?
Topics: Aspirin; Chronic Disease; Desensitization, Immunologic; Drug Hypersensitivity; Drug Tolerance; Human | 2014 |
Circulating myeloid-related protein-8/14 is related to thromboxane-dependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Calgranulin A; Calgranulin B; Chronic Disease; Dinoprost; Fe | 2014 |
Elevated platelet activation in patients with chronic urticaria: a comparison between aspirin-intolerant and aspirin-tolerant groups.
Topics: Adult; Aspirin; Biomarkers; Blood Platelets; Case-Control Studies; Chronic Disease; Female; Humans; | 2014 |
Aspirin-exacerbated cutaneous disease (AECD) is a distinct subphenotype of chronic spontaneous urticaria.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Asp | 2015 |
Challenge-proven aspirin hypersensitivity in children with chronic spontaneous urticaria.
Topics: Adolescent; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Chronic Disease; Co | 2015 |
Samter's triad with aural involvement: a novel approach to management.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease; Drug Hypersensitiv | 2014 |
Outcomes of complete vs targeted approaches to endoscopic sinus surgery.
Topics: Aspirin; Asthma; Chronic Disease; Endoscopy; Female; Humans; Male; Middle Aged; Nasal Polyps; Postop | 2015 |
A conserved linkage group on chromosome 6, the 8.1 ancestral haplotype, is a predisposing factor of chronic rhinosinusitis associated with nasal polyposis in aspirin-sensitive Hungarians.
Topics: Adolescent; Adult; Aged; Alleles; Aspirin; Case-Control Studies; Chromosomes, Human, Pair 6; Chronic | 2015 |
[Interaction of the Humoral Agonist During the Platelets Activation in Patients with Chronic Cerebral Ischemia].
Topics: Adenosine Diphosphate; Adult; Aspirin; Blood Platelets; Brain; Brain Ischemia; Chronic Disease; Epin | 2015 |
Aspirin prevents atrophy of esophageal nitrergic myenteric neurons in a mouse model of chronic Chagas disease.
Topics: Animals; Aspirin; Atrophy; Chagas Disease; Chronic Disease; Cyclooxygenase Inhibitors; Disease Model | 2017 |
Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study.
Topics: Aged; Aspirin; Blood Pressure; Chronic Disease; Drug Interactions; Eplerenone; Female; Glomerular Fi | 2016 |
Clinical Examination of Tissue Eosinophilia in Patients with Chronic Rhinosinusitis and Nasal Polyposis.
Topics: Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Eosinophilia; Female; Humans; Male; Middle | 2016 |
Management of pregnancies complicated by hypertensive disorders of pregnancy: Could we do better?
Topics: Adult; Antihypertensive Agents; Aspirin; Chronic Disease; Female; Guideline Adherence; Humans; Hyper | 2017 |
Omalizumab in patient with aspirin exacerbated respiratory disease and chronic idiopathic urticaria.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease; Female; Human | 2017 |
Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without AERD: a cross-sectional and longitudinal study.
Topics: Adult; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Cross-Sectional Studies; Female; Humans; L | 2017 |
Preeclampsia and Preterm Birth Associated With Visceral Adiposity in Early Pregnancy.
Topics: Adult; Aspirin; Body Mass Index; Chronic Disease; Female; Humans; Hypertension; Intra-Abdominal Fat; | 2017 |
Oral corticosteroid prescribing habits for rhinosinusitis: The American Rhinologic Society membership.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aspirin; Chronic Disease; Evidence-Based Medicine; Hu | 2017 |
Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Femal | 2008 |
[Peculiarities of hemostasis, metabolic activity of platelets, and rate of aspirin resistance in patients with chronic heart failure after aorto-coronary bypass surgery].
Topics: Aged; Aspirin; Blood Platelets; Chronic Disease; Coronary Artery Bypass; Dose-Response Relationship, | 2008 |
Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients.
Topics: Aspirin; Chronic Disease; Coronary Artery Disease; Drug Resistance; Female; Humans; Male; Middle Age | 2008 |
Correlation between the prostaglandin D(2)/E(2) ratio in nasal polyps and the recalcitrant pathophysiology of chronic rhinosinusitis associated with bronchial asthma.
Topics: Adult; Aged; Aspirin; Asthma; Cell Extracts; Chronic Disease; Dinoprostone; Drug Hypersensitivity; E | 2008 |
Otologic manifestations in Samter's syndrome.
Topics: Aspirin; Asthma; Chronic Disease; Cohort Studies; Drug Hypersensitivity; Ear Diseases; Ear, Middle; | 2009 |
Association of specific IgE to staphylococcal superantigens with the phenotype of chronic urticaria.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antigens; Aspirin; Bacterial Toxin | 2008 |
Proteomics blood testing to distinguish chronic rhinosinusitis subtypes.
Topics: Aspirin; Asthma; Biomarkers; Chronic Disease; Diagnosis, Differential; Drug Hypersensitivity; Fungi; | 2008 |
Histamine N-methyltransferase 939A>G polymorphism affects mRNA stability in patients with acetylsalicylic acid-intolerant chronic urticaria.
Topics: Adult; Alleles; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Basophils; Case-Control Studies; C | 2009 |
Atrial fibrillation and stroke risk prevention in real-life clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Clini | 2009 |
How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Drug | 2009 |
Prevention of chronic gastritis by fermented milks made with exopolysaccharide-producing Streptococcus thermophilus strains.
Topics: Animals; Aspirin; Body Weight; Chronic Disease; Cultured Milk Products; Cyclooxygenase Inhibitors; G | 2009 |
Familial chilblain lupus--a monogenic form of cutaneous lupus erythematosus due to a heterozygous mutation in TREX1.
Topics: Adolescent; Aspirin; Biopsy, Needle; Chronic Disease; Disease Progression; Drug Therapy, Combination | 2009 |
Patterns of medication use by chronic and episodic headache sufferers in the general population: results from the frequent headache epidemiology study.
Topics: Adolescent; Adult; Aged; Analgesics; Aspirin; Caffeine; Chronic Disease; Disease Progression; Female | 2010 |
Unmet needs in severe chronic upper airway disease (SCUAD).
Topics: Allergens; Aspirin; Child; Chronic Disease; Drug Hypersensitivity; Humans; Nasal Polyps; Prevalence; | 2009 |
Letter by Kan et al regarding Article, "randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart failure (WATCH) trial".
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chronic Disease; Clopidogrel; Death; Double-Blind Method; F | 2009 |
Detection of presumed hemorrhage in the ampullar endolymph of the semicircular canal: a case report.
Topics: Aspirin; Chronic Disease; Contrast Media; Endolymph; Female; Functional Laterality; Gadolinium DTPA; | 2009 |
[Influence of anticoagulants on the appearance of chronic subdural hematoma].
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cardiovascular Diseases; Chronic Disease; C | 2009 |
Infliximab for the treatment of refractory Adamantiades-Behçet disease with articular, intestinal, cerebral and ocular involvement.
Topics: Adolescent; Antibodies, Monoclonal; Arthritis; Aspirin; Azathioprine; Behcet Syndrome; Chronic Disea | 2010 |
Therapeutic effect of Linum usitatissimum (flaxseed/linseed) fixed oil on acute and chronic arthritic models in albino rats.
Topics: Acute Disease; Alanine Transaminase; Albinism; Animals; Arthritis, Experimental; Aspartate Aminotran | 2010 |
A case of aseptic pleuropericarditis in a patient with chronic plaque psoriasis under methotrexate therapy.
Topics: Anti-Inflammatory Agents; Aspirin; Chronic Disease; Colchicine; Dermatologic Agents; Drug Therapy, C | 2010 |
Cardiorenal syndromes--recommendations from clinical practice guidelines: the cardiologist's view.
Topics: Acute Disease; Acute Kidney Injury; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhib | 2010 |
Aspirin-intolerant chronic urticaria exacerbated by cutaneous application of a ketoprofen poultice.
Topics: Administration, Cutaneous; Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C | 2010 |
Chronic disease in men with newly diagnosed cancer: a nested case-control study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; beta Carotene; Car | 2010 |
[Antiplatelet therapy in patients with chronic obliterating diseases of lower-limb arteries].
Topics: Arteriosclerosis Obliterans; Aspirin; Chronic Disease; Fibrinolytic Agents; Hemorrhage; Humans; Leg; | 2010 |
Aspirin and the prevention of cardiovascular disease in chronic kidney disease: time to move forward?
Topics: Aspirin; Cardiovascular Diseases; Chronic Disease; Creatinine; Glomerular Filtration Rate; Hemorrhag | 2010 |
Aspirin sensitivity and the nose.
Topics: Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Humans; Nasal Polyps; Respiration Disorders | 2010 |
[Current status of medical therapy of chronic stable angina pectoris in mainland of China: the second survey].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angiotensin Receptor A | 2010 |
Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chronic Disease; Clopidogrel; Cohort Studies; Coronar | 2011 |
Aspirin treatment of mice infected with Trypanosoma cruzi and implications for the pathogenesis of Chagas disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chagas Disease; Chronic Disease; Cyclooxy | 2011 |
Effects of acetyl salycilic acid and ibuprofen in chronic liver damage induced by CCl4.
Topics: Animals; Aspirin; Blotting, Western; Carbon Tetrachloride; Cell Nucleus; Chronic Disease; Collagen; | 2012 |
A problem of rigidity.
Topics: Aspirin; Asthma; Biomedical Research; Chronic Disease; Comparative Effectiveness Research; Decision | 2011 |
[Security of proton pump inhibitors].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Chronic Disease; Drug Interactions; | 2011 |
Aspirin and arteriovenous graft thrombosis in hemodialysis: just what the doctor ordered?
Topics: Arteriovenous Shunt, Surgical; Aspirin; Chronic Disease; Dipyridamole; Humans; Kidney Diseases; Plat | 2011 |
Aspirin in the prevention of cancer.
Topics: Anticarcinogenic Agents; Aspirin; Chronic Disease; Gastrointestinal Hemorrhage; Humans; Iron; Neopla | 2011 |
Aspirin, clopidogrel, and warfarin use and outcomes in a cohort of 580 patients discharged after hospitalization for decompensated heart failure.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Chi-Square Distribution; Ch | 2012 |
Improvement of chronic rhinitis under aspirin.
Topics: Aspirin; Chronic Disease; Cyclooxygenase Inhibitors; Humans; Magnetic Resonance Imaging; Male; Middl | 2012 |
First-fill medication discontinuations and nonadherence to antihypertensive therapy: an observational study.
Topics: Age Factors; Aged; Antidepressive Agents; Antihypertensive Agents; Aspirin; Chronic Disease; Depress | 2012 |
High antiphospholipid antibody levels are associated with statin use and may reflect chronic endothelial damage in non-autoimmune thrombosis: cross-sectional study.
Topics: Aged; Antibodies, Antiphospholipid; Aspirin; Biomarkers; Chronic Disease; Cross-Sectional Studies; E | 2012 |
Predictors of thromboxane levels in patients with non-ST-elevation acute coronary syndromes on chronic aspirin therapy.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Chronic Disease; Coronary Angiography; Electroca | 2012 |
Low SPINK5 expression in chronic rhinosinusitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; | 2012 |
Recurrent pediatric thrombosis: the effect of underlying and/or coexisting factors.
Topics: Adolescent; Adult; Anticoagulants; Aspirin; Child; Child, Preschool; Chronic Disease; Factor VIII; F | 2012 |
A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case-control study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Databases, F | 2012 |
Incidence of aspirin hypersensitivity in patients with chronic rhinosinusitis and diagnostic value of urinary leukotriene E4.
Topics: Adult; Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Female; Humans; Leukotriene E4; Male | 2012 |
Aspirin sensitivity and coronary artery disease: implications for the practicing cardiologist.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Asthma; Chronic Disease; Coronary Artery Disease; Cyclooxyg | 2012 |
Overuse of paracetamol caffeine aspirin powders affects cerebral glucose metabolism in chronic migraine patients.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Br | 2013 |
Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Chronic Disease; | 2012 |
The natural history and clinical characteristics of aspirin-exacerbated respiratory disease.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchial Provocatio | 2002 |
Urinary metabolites of histamine and leukotrienes before and after placebo-controlled challenge with ASA and food additives in chronic urticaria patients.
Topics: Administration, Oral; Adult; Aspirin; Biomarkers; Bronchoconstrictor Agents; Chronic Disease; Contro | 2002 |
[A case for proton pump blocker... When cough comes from the stomach].
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antirheumatic Age | 2002 |
Aspirin intolerance in boy with primary ciliary dyskinesia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Chronic Disease; Cyclooxygenase Inhibitors; | 2003 |
ATP diphosphohydrolase in human platelets from patients with coronary arteries heart disease.
Topics: Acute Disease; Adult; Aged; Apyrase; Aspirin; Blood Glucose; Blood Platelets; Case-Control Studies; | 2003 |
Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in patients with advanced chronic heart failure.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Chronic Disease; Femal | 2003 |
The effect of ethanol on spermatogenesis and fertility in male Sprague-Dawley rats pretreated with acetylsalicylic acid.
Topics: Alcoholism; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Cyclooxygena | 2002 |
Towards better management of chronic atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Chronic Disease; Humans; Warfarin | 2003 |
Antithrombotic treatment of atrial fibrillation in a regional hospital in Hong Kong.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Chronic Disease; Contraindications; Fe | 2003 |
Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: a dose-mediated deleterious effect.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Arteries; Asp | 2003 |
Aspirin-angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure: a dose-related adverse effect of aspirin.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Chi-Square Distribution; Chronic Disease; Dose-Re | 2003 |
Massive chronic atrial thrombosis.
Topics: Anticoagulants; Aspirin; Chronic Disease; Coronary Thrombosis; Drug Therapy, Combination; Echocardio | 2003 |
The effect of aspirin in chronic urticaria.
Topics: Aspirin; Chronic Disease; Humans; Sodium Salicylate; Urticaria | 1960 |
The prevention of recurrent herpes simplex with aspirin.
Topics: Aspirin; Biomedical Research; Chronic Disease; Herpes Simplex; Herpesviridae Infections; Humans | 1962 |
ANALGESIC EFFECT OF PRODILIDINE HYDROCHLORIDE (5054) IN ELDERLY PATIENTS WITH CHRONIC PAIN SYNDROME.
Topics: Analgesics; Analgesics, Non-Narcotic; Antipyretics; Arthritis; Arthritis, Rheumatoid; Aspirin; Chron | 1964 |
RANTES, eotaxin and eotaxin-2 expression and production in patients with aspirin triad.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Asthma; Chemokine CCL11; Chemokine CCL24; Chemokine CCL5; C | 2003 |
Should aspirin be used to counteract 'salicylate deficiency'?
Topics: Alzheimer Disease; Aspirin; Cardiovascular Diseases; Chronic Disease; Fruit; Humans; Neoplasms; Publ | 2003 |
Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Case-Contr | 2004 |
Decrease in non-selective, non-sustained attention induced by a chronic visceral inflammatory state as a new pain evaluation in rats.
Topics: Acetaminophen; Analgesics; Animals; Anti-Inflammatory Agents; Aspirin; Attention; Behavior, Animal; | 2004 |
Multiple NSAID intolerance in chronic idiopathic urticaria is correlated with delayed, pronounced and prolonged autoreactivity.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; | 2004 |
Thromboembolic prophylaxis in nonrheumatic atrial fibrillation: utilization patterns, efficacy, and complications in a long-term follow-up of community patients.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Femal | 2004 |
Aspirin withdrawal and acute lower limb ischemia.
Topics: Aged; Aged, 80 and over; Arterial Occlusive Diseases; Aspirin; Chronic Disease; Female; Humans; Isch | 2004 |
[Chronic diarrhea caused by NSAIDs].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Colitis; Collagen; Colonoscopy; D | 2004 |
Physicians' attitudes toward anticoagulant therapy in patients with chronic atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Attitude of Health Personnel; | 2004 |
Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis.
Topics: Adult; Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Enterotoxins; Female; Humans; Immuno | 2004 |
[Stroke and other tromboembolic complications in atrial fibrillation. Part I. Prevalence and risk factors].
Topics: Age Factors; Aged; Aspirin; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Chronic Disease; Cros | 2004 |
Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs.
Topics: Acute Disease; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Di | 2004 |
Healing of chronic gastric ulcers in diabetic rats treated with native aspirin, nitric oxide (NO)-derivative of aspirin and cyclooxygenase (COX)-2 inhibitor.
Topics: Animals; Aspirin; Chronic Disease; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inh | 2004 |
Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Epithelial Cells; Fe | 2005 |
Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Chr | 2005 |
Statins and aspirin in chronic kidney disease: what does the UK-HARP-I trial tell us?
Topics: Aspirin; Cardiovascular Diseases; Cholesterol; Chronic Disease; Disease Progression; Hemorrhage; Hum | 2005 |
"Polypill-aspostatinoprilololazide folate"--coprescription for at the risk Asian Indian in chronic non communicable diseases.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; | 2005 |
Influence of gastric colonization with Candida albicans on ulcer healing in rats: effect of ranitidine, aspirin and probiotic therapy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Biopsy; Blood Flow Vel | 2005 |
Improvements in an oral aspirin challenge protocol for the diagnosis of aspirin hypersensitivity.
Topics: Administration, Oral; Adult; Anaphylaxis; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspir | 2005 |
Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease.
Topics: Adult; Aspirin; Asthma; Case-Control Studies; Chronic Disease; Cohort Studies; Drug Hypersensitivity | 2005 |
Characterisation of patients with frequent exacerbation of asthma.
Topics: Adrenal Cortex Hormones; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; As | 2006 |
Characterisation of patients with frequent exacerbation of asthma.
Topics: Adrenal Cortex Hormones; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; As | 2006 |
Characterisation of patients with frequent exacerbation of asthma.
Topics: Adrenal Cortex Hormones; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; As | 2006 |
Characterisation of patients with frequent exacerbation of asthma.
Topics: Adrenal Cortex Hormones; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; As | 2006 |
Not all food additive related reactions originate from commercial foods: chronic urticaria due to home-made canned tomato.
Topics: Adult; Aspirin; Chronic Disease; Food Hypersensitivity; Food Preservatives; Humans; Male; Solanum ly | 2005 |
Aspirin use in chronic heart failure: what should we recommend to the practitioner?
Topics: Aspirin; Chronic Disease; Heart Failure; Humans; Platelet Aggregation Inhibitors; Practice Guideline | 2005 |
Therapeutic significance of aspirin mediated lipoxin biosynthesis in attenuation of chronic inflammation.
Topics: Aspirin; Chronic Disease; Humans; Inflammation; Lipoxins | 2006 |
Association between body mass index and CKD in apparently healthy men.
Topics: Adult; Aspirin; beta Carotene; Body Mass Index; Cardiovascular Diseases; Chronic Disease; Cohort Stu | 2005 |
An aspirin responsive non-progressive chronic chorea.
Topics: Adult; Antiphospholipid Syndrome; Aspirin; Chorea; Chronic Disease; Diagnosis, Differential; Female; | 2006 |
[New pathophysiological concepts on aspirin hypersensitivity (Widal syndrome); diagnostic and therapeutic consequences].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease; Drug Hypersensitiv | 2005 |
Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy; Chronic Disease; Drug Hyperse | 2006 |
Polypill holds promise for people with chronic disease.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Chemoprevention; Chronic Disease; Develop | 2005 |
High glucose contributes to aspirin insensitivity in streptozotocin-diabetic rats: a multiparametric aggregation study.
Topics: Animals; Aspirin; Blood Glucose; Blood Platelets; Chronic Disease; Diabetes Mellitus, Experimental; | 2006 |
Does it make sense to "desens"? Aspirin desensitization in the treatment of chronic rhinosinusitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease; Desensitization, Immunolo | 2006 |
Use of whole blood platelet lumi-aggregometry to optimize anti-platelet therapy in patients with chronic myeloproliferative disorders.
Topics: Aspirin; Chronic Disease; Clopidogrel; Dietary Supplements; Dose-Response Relationship, Drug; Garlic | 2006 |
Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial.
Topics: Angina Pectoris; Aspirin; Chronic Disease; Coronary Stenosis; Drug Therapy, Combination; Humans; Mal | 2006 |
Clinically important drug-disease interactions and their prevalence in older adults.
Topics: Aged; Aspirin; Calcium Channel Blockers; Chronic Disease; Drug-Related Side Effects and Adverse Reac | 2006 |
[A case of acute exacerbation of chronic pulmonary thromboembolism with essential thrombocythemia during treatment for hemoptysis].
Topics: Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Chronic Disease; Female; Hemoptysis; Humans; Ox | 2006 |
Significant association of FcepsilonRIalpha promoter polymorphisms with aspirin-intolerant chronic urticaria.
Topics: Aspirin; Basophils; Chronic Disease; DNA-Binding Proteins; Drug Hypersensitivity; Histamine Release; | 2007 |
Dermacase. Chronic venous insufficiency.
Topics: Aged; Aspirin; Chronic Disease; Edema; Fibrinolytic Agents; Humans; Leg; Male; Stockings, Compressio | 2006 |
Clopidogrel inhibits platelet aggregation in patients on aspirin with stable chronic angina pectoris.
Topics: Angina Pectoris; Aspirin; Chronic Disease; Clopidogrel; Humans; Platelet Aggregation; Platelet Aggre | 2008 |
Impact of aspirin intolerance on outcomes of sinus surgery.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chi-Square Distribution; Chronic Dise | 2007 |
Acute myocardial infarction after consumption of aspirin in a chronic methadone user patient.
Topics: Adult; Aspirin; Chronic Disease; Cyclooxygenase Inhibitors; Electrocardiography; Humans; Male; Metha | 2007 |
[Control of aspirin effect in chronic cardiovascular patients using two whole blood platelet function assays. PFA-100 and Multiplate].
Topics: Aspirin; Blood Coagulation; Blood Donors; Blood Platelets; Cardiovascular Diseases; Chronic Disease; | 2007 |
[Control of aspirin effect in chronic cardiovascular patients using two whole blood platelet function assays. PFA-100 and Multiplate].
Topics: Aspirin; Blood Coagulation; Blood Donors; Blood Platelets; Cardiovascular Diseases; Chronic Disease; | 2007 |
[Control of aspirin effect in chronic cardiovascular patients using two whole blood platelet function assays. PFA-100 and Multiplate].
Topics: Aspirin; Blood Coagulation; Blood Donors; Blood Platelets; Cardiovascular Diseases; Chronic Disease; | 2007 |
[Control of aspirin effect in chronic cardiovascular patients using two whole blood platelet function assays. PFA-100 and Multiplate].
Topics: Aspirin; Blood Coagulation; Blood Donors; Blood Platelets; Cardiovascular Diseases; Chronic Disease; | 2007 |
The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Asthma; Child; Child, Preschool; Chronic Diseas | 2007 |
Ischemic stroke in a child mistaken as functional disorder.
Topics: Adolescent; Aspirin; Chronic Disease; Diagnostic Errors; Diffusion Magnetic Resonance Imaging; Dysar | 2007 |
Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Anti-Inflammatory Age | 2008 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2007 |
Colorectal cancer risk, chronic illnesses, operations and medications: case control results from the Melbourne Colorectal Cancer Study. 1988.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Chronic Disease; Colorectal | 2007 |
Risk factors for chronic constipation and a possible role of analgesics.
Topics: Acetaminophen; Adult; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; | 2007 |
The editor's roundtable: chronic stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Calcium Chann | 2007 |
2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; | 2008 |
The assessment and management of albuminuria in primary care.
Topics: Aged; Albuminuria; Aspirin; Blood Glucose; Cardiovascular Diseases; Chronic Disease; Diabetes Mellit | 2008 |
Neutrophil activation in patients with ASA-induced urticaria.
Topics: Acute Disease; Administration, Oral; Adult; Angioedema; Aspirin; Chronic Disease; Cytokines; Drug Hy | 2008 |
Gene expression profiling of nasal polyps associated with chronic sinusitis and aspirin-sensitive asthma.
Topics: Adipokines; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Carrier Proteins; Chrom | 2008 |
[ASA-intolerance (Samter's syndrome): an important differential diagnosis for chronic airway diseases].
Topics: Aspirin; Asthma; Chronic Disease; Diagnosis, Differential; Drug Hypersensitivity; Humans; Nasal Poly | 2008 |
Effect of salicylates in urticaria.
Topics: Adolescent; Adult; Aged; Aspirin; Child; Child, Preschool; Chronic Disease; Drug Hypersensitivity; F | 1967 |
Chronic urticaria. Possible causes, suggested treatment alternatives.
Topics: Allergens; Aspirin; Chronic Disease; Drug Administration Schedule; Drug Hypersensitivity; Female; Fo | 1983 |
Investigation of the possible involvement of IgE anti-salicyloyl antibodies in patients with urticaria.
Topics: Aspirin; Chronic Disease; Histamine Release; Humans; Immunoglobulin E; Polylysine; Radioallergosorbe | 1981 |
Factors determining the site of chronic gastroduodenal ulcers.
Topics: Animals; Aspirin; Chronic Disease; Diet; Digestive System; Duodenum; Gastric Acid; Gastric Mucins; G | 1982 |
The management of the patient with chronic pain due to advanced malignancy.
Topics: Acetaminophen; Analgesics; Aspirin; Chronic Disease; Drug Therapy, Combination; Humans; Narcotics; N | 1982 |
Chronic pain: when aspirin doesn't work.
Topics: Aspirin; Chronic Disease; Humans; Pain; Pain Management | 1984 |
Cadmium, analgesics, and the chronic progressive nephrosis in the female Sprague-Dawley rat.
Topics: Acetylglucosaminidase; Analgesics; Animals; Aspirin; Cadmium; Chronic Disease; Female; Kidney; Nephr | 1984 |
[Effect of acetylsalicylic acid and dipyridamole on the microcirculatory state of diabetes mellitus patients based on biomicroscopy and rheography data].
Topics: Adolescent; Adult; Aged; Aspirin; Chronic Disease; Conjunctiva; Diabetic Angiopathies; Dipyridamole; | 1983 |
[Bronchial asthma, nasal polyposis and analgesic intolerance (the ASA triad). A successful computer based analysis of free texts].
Topics: Analgesics; Aspirin; Asthma; Chronic Disease; Computers; Drug Tolerance; Humans; Nasal Polyps; Rhini | 1984 |
Role of acetyl salicylic acid and sodium metabisulfite in chronic childhood asthma.
Topics: Adolescent; Aspirin; Asthma; Bronchial Provocation Tests; Bronchial Spasm; Child; Child, Preschool; | 1984 |
Chronic myeloproliferative disorders: a quantitative assessment of platelet ultrastructure.
Topics: Aspirin; Blood Platelets; Chronic Disease; Cytoplasmic Granules; Humans; Myeloproliferative Disorder | 1980 |
The effect of some antirheumatic drugs in vivo on the response of spleen cells to concanavalin A in rats with chronic inflammation.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Chloroquine; Chronic Disease; Concanavalin A; Female; Go | 1982 |
Elevated lipid peroxide levels in platelets of chronic ischemic heart disease patients.
Topics: Anticoagulants; Aspirin; Blood Platelets; Chronic Disease; Citrates; Citric Acid; Coronary Disease; | 1982 |
Effect of acetylsalicylic acid on vascular damage and myointimal proliferation in canine pulmonary arteries subjected to chronic injury by Dirofilaria immitis.
Topics: Animals; Aspirin; Chronic Disease; Dirofilaria immitis; Dirofilariasis; Dog Diseases; Dogs; Endothel | 1983 |
[Use of the preparation essentiale in the therapy of lupus erythematosus].
Topics: Adolescent; Adult; Aged; Aspirin; Chloroquine; Chronic Disease; Drug Combinations; Drug Evaluation; | 1983 |
Aspirin intolerance presenting as chronic rhinitis.
Topics: Aspirin; Chronic Disease; Diagnosis, Differential; Drug Hypersensitivity; Eosinophilia; Female; Head | 1980 |
Fibromyalgia or the fibrositis syndrome: a new look.
Topics: Antidepressive Agents, Tricyclic; Aspirin; Blood Circulation; Chronic Disease; Fibromyalgia; Humans; | 1981 |
Pharmacological treatment of cancer pain with special reference to the oral use of morphine.
Topics: Acetaminophen; Administration, Oral; Aspirin; Biological Availability; Chronic Disease; Codeine; Hum | 1982 |
[Clinical significance of the electrolyte barrier and the regenerative capacity of the gastric mucosa].
Topics: Aspirin; Biological Transport; Chronic Disease; Diffusion; Electrolytes; Gastric Mucosa; Gastritis; | 1981 |
Tartrazine and benzoate challenge and dietary avoidance in chronic asthma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aspirin; Asthma; Azo Compounds; Benzoates; Chronic Disease; Fe | 1982 |
[Pain and its management with drugs].
Topics: Acute Disease; Analgesics; Aspirin; Chronic Disease; Humans; Inflammation; Pain; Prostaglandin Antag | 1982 |
In vitro stimulation of lymphocytes in patients with chronic urticaria induced by additives and food.
Topics: Angioedema; Animals; Aspirin; Cattle; Chronic Disease; Female; Food Additives; Food Hypersensitivity | 1980 |
Management of juvenile rheumatoid arthritis.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Arthritis, Juvenile; Aspirin; Child; Chloroquine; Chroni | 1981 |
Newer concepts in pain therapy by applied pharmacology of the analgesics.
Topics: Acetaminophen; Analgesics; Aspirin; Chronic Disease; Humans; Hydroxyzine; Morphine; Morphine Derivat | 1981 |
[Hemostasis disorders and their treatment in patients with chronic myeloproliferative diseases].
Topics: Aged; Aspirin; Chronic Disease; Hemorrhagic Disorders; Humans; Male; Myeloproliferative Disorders; P | 1981 |
Practical impact of hemorheology on the treatment of chronic peripheral ischemia.
Topics: Ancrod; Aspirin; Blood Viscosity; Chronic Disease; Erythrocyte Count; Fibrinogen; Humans; Intermitte | 1981 |
Problems with the use of oxycodone compound in patients with chronic pain.
Topics: Aspirin; Caffeine; Chronic Disease; Codeine; Dextropropoxyphene; Drug Combinations; Female; Humans; | 1981 |
[Hypersensitivity to acetysal in bronchial asthma].
Topics: Adolescent; Adult; Aged; Aspirin; Asthma; Bronchial Spasm; Chronic Disease; Drug Hypersensitivity; F | 1980 |
[Effectiveness of the combined use of cardiac glycosides and de-aggregating agents in chronic pulmonary cardiac insufficiency].
Topics: Adult; Aged; Aspirin; Cardiac Glycosides; Chronic Disease; Dipyridamole; Drug Evaluation; Drug Thera | 1980 |
Control of chronic erythema nodosum with naproxen.
Topics: Adult; Aspirin; Chronic Disease; Erythema Nodosum; Female; Humans; Naproxen; Phenylbutazone | 1980 |
Non-steroidal anti-inflammatory drugs in elderly people. Enteric coated aspirin may reduce risk.
Topics: Aged; Aspirin; Chronic Disease; Humans; Pain; Tablets, Enteric-Coated | 1995 |
Conservative management of severe chronic hypertension in pregnancy.
Topics: Adult; Antihypertensive Agents; Aspirin; Chronic Disease; Female; Humans; Hypertension; Pregnancy; P | 1994 |
Does aspirin heal leg ulcers?
Topics: Administration, Oral; Aspirin; Bandages; Chronic Disease; Combined Modality Therapy; Double-Blind Me | 1995 |
Treatment of chronic leg ulcers.
Topics: Aspirin; Bandages; Chronic Disease; Clinical Trials as Topic; Combined Modality Therapy; Data Interp | 1994 |
Oral challenge tests for urticaria--an ethical dilemma.
Topics: Aspirin; Chronic Disease; Ethics, Medical; Food Additives; Humans; Urticaria | 1994 |
Treatment of chronic leg ulcers.
Topics: Aspirin; Bandages; Chronic Disease; Clinical Trials as Topic; Combined Modality Therapy; Humans; Var | 1994 |
[Liver function in patients with aspirin-induced bronchial asthma].
Topics: Aspirin; Asthma; Chronic Disease; Humans; Liver Diseases; Liver Function Tests; Severity of Illness | 1994 |
[Present possibilities of treatment of primary chronic glomerulonephritis].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Chronic Disease; Cyclophosphamide; Drug Therapy, | 1994 |
Warfarin in chronic atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Chronic Disease; Humans; Thromboembolism; W | 1993 |
[Is it justifiable to use antiplatelet drugs as a universal protection in patients with chronic glomerular damage?].
Topics: Adolescent; Adult; Aged; Aspirin; Chronic Disease; Clinical Protocols; Dipyridamole; Female; Glomeru | 1993 |
[Optic neuropathy in type-1 diabetes and acetylsalicylic acid-refractory thrombocyte activation].
Topics: Adult; Aspirin; Chronic Disease; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Diabetic Neuropa | 1993 |
Effective treatment with interferon-alpha in chronic recurrent multifocal osteomyelitis.
Topics: Adult; Aspirin; Chronic Disease; Drug Therapy, Combination; Humans; Interferon alpha-2; Interferon-a | 1995 |
Perinatal morbidity in chronic hypertension.
Topics: Adult; Aspirin; Chronic Disease; Cohort Studies; Female; Fetal Death; Humans; Hypertension; Infant M | 1996 |
Systemic inflammatory response syndrome caused by chronic salicylate intoxication.
Topics: Acid-Base Imbalance; Adult; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin | 1996 |
Long-term aspirin therapy for hepatopulmonary syndrome.
Topics: Aspirin; Child; Chronic Disease; Cyanosis; Dilatation, Pathologic; Female; Humans; Hypoxia; Liver Di | 1996 |
Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease.
Topics: Analysis of Variance; Anticoagulants; Aspirin; Cardiovascular Diseases; Chronic Disease; Cross-Over | 1996 |
Pathogenetic factors in chronic subdural haematoma and causes of recurrence after drainage.
Topics: Adult; Aged; Aspirin; Chronic Disease; Drainage; Female; Hematoma, Subdural; Humans; Male; Middle Ag | 1995 |
Anticoagulation for cardioversion of atrial fibrillation.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Heparin; Humans; M | 1996 |
Orbital complications of sinusitis in the aspirin triad syndrome.
Topics: Adolescent; Adult; Aged; Aspirin; Asthma; Chronic Disease; Female; Humans; Male; Middle Aged; Orbita | 1996 |
[Chronic anemia protects against gastric damage by alcohol and aspirin. The role of the toxic radicals and lipid peroxidation].
Topics: Anemia; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Central Nervous System Depressant | 1996 |
Helicobacter pylori infection status in relation to antibiotic and non-steroidal prescribing in patients on maintenance treatment for chronic duodenal ulcer.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy; Chroni | 1997 |
The role of oxygen free radicals in idiopathic facial pain.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; | 1997 |
Risk factors between analgesic use and chronic nephropathy in Thailand.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Ca | 1996 |
[Progress on therapy and etiological study of bronchial asthma].
Topics: Administration, Inhalation; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspir | 1997 |
Chronic atrial fibrillation: optimizing anticoagulation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Drug Therapy, Combination; Humans; In | 1997 |
ASHP therapeutic position statement on antithrombotic therapy in chronic atrial fibrillation. American Society of Health-System Pharmacists.
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; C | 1998 |
Aspirin-sensitive urticaria: provocation with a leukotriene receptor antagonist.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chromones; Chronic Di | 1998 |
[Acetylsalicylic acid in therapy of migraine].
Topics: Aspirin; Chronic Disease; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Humans; Middl | 1998 |
Successful treatment of chronic urticaria with leukotriene antagonists.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Controlled Clinical Trials | 1998 |
Drug therapy before coronary artery surgery: nitrates are independent predictors of mortality and beta-adrenergic blockers predict survival.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagul | 1999 |
Incidence of new thromboembolic stroke in persons 62 years and older with chronic atrial fibrillation treated with warfarin versus aspirin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic | 1999 |
[Anticoagulation in aged patients with chronic non-rheumatic atrial fibrillation].
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascul | 1999 |
Underuse of anticoagulation in older patients with chronic atrial fibrillation: malpractice or accuracy?
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; C | 1999 |
[A case of aspirin triad].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Drug Hypersensitivity; Follow-Up | 1999 |
Effects of sinus surgery on asthma in aspirin triad patients.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Airway Resistance; Aspirin; Asthma; Chro | 1999 |
Safety of labor epidural anesthesia for women with severe hypertensive disease. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.
Topics: Adult; Anesthesia, Epidural; Aspirin; Cesarean Section; Chronic Disease; Double-Blind Method; Female | 1999 |
NSAID-induced bronchospasm--a common and serious problem. A report from MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority.
Topics: Adult; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchial Spasm; Chroni | 1999 |
Outcome analysis of endoscopic sinus surgery for chronic sinusitis in patients having Samter's triad.
Topics: Adult; Age of Onset; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease | 2000 |
Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; | 2000 |
Anticoagulation for chronic atrial fibrillation.
Topics: Aged; Algorithms; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Echocardiography, T | 2000 |
Beyond willow bark: aspirin in the prevention of chronic disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Humans; Myocardial Infarction; Pr | 2000 |
Successful treatment of chronic Henoch-Schonlein purpura with colchicine and aspirin.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Colchicine; Drug Ther | 2000 |
Influence of aspirin on early allograft thrombosis and chronic allograft nephropathy following renal transplantation.
Topics: Aspirin; Biopsy, Needle; Chronic Disease; Cyclooxygenase Inhibitors; Follow-Up Studies; Graft Reject | 2001 |
Multifocal pyogranulomatous osteomyelitis resembling chronic recurrent multifocal osteomyelitis in a lemur.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy, Needle; Chronic Disease; Femur; F | 2001 |
Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Cyclooxygenase 1; Cycloo | 2001 |
Outcomes in the management of atrial fibrillation: clinical trial results can apply in practice.
Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Databases, Factual; Fema | 2001 |
Aspirin desensitization for chronic hyperplastic sinusitis, nasal polyposis, and asthma triad.
Topics: Adult; Aged; Aspirin; Asthma; Chronic Disease; Desensitization, Immunologic; Drug Hypersensitivity; | 2001 |
Guidelines for the management of patients with chronic stable angina: treatment.
Topics: Adrenergic beta-Antagonists; Adult; Algorithms; Angina Pectoris; Aspirin; Calcium Channel Blockers; | 2001 |
[Thoracic aortic aneurysm with chronic disseminated intravascular coagulation treated successfully with orally administered camostat mesilate, warfarin and aspirin].
Topics: Administration, Oral; Aged; Anticoagulants; Aortic Aneurysm, Thoracic; Aspirin; Chronic Disease; Dis | 2002 |
Chronic pain, bereavement and overdose in a depressed elderly woman.
Topics: Acetaminophen; Aged; Aged, 80 and over; Aging; Aortic Aneurysm, Thoracic; Aspirin; Back Pain; Bereav | 2002 |
Hypersensitivity to non-steroidal anti-inflammatory drugs and chronic urticaria cured by treatment of Blastocystis hominis infection.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blastocystis hominis; Blastocystis Infect | 2002 |
Chemical mediators of the muscle ergoreflex in chronic heart failure: a putative role for prostaglandins in reflex ventilatory control.
Topics: Aged; Aspirin; Bradykinin; Chemoreceptor Cells; Chronic Disease; Cyclooxygenase Inhibitors; Exercise | 2002 |
[Urticaria. Recent findings on pathogenesis, diagnosis and therapy].
Topics: Angioedema; Antigens; Aspirin; Chronic Disease; Danazol; Histamine H1 Antagonists; Humans; Immunoglo | 1977 |
Upper gastrointestinal haemorrhage in hepatic cirrhosis: causes and relation to hepatic failure and stress.
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aspirin; Chronic Disease; Esophagea | 1977 |
Platelet activation in acute cerebral ischaemia. Serial measurements of platelet function in cerebrovascular disease.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Aspirin; Blood Cell Count; Blood Platelets; Cerebrovascu | 1977 |
[Etiology of urticaria; a retrospective study on 200 patients].
Topics: Acute Disease; Aspirin; Chronic Disease; Drug Eruptions; Humans; Hypersensitivity; Psychophysiologic | 1976 |
Effects of verapamil and aspirin on experimental chronic hypoxic pulmonary hypertension and right ventricular hypertrophy in rats.
Topics: Animals; Aspirin; Biological Transport; Calcium; Cardiomegaly; Chronic Disease; Female; Haplorhini; | 1979 |
[What is certain in the therapy of porphyrias?].
Topics: Acute Disease; Aspirin; Barbiturates; Chloramphenicol; Chronic Disease; Diazepam; Humans; Porphyrias | 1977 |
[Inducing factors in chronic urticaria].
Topics: Aspirin; Azo Compounds; Benzoates; Candidiasis; Chronic Disease; Coloring Agents; Drug Hypersensitiv | 1977 |
[Significance of aspirin, dyes and preservatives for chronic urticaria].
Topics: Aspirin; Chronic Disease; Coloring Agents; Food Preservatives; Humans; Urticaria | 1978 |
[Severe acetylsalicylic acid poisoning: epidemiologic data. 10-year study].
Topics: Acute Disease; Adolescent; Adult; Aspirin; Child; Child, Preschool; Chronic Disease; Epidemiologic M | 1979 |
Chronic and recurrent urticaria: new concepts of drug-group sensitivity.
Topics: Aspirin; Barbiturates; Blood Coagulation Tests; Chronic Disease; Cross Reactions; Dose-Response Rela | 1977 |
Influence of aspirin on healing of chronic gastric ulcers in dogs.
Topics: Acetates; Animals; Aspirin; Chronic Disease; Dogs; Gastric Mucosa; Gastroscopy; Male; Peptic Ulcer P | 1977 |
[Coloring and preservative agents in chronic urticaria. Value of a provocation test and elimination diet].
Topics: Adolescent; Adult; Aged; Aspirin; Child; Chronic Disease; Drug Hypersensitivity; Female; Follow-Up S | 1978 |
[Lactate dehydrogenase (LDH) activity of the gastric juice depending on the metabolic state and protective barrier of the gastric mucosa].
Topics: Adult; Aspirin; Chronic Disease; Duodenal Ulcer; Enzyme Activation; Gastric Juice; Gastric Mucosa; G | 1978 |
[Irritative activity of antiinflammatory agents, betamethasone 17-valerate, beclomethasone 17, 21-dipropionate, betamethasone 17, 21-dipropionate, or indomethacin on the gastrointestinal tract in rats and dogs (author's transl)].
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Beclomethasone; Betamethasone; Betamethasone Valerate; C | 1978 |
Aspirin overdosage: incidence, diagnosis, and management.
Topics: Aspirin; Child, Preschool; Chronic Disease; Drug Packaging; Humans; Safety; United States | 1978 |
[Modern aspects in the pathogenesis of urticaria with special reference to intolerance phenomena].
Topics: Anaphylaxis; Antigen-Antibody Reactions; Aspirin; Autoantigens; Chronic Disease; Cold Temperature; D | 1977 |
Dietary treatment of patients with chronic urticaria and intolerance to aspirin and food additives.
Topics: Aspirin; Chronic Disease; Drug Hypersensitivity; Food Additives; Humans; Urticaria | 1977 |
A ten year study of heparin therapy for thrombophlebitis in ambulatory patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Ambulatory Care; Aspirin; Blood Coagulation Tests; Chronic D | 1977 |
Alteration of Hepatic microsomal enzyme systems and the lethal action of non-steroidal anti-arthritic drugs in acute and chronic models of inflammation.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Aspirin; Carrageenan; Chr | 1977 |
Effects of acetylsalicylic acid (ASA), ASA plus L-glutamine and L-glutamine on healing of chronic gastric ulcer in the rat.
Topics: Animals; Aspirin; Chronic Disease; Drug Evaluation, Preclinical; Glutamine; Male; Rats; Recurrence; | 1976 |
Effects of carbenoxolone Na on acute and chronic gastric ulcer models in experimental animals.
Topics: Acute Disease; Animals; Aspirin; Carbenoxolone; Chronic Disease; Disease Models, Animal; Dogs; Gastr | 1976 |
Intractable peptic ulcer disease.
Topics: Aspirin; Chronic Disease; Humans; Hypercalcemia; Hyperparathyroidism; Peptic Ulcer; Peptic Ulcer Per | 1976 |
[Etiopathogenic diagnosis and therapy of chronic urticaria--with special reference to aspirin provocation].
Topics: Aspirin; Chronic Disease; Humans; Skin Tests; Urticaria | 1976 |
[Chronic urticaria. Provocation test].
Topics: Aspirin; Benzoates; Chronic Disease; Diagnostic Uses of Chemicals; Humans; Hydroxybenzoates; Methods | 1976 |
Trauma of cervical spine as cause of chronic headache.
Topics: Adolescent; Adult; Aged; Aspirin; Cervical Vertebrae; Child; Chronic Disease; Female; Food Hypersens | 1975 |
Cystic fibrosis and hypertrophic osteoarthropathy in children. Report of three cases.
Topics: Adolescent; Aspirin; Child; Chronic Disease; Cystic Fibrosis; Female; Humans; Joint Diseases; Male; | 1975 |
Aspirin and gastric ulcer.
Topics: Adult; Animals; Aspirin; Chronic Disease; Dose-Response Relationship, Drug; Female; Gastric Mucosa; | 1975 |
A simple nonradioisotope technic for the determination of platelet life-span.
Topics: Aspirin; Blood Platelets; Cell Survival; Chromium Radioisotopes; Chronic Disease; Epinephrine; Ethyl | 1975 |
Factors relevant to the prognosis of chronic gastric ulcer.
Topics: Age Factors; Aspirin; Chronic Disease; Female; Follow-Up Studies; Humans; Male; Prognosis; Recurrenc | 1975 |
[Methoxypropriocin in the treatment of degenerative bone disease (comparative studies)].
Topics: Aspirin; Benzydamine; Chronic Disease; Humans; Indomethacin; Naphthaleneacetic Acids; Naproxen; Oste | 1976 |
Editorial: Aspirin and chronic gastric ulcer.
Topics: Adult; Aspirin; Australia; Chronic Disease; Female; Humans; Middle Aged; Stomach Ulcer; Substance-Re | 1976 |
Alcohol, aspirin, depression, smoking, stress and the patient with a gastric ulcer.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Aspirin; Chronic Disease; Depression; Ethnicity; Female; | 1976 |
Challenge test battery in chronic urticaria.
Topics: Adolescent; Adult; Aged; Aspirin; Azo Compounds; Benzenesulfonates; Benzoates; Child; Child, Prescho | 1976 |
Letter: Aspirin and chronic gastric ulcer.
Topics: Animals; Aspirin; Chronic Disease; Humans; Stomach Ulcer | 1976 |
Recurring and chronic urticaria: identification of etiologies.
Topics: Aspirin; Barbiturates; Blood Coagulation Tests; Bromides; Chronic Disease; Drug Hypersensitivity; Hu | 1976 |
Editorial: Chronic urticaria.
Topics: Aspirin; Chronic Disease; Food Additives; Humans; Urticaria | 1976 |
[The effect of decreased thromboxane synthesis on proliferative glomerulonephritis].
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aspirin; Chronic Disease; Creatinine; Female; Glomerular Filtra | 1991 |
Experimental reactivation of chronic gastric lesions exposed to different aggressive conditions.
Topics: Acetates; Animals; Aspirin; Chronic Disease; Ethanol; Female; Gastric Acid; Gastric Mucosa; Random A | 1991 |
Helicobacter pylori-negative duodenal ulcer.
Topics: Aspirin; Chronic Disease; Duodenal Ulcer; Duodenoscopy; Female; Gastritis; Helicobacter Infections; | 1991 |
Nonnarcotic analgesics and tricyclic antidepressants for the treatment of chronic nonmalignant pain.
Topics: Acetaminophen; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Tricyclic | 1991 |
Pseudosepsis syndrome, multiple-system organ failure, and chronic salicylate intoxication. Inhibition of regulatory eicosanoids?
Topics: Aspirin; Chronic Disease; Eicosanoids; Humans; Multiple Organ Failure; Sepsis; Syndrome | 1991 |
[Chronic arterial occlusive diseases--drug therapy and thromboxane A2 synthetase inhibitor].
Topics: Arterial Occlusive Diseases; Aspirin; Chronic Disease; Epoprostenol; Fatty Acids, Monounsaturated; H | 1991 |
Pattern of rheumatic diseases in south India. IV. Clinical profile of juvenile rheumatoid arthritis.
Topics: Arthritis, Juvenile; Aspirin; Child; Chronic Disease; Female; Humans; Ibuprofen; India; Indomethacin | 1990 |
Aspirin use and chronic diseases.
Topics: Aspirin; Chronic Disease; Cohort Studies; Coronary Disease; Humans; Kidney Neoplasms | 1990 |
Surgery for sinusitis and aspirin triad.
Topics: Adolescent; Adult; Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Female; Follow-Up Studie | 1990 |
[Rotation angioplasty of chronic coronary artery stenosis].
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Chronic Disease; Coronary Angiography; Coronary Dise | 1990 |
[The effect of acetylsalicylic acid and dipyridamole on glomerular filtration and proteinuria in chronic glomerulonephritis].
Topics: Adult; Aspirin; Chronic Disease; Dipyridamole; Female; Glomerular Filtration Rate; Glomerulonephriti | 1990 |
[Treatment of chronic glomerulonephritis with small doses of acetylsalicylic acid].
Topics: Adult; Aspirin; Chronic Disease; Female; Glomerulonephritis; Humans; Male; Middle Aged | 1990 |
[Treatment of chronic proliferative glomerulonephritis using acetylsalicylic acid and dipyridamole].
Topics: Adult; Aspirin; Chronic Disease; Dipyridamole; Drug Therapy, Combination; Epoprostenol; Female; Glom | 1989 |
Slow release delivery of rioprostil by an osmotic pump inhibits the formation of acute aspirin-induced gastric lesions in dogs and accelerates the healing of chronic lesions without incidence of side effects.
Topics: Acute Disease; Administration, Oral; Animals; Anti-Ulcer Agents; Aspirin; Chronic Disease; Dogs; Fem | 1989 |
Aspirin use and chronic diseases: a cohort study of the elderly.
Topics: Aged; Aged, 80 and over; Aspirin; California; Cataract; Chronic Disease; Cohort Studies; Coronary Di | 1989 |
[The relationship between high-density lipoproteins, thromboxane B2 and arteriosclerosis in a case of primary hypoalphalipoproteinemia].
Topics: Adult; Arteriosclerosis; Aspirin; Chronic Disease; Histiocytes; Humans; Hypolipoproteinemias; Lipopr | 1989 |
Analgesic use and chronic renal disease.
Topics: Acetaminophen; Analgesics; Aspirin; Chronic Disease; Data Collection; Humans; Kidney Diseases; Phena | 1989 |
[Cerebral complications in chronic acetylsalicylic acid poisoning].
Topics: Aspirin; Chronic Disease; Cognition Disorders; Coma; Combined Modality Therapy; Consciousness Disord | 1989 |
[Chronic refractory pain in cancer patients. Value of the spinal injection of lysine acetylsalicylate. 60 cases].
Topics: Adult; Aged; Analgesics; Aspirin; Chronic Disease; Female; Humans; Injections, Spinal; Lysine; Male; | 1987 |
[Analgesia with an implanted device for repetitive intrathecal injections of morphine].
Topics: Adolescent; Adult; Aged; Aspirin; Chronic Disease; Clonidine; Drug Tolerance; Humans; Injections, Sp | 1985 |
Scratching behaviour in arthritic rats: a sign of chronic pain or itch?
Topics: Animals; Arthritis; Arthritis, Experimental; Aspirin; Astemizole; Behavior, Animal; Benzimidazoles; | 1987 |
Gastric mucosal protection by new aryl sulfhydryl drugs.
Topics: Animals; Aspirin; Chronic Disease; Dose-Response Relationship, Drug; Ethanol; Ethylmaleimide; Female | 1988 |
[Pseudo-crossreactivity between aspirin and tartrazine].
Topics: Adult; Angioedema; Aspirin; Azo Compounds; Chronic Disease; Cross Reactions; Drug Hypersensitivity; | 1988 |
Environmental factors and chronic unexplained dyspepsia. Association with acetaminophen but not other analgesics, alcohol, coffee, tea, or smoking.
Topics: Acetaminophen; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Coffee | 1988 |
Concerning the management of pain associated with herpes zoster and of postherpetic neuralgia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Chloroform; Chronic Disease; Female; Herpes Zos | 1988 |
Cell-mediated immune responses to artificial food additives in chronic urticaria.
Topics: Adolescent; Adult; Aspirin; Benzoates; Benzoic Acid; Cell Migration Inhibition; Chronic Disease; Fem | 1986 |
Molecular weight of gastric mucus glycoprotein is a determinant of the degree of subsequent aspirin induced chronic gastric ulceration in the rat.
Topics: Amino Acids; Animals; Aspirin; Carbohydrates; Chromatography, Gel; Chronic Disease; Gastric Mucosa; | 1987 |
Chronic paroxysmal hemicrania: the first possible bilateral case.
Topics: Aged; Aspirin; Chronic Disease; Female; Humans; Indomethacin; Migraine Disorders | 1986 |
Exacerbating factors in recurrent urticaria.
Topics: Adult; Angioedema; Aspirin; Chronic Disease; Female; Hot Temperature; Humans; Male; Recurrence; Urti | 1986 |
[Chronic paroxysmal migraine. A review and presentation of 4 new cases].
Topics: Aspirin; Chronic Disease; Diagnosis, Differential; Female; Humans; Indomethacin; Male; Middle Aged; | 1986 |
Reduction in locomotor activity of arthritic rats as parameter for chronic pain: effect of morphine, acetylsalicylic acid and citalopram.
Topics: Animals; Arthritis; Arthritis, Experimental; Aspirin; Chronic Disease; Citalopram; Exploratory Behav | 1985 |
Nasal polypectomy and sinus surgery in patients with asthma and aspirin idiosyncrasy.
Topics: Adolescent; Adult; Aspirin; Asthma; Bronchial Provocation Tests; Chronic Disease; Drug Hypersensitiv | 1986 |
Mental confusion in an elderly, chronically ill patient.
Topics: Aged; Aspirin; Chronic Disease; Cognition Disorders; Confusion; Emergencies; Female; Humans; Renal D | 1986 |
Environmental factors in aetiology of chronic gastric ulcer: a case control study of exposure variables before the first symptoms.
Topics: Acetaminophen; Alcohol Drinking; Analgesics; Anti-Inflammatory Agents; Aspirin; Chronic Disease; Fem | 1985 |
An elimination diet for chronic urticaria of childhood.
Topics: Adolescent; Aspirin; Benzoates; Benzoic Acid; Child; Child, Preschool; Chronic Disease; Drug Hyperse | 1985 |
Effects of 5-acetylspiro[benzofuran-2(3H),1'-cyclopropan]-3-one, a new anti-ulcer agent, on experimental acute and chronic ulcers.
Topics: Acetates; Acetic Acid; Acute Disease; Animals; Anti-Ulcer Agents; Aspirin; Benzofurans; Chronic Dise | 1985 |
Pain patterns in the rheumatic disorders.
Topics: Anxiety; Arthritis; Arthritis, Rheumatoid; Aspirin; Chronic Disease; Depression; Giant Cell Arteriti | 1972 |
Effects of antihistamines, acetylsalicylic acid and prednisone on cutaneous reactions to kallikrein and prostaglandin E1.
Topics: Adult; Aspirin; Bradykinin; Chronic Disease; Cyproheptadine; Drug Hypersensitivity; Eczema; Female; | 1970 |
Acetylsalicylic acid intolerance.
Topics: Adult; Aged; Allergens; Animals; Antibodies; Antigens; Aspirin; Asthma; Chronic Disease; Drug Hypers | 1974 |
[Research on the chronic audio-toxicity of aspirin in the guinea pig].
Topics: Animals; Aspirin; Audiometry; Chronic Disease; Deafness; Ear; Guinea Pigs; Hearing; Labyrinth Diseas | 1974 |
Erosive gastritis with special reference to the role of aspirin and bile.
Topics: Acute Disease; Age Factors; Aged; Animals; Aspirin; Bile; Chronic Disease; Drainage; Female; Gastrec | 1974 |
[Incidence of thrombosis and the status of coagulation in ischaemic heart disease].
Topics: Acute Disease; Aspirin; Blood Coagulation; Chronic Disease; Coronary Disease; Depression, Chemical; | 1974 |
Cancer and upper gastrointestinal tract hemorrhage. Benign causes of bleeding demonstrated by endoscopy.
Topics: Acute Disease; Adenocarcinoma; Aspirin; Chronic Disease; Endoscopy; Esophageal and Gastric Varices; | 1973 |
[Endoscopic diagnosis of acute medication (aspirin) ulcers of the duodenal bulb].
Topics: Acute Disease; Adult; Aspirin; Chronic Disease; Duodenal Ulcer; Endoscopy; Gastrointestinal Hemorrha | 1974 |
The management of a patient with a duodenal ulcer.
Topics: Adult; Alcohol Drinking; Alkalies; Aspirin; Chronic Disease; Diet Therapy; Duodenal Ulcer; Humans; P | 1972 |
Chronic intravascular coagulation syndrome associated with atherosclerotic aortic aneurysm.
Topics: Aged; Aortic Aneurysm; Arteriosclerosis; Aspirin; Blood Cell Count; Blood Platelets; Chronic Disease | 1973 |
Aspirin and subtypes of asthma: risk factor analysis.
Topics: Adolescent; Age Factors; Aspirin; Asthma; Child; Chronic Disease; Drug Hypersensitivity; Eczema; Fem | 1973 |
Correlation of mucosal histology and aspirin intake in chronic gastric ulcer.
Topics: Adult; Aged; Aspirin; Caffeine; Chronic Disease; Epithelium; Female; Gastric Mucosa; Gastritis; Huma | 1973 |
Chronic gastric ulcer induced by aspirin: an experimental model.
Topics: Animals; Aspirin; Chronic Disease; Disease Models, Animal; Gastric Juice; Gastric Mucosa; Glycoprote | 1973 |
Thrombotic thrombocytopenic purpura. A ten-year survey.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aspirin; Biopsy; Chronic Disease; Dextrans; Female; F | 1973 |
Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Aspirin; Biopsy; Chemical and Drug Induced | 1974 |
The management of juvenile chronic polyarthritis (Still's disease).
Topics: Adolescent; Adrenal Cortex Hormones; Antimalarials; Antineoplastic Agents; Arthritis, Juvenile; Aspi | 1972 |
Chronic and high risk asthma in children.
Topics: Adolescent; Adrenal Cortex Hormones; Aerosols; Airway Obstruction; Aspergillosis; Aspirin; Asthma; B | 1972 |
[Use of indomethacin in combination with other antirheumatic drugs in the therapy of chronic inflammatory rheumatism].
Topics: Arthritis, Rheumatoid; Aspirin; Chronic Disease; Dexamethasone; Drug Synergism; Flufenamic Acid; Gol | 1972 |
Slowed lysosomal enzyme release and its normalization by drugs in adjuvant-induced polyarthritis.
Topics: Acid Phosphatase; Amino Acids; Animals; Arthritis; Aspirin; Chronic Disease; Disease Models, Animal; | 1971 |
Headache nostrums and chronic illness.
Topics: Analgesics; Aspirin; Chronic Disease; Gastrointestinal Hemorrhage; Headache; Kidney Diseases; Monoam | 1966 |
[Medical therapeutic management of chronic inflammatory rheumatism].
Topics: Adrenal Cortex Hormones; Antimalarials; Antineoplastic Agents; Arthritis, Rheumatoid; Aspirin; Chron | 1969 |
[Drug therapy of rheumatism].
Topics: Acute Disease; Aluminum; Aspirin; Calcium; Chronic Disease; Humans; Humic Substances; Prednisolone; | 1967 |
Aspirin and gastrointestinal bleeding.
Topics: Aspirin; Chronic Disease; Female; Gastrointestinal Hemorrhage; Humans; Melena; Stomach Ulcer | 1970 |
Hemorrhagic gastritis. Importance of associated chronic gastritis.
Topics: Acute Disease; Alcoholism; Aspirin; Atrophy; Biopsy; Chronic Disease; Gastric Mucosa; Gastritis; Gas | 1971 |
Recurrent meningitis.
Topics: Ampicillin; Aspirin; Child, Preschool; Chloramphenicol; Chronic Disease; Humans; Leukocyte Count; Ma | 1969 |
Chronic urticaria: the effect of aspirin.
Topics: Aspirin; Chronic Disease; Humans; Urticaria | 1970 |
[Experimental chronic gastritis].
Topics: Animals; Aspirin; Chronic Disease; Gastritis; Rats; Stomach | 1968 |
[Judgement of the therapeutic effects of non-steroid anti-inflammatory drugs in chronic rheumatoid arthritis].
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Chronic Disease; Gold; Humans; Prednisolon | 1968 |
[Aspirin in the treatment of chronic evolutive polyarthritis].
Topics: Arthritis, Rheumatoid; Aspirin; Chronic Disease; Humans | 1966 |